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The development of viral resistance to antiretroviral drugs used for treatment 
of human immunodeficiency virus 1 (HIV) infection is an important cause of 
antiretroviral treatment (ARV) failure and limits options for alternative 
antiretroviral regimens. Prevention, characterisation and clinical management 
of such resistance are receiving increasing attention. 
The primary objective of this project was to study the naturally occurring 
variants of HIV-1 present in a group of ARV-naiVe patients. The presence of 
pre-existing mutations may aid clinicians in designing optimal ARV 
combinations for the country. The secondary objective was to choose a 
suitable method for doing the analysis. Published primer sequences and in-
house methods for the different steps of the procedure were used, but this 
was changed to an established commercial system (viroseq) because of 
superior sensitivity and the fact that it is FDA approved. The study population 
consisted of 19 adult ARV-na·ive AIDS patients recruited from Tsepo House, 
and Medi Inn, Bloemfontein. 
The CD4 counts indicated that the immune systems of these patients were 
severely compromised, the highest count being 348 and the mean value 184 
cells/mm3 whole blood. Therefore, according to the Department of Health's 
criteria, all of them qualified for ARV treatment. The viral loads were high, 
varying from 23 000 to >750 000 RNA copies/ml plasma. This demonstrates 
how people differ in their response to the viral infection. All patients were in 
the terminal stage of disease, yet displayed up to thirty-fold differences in viral 
load. 
After RT-PCR and sequencing, the sequences were trimmed to 99 codons of 
the full protease and the first 335 codons of the reverse transcriptase reading 
frames. These were translated to amino acids and used separately in 
phylogenetic analyses to study their relatedness to each other and to other 
isolates. A benefit of phylogenetic analysis is to indicate possible 
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contamination of one sample by another as this will show tight clustering of 
some samples. The form and branch distances of the trees found clearly 
eliminated this possibility. The sequences were compared to 20 other South 
African isolates, randomly chosen from the Los Alamos 
(http://www.hiv.lanl.gov/content/index) HIV-1 sequence database. Both the 
protease and reverse transcriptase trees revealed that the Bloemfontein 
sequences do not differ appreciably from those found in the rest of the 
country, since they tend to diffuse through the tree rather than to cluster on 
their own. 
All the patients tested positive for subtype C, complying with the 
demographical data. Very few mutations were detected in the reverse 
transcriptase (RT) reading frame, although a mutation (K103N) which confers 
high level resistance against non-nucleoside RT inhibitors was found in one 
isolate. This may mean that a small percentage of patients may harbour a 
virus that is naturally resistant to these drugs. In the protease reading frame, 
mutations at nine amino acid positions have been designated primary or 
major resistance mutations. None of the primary mutations were found, 
although several secondary mutations (of lesser significance) contributing to 
reduced susceptibility (e.g., M361 and 193L) were found in 95% of our 
samples. This was not unexpected as these polymorphisms are extremely 
common in subtype C viruses. These genetic differences may be clinically 
relevant when considering long-term strategies for patients infected with non-
S subtypes. 
As the public sector ARV rollouts gather momentum, the emergence of drug-
resistant isolates is sure to follow and the laboratory services must be geared 
to provide the backup needed by the clinicians to plan salvage therapy. This 
project has contributed to the baseline knowledge of the infected population 
enabling us to anticipate the emerging resistance mutations. 
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Ontwikkeling van virale weerstandigheid teen antiretrovirale middels wat 
gebruik word vir die behandeling van menslike immuniteitsgebrek virus 1 
(MIV-1) infeksies is 'n belangrike oorsaak van mislukking van antiretrovirale 
behandeling en beperk die opsies vir alternatiewe behandeling. Voorkoming, 
karakterisering en kliniese beheer van sulke weerstandigheid geniet al hoe 
meer aandag. 
Die primere doelwit van hierdie projek was om die natuurlike variante van 
MIV-1 te bestudeer in 'n groep antiretrovirale naiewe pasiente. Die 
teenwoordigheid van voorafbestaande mutasies mag geneeshere help in die 
daarstelling van optimale antiretrovirale kombinasies vir die land. Die 
sekondere doelwit was om 'n geskikte metode vir die uitvoering van analises 
te kies. Gepubliseerde priemstuk nukleotiedvolgordes en metodes vir die 
verskillende stappe van die prosedure was gebruik, maar is later vervang met 
'n gevestigde kommersiele sisteem (Viroseq) as gevolg van beter sensitiwiteit 
en die feit dat dit FDA goedgekeur is. Die studiepopulasie het bestaan uit 19 
volwasse antiretrovirale naiewe pasiente gewerf vanaf Tsepo Huis en Medi 
Inn, Bloemfontein. 
Die CD4 telling toon dat die immuunsisteme van hierdie pasiente erg 
gekompromitteer was met 'n hoogste telling van 348 en 'n mediaanwaarde 
van 184 selle/mm3 heelbloed. Gevolglik, na aanleiding van die Departement 
van Gesondheid se kriteria, kwalifiseer almal vir antiretrovirale behandeling. 
Die virusladings was hoog en varieer van 23 000 tot > 750 000 RNA kopiee/ml 
plasma. Dit demonstreer hoe mense verskil in hul reaksie tot virale infeksie. 
Aile pasiente was in die terminale fase, maar het tog 30-voudige verskille in 
viruslading getoon. 
Na trutranskripsie en amplifikasie is die nukleotiedvolgordes bepaal. Die 
volgordes is beperk tot die 99 kodons van die valle protease en die eerste 
335 kodons van die trutranskriptase leesrame. Daarna is dit omgeskakel na 
© Central University of Technology, Free State
XI 
aminosure en afsonderlik gebruik in filogenetiese analise om die verwantskap 
aan mekaar en aan ander isolate te bestudeer. 'n Voordeel van filogenetiese 
analise is om kontaminasie van een monster deur 'n ander aan te dui 
aangesien dit digte groepering van sommige monsters toon. Die vorm en 
afstande van die borne gevind elimineer hierdie moontlikheid. Die 
nukleotiedvolgordes is vergelyk met 20 ander Suid-Afrikaanse isolate, lukraak 
gekies van die Los Alamos MIV-1 databasis. Seide die protease en die 
trutranskriptase borne toon dat die Bloemfonteinse nukleotiedvolgordes nie 
merkwaardig verskil van die in die res van die land nie, aangesien hulle deur 
die boom versprei eerder as om afsonderlik saam te groepeer. 
AI die pasiente het positief getoets vir subtipe C, wat ooreenstem met die 
demografiese data. Min mutasies is opgespoor in die trutranskriptase 
leesraam, alhoewel een mutasie (K103N), wat aanduidend is van 'n hoe vlak 
van weerstandigheid teen nie-nukleosied trutranskriptase inhibeerders in een 
isolaat gevind is. Dit mag beteken dat 'n klein persentasie van pasiente 'n 
virus huisves wat van nature weerstandig is teen hierdie middels. In die 
protease leesraam word mutasies by nege aminosuur posisies aangedui as 
primere of hoof weerstands-mutasies. Nie een van die primere mutasies is 
.· 
gevind nie, alhoewel verskeie sekondere mutasies (van mindere belang) wat 
bydra tot verminderde vatbaarheid (bv. M361 en 193L) in 95% van ons 
monsters gevind is. Dit was nie onverwags nie aangesien hierdie 
polimorfismes uiters algemeen in subtipe C virusse voorkom. Hierdie 
genetiese verskille mag klinies betekenisvol wees wanneer langtermyn 
strategiee in ag geneem word vir pasiente wat ge·infekteer is deur nie-8 
subtipes. 
Soos wat die publieke sektor se antiretrovirale program momentum opbou, is 
die verskyning van middel-weerstandige isolate onvermydelik en sal 
laboratoriums gerat moet wees om die nodige ondersteuning aan geneeshere 
te verskaf rakende terapie. Hierdie projek het bygedra tot die basislyn kennis 
van die geinfekteerde populasie wat ons in staat stel om verwagte 
weerstandbiedende mutasies te antisipeer. 
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The development of viral resistance to antiretroviral drugs used for treatment of 
human immunodeficiency virus (HIV) infections is an important cause of 
treatment failure (Saag et a/., 1993; Kozal et a/., 1994; Richman et a/., 1994; 
D'Aquila et a/., 1995; Schuurman et a/., 1995; Havlir et a/., 1996) and limits 
options for alternative antiretroviral regimens. Prevention, characterization and 
clinical management of such resistance are receiving increasing attention. 
The virus population in a person infected with an RNA virus (e.g., 
HIV-1, hepatitis C virus) has been termed quasi species (Eigen, 1993), which 
refers to the existence of genetically distinct viral variants that evolve from the 
initial virus inoculum. The variants are generated because DNA proofreading 
mechanisms that preserve the genetic composition of organisms with double-
stranded DNA genomes do not exist for RNA viruses. Thus as single-stranded 
RNA viruses replicate, each newly copied genome differs from the parental virus 
on average by a single nucleotide (Drake, 1993; Mansky & Temin, 1995). Viral 
polymorphisms (genetic variants with apparently equivalent fitness [replication 
capacity]) are commonly seen in virus populations in infected persons. 
Nucleotide differences may be "neutral", be deleterious, or confer replicative 
advantage if selective pressures such as immune responses or drug treatments 
change. These possibilities illustrate the survival strategy of organisms with high 
mutation rates that provides a large pool of genetic variants able to adapt rapidly 
to changing selective pressures (Coffin, 1996; Leigh Brown & Richman, 1997). 
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An estimated 10 billion HIV-1 virions are produced daily in established HIV 
infection (Perelson eta/., 1996). If each contains on average 1 mutation per 
9200-nucleotide genome, replication-competent virus with every possible single 
drug-resistance mutation is likely to be generated daily. Double mutants are less 
likely, and the probability of 3 or more drug-resistant mutations in the same 
genome is very low (Perelson eta/., 1996). These estimates are supported by 
observations in infected persons. Virus or HIV-1 RNA with single drug-resistance 
mutations have been isolated from treatment-na'ive patients or those infected 
before antiretroviral drug availability (Najera et a/., 1994; Najera et a/., 1995; 
Wong eta/., 1997). Mathematical modelling of the rate of resistance emergence 
after nevirapine treatment in previously untreated persons permits estimates of 
plasma prevalence of HIV-1 variants with nevirapine-resistance mutations before 
treatment. About 1 in 1000 copies/ml of plasma HIV-1 RNA contains the 
tyrosine-to-cysteine mutation at amino acid residue 181 of the reverse 
transcriptase conferring nevirapine resistance (Havlir eta/., 1996). 
When antiviral drug selective pressure is applied to viral quasi species in an 
infected person, pre-existing minor viral species resistant to that drug rapidly 
become predominant and are selected as the most fit species in the presence of 
the drug. For some antiretroviral drugs, such as lamivudine and certain non-
nucleoside reverse transcriptase inhibitors (NNRTis), a single mutation can 
confer high-level resistance. When these drugs are given in combinations only 
partially suppressing virus replication, drug-resistant mutants predominate within 
weeks (Havlir eta/., 1996; Wei eta/., 1995; Van Leeuwen et a/., 1995). For 
some other drugs, such as zidovudine and certain protease inhibitors, high-level 
resistance requires the accumulation of 3 or more mutations in a single viral 
genome (Larder & Kemp, 1989; Condra et a/., 1995; Moll a et a/., 1996). These 
highly resistant variants emerge more slowly, requiring months to predominate 
during less than maximum viral suppression (Condra eta/. , 1995; Molla eta/., 
1996; Larder eta/. , 1989; Richmann eta/. , 1991 ), supporting the prediction that 
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genetic variants with multiple mutations are present at much lower levels than 
those with single mutations in untreated patients. Development of high-level 
resistance to these drugs requires viral replication and selective drug pressure. 
Persistent viral replication permits further viral evolution leading to drug 
resistance by cumulative mutation acquisition. 
Assuming a high degree of adherence and adequate drug absorption, the 
settings in which resistance testing is likely to prove helpful are (1) early after 
therapy initiation if only a minimal plasma HIV RNA decline occurs over the first 4 
to 12 weeks, suggesting sub-optimal treatment response; (2) during early 
virologic breakthrough; (3) during more prolonged virologic replication in which 
more extensive resistance might be suspected; and (4) prior to therapy to provide 
a baseline for longitudinal testing, likely to become a more common component 
of patient monitoring. Therefore, to conclude, emerging data indicate that, 
despite limitations, resistance testing should be incorporated into patient 
management in some settings. Resistance testing is recommended to help 
guide the choice of new regimens after treatment failure and for guiding therapy 
for pregnant women. It should be considered in treatment-narve patients with 
established infection, but cannot be firmly recommended in this setting. Testing 
should also be considered prior to initiating therapy in patients with acute HIV 
infection, although therapy should not be delayed pending the results. 
The scale of the HIV/AIDS epidemic in South Africa needs no further explanation. 
The patients fall into two treatment categories, namely state and private. At the 
moment only a limited amount of antiretroviral treatment is being done in the 
state sector, where treatment is restricted to general immune system boosting 
and symptomatic treatment. In the private sector, however, anti-retrovirals are 
being prescribed on a par with the developed world. Antiretrovirals do prolong 
the lifespan of AIDS patients, but they do have several disadvantages. The cost 
of the medication is very high, and there are sometimes side-effects. The most 
worrying problem, however, is that of resistance to the drugs. In resistant cases, 
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viral loads creep up after being low for anything from one to five years, indicating 
impending relapse into full-blown AIDS. The resistance develops due to 
mutations that accumulate in the viral genes coding for the reverse transcriptase 
and the protease. The type of mutation can be correlated with a specific drug as 
each drug has a series of mutations conferring resistance to it. There are several 
ways of determining these mutations, but these have all been developed in 
Europe or North America and are specific for the virus strains occurring there. It 
needs to be established whether these assays will work reliably with the strains 
common in South Africa. 
Having access to both treated and untreated patients puts us in an ideal situation 
to study the phenomenon of drug resistance. Therefore, the main objective of 
this study was to optimise and implement a method for the detection of all 
variants of the HIV-1 virus. In the cohort of untreated patients the naturally 
occurring variants of the virus, which could yield information of possible existing 
resistance against drugs, was established. In the process, previously-published 
methods for viral RNA isolation, RT-PCR and sequencing were evaluated, but 
the final decision was to use a commercial assay because of superior sensitivity 
and quality of sequence. 
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2.1 HISTORICAL OVERVIEW 
In 1981 the Centres for Disease Control (CDC) began to receive reports of 
an increasing incidence of two previously very rare conditions. One was a 
form of pneumonia caused by Pneumocystis carinii and the other a very 
unusual skin cancer named Karposi's sarcoma (Muesing et a/. , 1985). 
Some patients were afflicted by both conditions. It was determined that 
the immune system of these patients was impaired, and in 1982 the CDC 
recognised a new disease called acquired immune deficiency syndrome 
(AIDS) . Unlike any other infectious disease in modern medical history, 
AIDS has galvanised the concern and efforts of physicians, scientists, and 
the lay public alike. The magnitude of the mounting AIDS problem is 
indeed sobering. It became clear that an infectious agent was involved 
and that transmission of the disease required the transfer of bodily fluids 
(sexual contact, exposure to infected blood or blood products, and 
perinatal transmission from mother to child) from an infected to an 
uninfected individual (Greene, 1991 ). 
Thus while AIDS is primarily a sexually transmitted disease, some people 
who had received blood transfusions or blood products such as Factor 
VIII, used in the treatment of haemophilia, were also affected. Blood 
supplies are now protected, but intravenous drug users who share 
needles remain a major risk group (Levine, 1985). It was in 1983, only 2 
years after the appearance of the previously unknown disease, that the 
causative agent of AIDS was isolated. It was found to be a human 
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retrovirus that was later named human immunodeficiency virus (HIV-1). 
Subsequently a second virus, HIV-2, was discovered in Africa, therefore it 
became a catastrophic epidemic that no country, and no group of 
individuals, has escaped (Levy eta/., 1985). 
Acquired immune deficiency syndrome (AIDS) ranks as one of the most 
important infectious diseases. Since its identification more than two 
decades ago, the AIDS epidemic has resulted in a total of 21.8 million 
deaths, including the deaths of 4.3 million children (UNAIDSIWHO, 2000). 
Thirty-six million people are currently living with the human 
immunodeficiency virus (HIV) and 5.3 million people were infected with 
HIV in 2000 alone. Clearly, AIDS represents an international health crisis 
that threatens to overwhelm even the best systems of health care delivery. 
The rational design and development of drug therapies to control the virus 
and the preparation of an effective vaccine to prevent infection represent 
public health goals of the highest priority. However, substantial progress 
in these areas will probably hinge on achieving a more complex 
understanding, in molecular and biochemical terms, of this pathogenic 
retrovirus and the nature of its cytopathic interplay with its cellular host. 
2.2 IS HUMAN IMMUNODEFICIENCY VIRUS THE CAUSE OF AIDS? 
Is there any evidence that can prove that AIDS is caused by the Human 
Immunodeficiency Virus? HIV was identified as the causative agent for 
AIDS in 1983 (Barre-Sinnoussi eta/., 1983; Gallo eta/., 1984). The most 
straightforward evidence is that HIV can be isolated from almost all 
patients with AIDS, and that patients with more advanced disease have 
higher amounts of the virus present. Also, antibodies to HIV are found in 
asymptomatic individuals who later go on to develop full-blown AIDS. 
Furthermore, recipients of blood contaminated with HIV will subsequently 
develop AIDS, even if they do not have any of the other risk factors 
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associated with AIDS. Similarly, medical and laboratory staff with needle 
stick injuries involving HIV-infected blood has developed AIDS. About 
thirty percent of HIV-infected mothers transmit the virus to their unborn 
children, who subsequently develop AIDS. The uninfected siblings of 
these children do not develop AIDS. Thus, the common link between 
AIDS-affected individuals in very different social groups is the presence of 
HIV. Although the principal modes of transmission of HIV differ in different 
populations, epidemiological data currently show an absolute correlation 
between HIV infection and the subsequent development of AIDS; AIDS 
does not appear in a new location without evidence of prior HIV infection. 
Epidemiological studies and attempts to predict the course of the epidemic 
are difficult because of the interval -up to 8 to 10 years- between infection 
with HIV and the development of AIDS. Indeed, it is not yet certain that all 
individuals infected with HIV will go on to develop AIDS. It is clear, 
however, that there is a very high mortality among individuals who develop 
AIDS. 
2.3 HIV SUBTYPES 
Like the epidemic, the viruses responsible for AIDS have proven to be 
more complicated and much more unpredictable than initially thought. 
The AIDS viruses are members of the lentivirus family of retroviruses and 
have been demonstrated to exhibit remarkable properties of insidious 
disease induction, persistence, latency, variation, recombination, and 
escape from immune and drug pressures. 
There are two distinct types of HIV namely, HIV-1 and HIV-2. These two 
types are distinguished on the basis of their genome organisation and 
phylogenetic relationships with other primate lentiviruses. Both have been 
further sub-classified on the basis of phylogenetic criteria. HIV-1 consists 
of three distinct virus groups, which have been termed groups M (main), 0 
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(outlier) and N (non-M, non-0). The predominant HIV-1 group M 
comprises 11 clades denoted subtypes (A to K). The other type of HIV is 
HIV-2 and comprises 6 distinct phylogenetic lineages, subtypes (A to F) 
(Hahn eta/., 2000). The elucidation of the simian origins of AIDS as well 
as circumstances and factors contributing to the initiation of the epidemic 
was achieved by the reconstruction of the phylogenetic relationships 
among the many strains of HIV-1 and HIV-2, as well as related viruses 
from African primates. 
Current evidence indicates that the SIV counterparts of HIV-1 and HIV-2 
were introduced into the human population at least seven times or more 
(Gao et a/., 1999; Chen et a/., 1997). However, the HIV-1 group M 
viruses, which are responsible for the great majority of all HIV infections 
worldwide, appear to have arisen from just one such cross-species 
transmission event. The human race is not the natural host of either the 
HIV-1 or HIV-2 types. These two types of HIV have entered the human 
population as a result of cross-species transmission from chimpanzees 
(Gao eta/., 1999) and sooty mangabeys (Hirsch eta/., 1989; Gao eta/. , 
1992), respectively. 
The initial epicentres of HIV both HIV-1 and HIV-2 infection appeared to 
be Central Africa and West Africa, with HIV-2 primarily in West Africa. 
HIV-1, on the other hand, spread globally. Direct human contact with 
infected simian blood probably resulted in the cross-species transmission 
of SIV to humans, and social, economic and behavioural changes that 
occurred in the early- and mid-20th century provided the circumstances 
whereby these viruses could expand and reach epidemic proportions (Gao 
eta/., 1999; Hahn eta/., 2000; Kober eta/. , 2000). 
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2.4 THE HIV-1 VIRION STRUCTURE 
The HIV-1 virion is an icosahedral structure, (Gelderblom et a/., 1987) 
containing 72 external spikes and is about 110 nm in diameter (Figure 
2.4.1). Two major viral-envelope proteins, gp120 and gp41 form the 
spikes. The HIV-1 lipid bilayer is studded with various host proteins, 
including Class I and Class II histocompatibility antigens, obtained during 
virion budding. Four nucleocapsid proteins, p24, p17, p9, and p7 are 
contained in the core of HIV-1, each of which is proteolytically cleaved 
from a 53-kd Gag precursor by the HIV-1 protease. The main component 
of the inner shelf of the nucleocapsid is formed by the phosphorylated p24 
polypeptide (Figure 2.4.1), whereas the myristoylated p17 protein is 
associated with the inner surface of the lipid bilayer and probably 
stabilises the exterior and interior components of the virion. The p7 
protein binds directly to the genomic RNA through a zinc-finger structural 
motif and, together with p9, forms the nucleoid core. Importantly, this 
retroviral core also contains two copies of the single-stranded HIV-1 
genomic RNA that is associated with the various pre-formed viral 
enzymes, including the reverse transcriptase, integrase, and protease 
(Coffin, 1995; Parren eta/., 1999; Turner and Summers, 1999). 
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2.5 THE HIV-1 GENOME STRUCTURE 
Nine open reading frames are contained within the HIV-1 genome (Figure 
2.5.1 ). Three of these reading frames encode the Gag, Pol and Env 
polyproteins, which are subsequently proteolysed into individual proteins, 
a process very common to all the retroviruses. The core of the virion and 
the outer membrane envelope are made up of the structural components 
which include the four Gag proteins MA (matrix), CA (capsid), NC 
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(nucleocapsid), and p6, and the two Env proteins, SU (surface or gp120) 
and TM (transmembrane or gp41 ). The three Pol proteins include the PR 
(protease), RT (reverse transcriptase) and IN (integrase) and are 
encapsulated within the particle and have essential enzymatic functions. 
HIV-1 also encodes six additional proteins, often called the accessory 
proteins. Three of these proteins (Vif, Vpr, and Nef) are found within the 
viral particle. The two other accessory proteins, Tat and Rev, provide 
essential gene regulatory functions, and the last protein, namely Vpu, 
indirectly assists in the assembly of the virion. The HIV-1 genome is 
encoded by a - 9-kb RNA, and two genomic-length RNA molecules are 
packaged in the particle (Turner and Summers, 1999). 
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2.6 THE ENVELOPE PROTEINS 
2.6.1 TM (gp41) 
TM is a 345-amino acid protein located in the viral membrane 
(Figure 2.5.1) and its primary function is to mediate the fusion 
between the viral and cellular membranes following receptor 
binding. It has been predicted that the fusion is initiated by an N-
terminal hydrophobic glycine-rich "fusion peptide" and the trans-
membrane region is important for both fusion and for anchoring of 
Env in the viral membrane. Two crystal structures of the core 
region (TMcore) have been identified (Chan et a/., 1997; 
Weissenhorn et a/., 1997). In the larger of the two structures 
(Figure 2.6.1 ) , residues 30-79 and 113-154 of TM were fused to a 
31-residue trimeric coiled-coil from GCN4 in place of the N-terminal 
fusion peptide (Weissenhorn et a/., 1997). The TMcore lacks 
residues 80-112 of TM. 
Figure 2.6.1 
Helix packing of the trimeric coiled-coil structure of the HIV-1 
TM ectodomain. 
N-and C- terminal helices are coloured blue and purple, respectively. Viewed from top (left) and side 
(right). 
(adapted from Chan et at., 1997) 
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TMcore forms a trimer that consists of a parallel a.-helical coiled-coil 
(residues 1-77) and an outer antiparallel a.-helical layer (residues 
117-154) (Weissenhorn eta/., 1997). The structure of the TMcore 
represents a structure formed during the fusion reaction, as 
suggested by the following. First, mutations at the interface 
between the outer and the central helical layers (including lle62) 
specifically block membrane fusion. Secondly, the TMcore is 
extremely thermostable, a feature predicted for the fusion-active 
protein and not the native protein (Chan eta/. , 1997; Weissenhorn 
eta/., 1997). Thirdly, the structures of the TMcore and a low pH 
fusion-active form of the influenza virus HA2 protein are strikingly 
similar (Chan eta/., 1997; Weissenhorn eta/., 1997). Fourthly, the 
18 C-terminal extracellular residues missing from the structure 
cannot span the estimated distance between the C-terminus of 
TMcore and the viral lipid. However, the distance is consistent with a 
conformation in which the fusion peptides and the transmembrane 
regions are located at the same end of the central rod structure 
when viral and cell membranes are brought together (Weissenhorn 
et a/., 1997). The structure helps to explain how two peptides 
known to inhibit fusion may act. A peptide from the C-terminus may 
bind to the central trimer, disrupting the structure of the N-terminal 
region, whereas a peptide from theN-terminus may either compete 
with folding of the central trimer or bind to the C-terminal region and 
prevent association with the central core (Chan et a/., 1997; 
Weissenhorn eta/., 1997). Emerging rules for the design of coiled-
coils may aid in the development of new fusion inhibitors. 
2.6.2 su (gp120) 
Viral entry is initiated by binding of the SU glycoprotein, located on 
the viral membrane surface, to specific cell surface receptors. CD4 
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is the major receptor for HIV-1 and is an immunoglobulin (lg)-like 
protein expressed on the surface of a subset of T cells and primary 
macrophages. The 515-residue SU protein binds CD4 with high 
affinity (Kd-4 nM). Amino acids important for binding have been 
primarily mapped to four separate conserved regions of SU and to 
the C'-C" ridge of CD4, which protrudes from the first lg-like 
extracellular domain (luciw, 1996). The structural details of the 
interactions are not yet known. 
The SU-CD4 interaction is not sufficient for HIV-1 entry. Therefore, 
a group of chemokine receptors (a family of seven transmembrane 
G-coupled proteins) that mobilise intracellular calcium and induce 
leukocyte chemotaxis, serve as essential viral co-receptors 
(Clapham & Weiss, 1997). HIV-1 is divided into two major classes: 
those that are macrophage (M)-tropic and non-syncytium inducing 
(NSI) and those that are T-cell (T)-tropic and syncytium inducing 
(SI). CXCR4/Fusin was the first core-receptor identified; it permits 
entry of T-tropic but not M-tropic viruses. CCR5 is a major co-
receptor for M-tropic but not T -tropic viruses. Other molecules, 
including CCR3, CCR2b, Bonzo/STRL33 and BOB/GPR15, serve 
as co-receptors for some HIV-1 isolates (Clapham & Weiss, 1997). 
The physiological ligands for CXCR4, CCR5, and CCR3 (SDF-1, 
RANTES/MIP-1 a/MIP-1p, and eotaxin, respectively) are each able 
to inhibit viral entry by competing with the cognate co-receptor 
(Bieul eta/., 1996; Oberlin eta/. , 1996; Choe eta/., 1996; Clapham, 
1997). Some ligand derivatives have been described that block 
infection without activating chemokine signalling pathways and may 
represent a novel class of HIV-1 therapeutics (Clapham, 1997). 
Binding of CD4 to SU appears to cause structural changes in Env 
that facilitate co-receptor binding and subsequent viral entry 
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(Clapham, 1997). The variable V3 loop of SU is an important 
determinant of viral tropism. It becomes exposed upon CD4 
binding and presumably interacts with the cognate co-receptor 
(Figure 2.6.2) (Clapham, 1997). However, the V3 loop is probably 
not the sole determinant of co-receptor specificity, because HIV-1 
isolates that use the same co-receptor can have highly variable V3 
sequences (Choe eta/. , 1996; Cocchi eta/. , 1996; Oravecz eta/., 
1996). Determinants for virus specificity are located in each of the 
extracellular regions of the co-receptors, and the signalling 
functions of these receptors are apparently not important for viral 
infection (Clapham, 1997). 
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2.7 THE STRUCTURAL PROTEINS 
2.7.1 Matrix (MA) 
The matrix is the terminal component of the Gag polyprotein and is 
important for targeting Gag and Gag-Pol precursor polyproteins to 
the plasma membrane prior to viral assembly. In a mature viral 
particle, the 132-residue MA protein lines the inner surface of the 
virion membrane. 
There are two distinct features that play an important role in 
membrane targeting: an N-terminal myristoyl group and basic 
residues located within the first 50 amino acids (Figure 2.7.1). The 
crystal structure of residues 1 through 104 (Hill et at., 1996) shows 
five a.-helices capped by a three-stranded mixed ~-sheet, with three 
monomers arranged like a triskelion. The trimeric form is of 
biological relevance because mutation of residues involved in 
trimerisation (residues 42-77) abolishes viral assembly, and 
because basic residues important for membrane localisation 
(lysines 26, 27, 30, 32) are arranged on the putative membrane-
binding surface of the trimer. The MA structure suggests an 
obvious model for membrane binding that involves the insertion of 
three myristoyl groups into the lipid bilayer located directly above 
the trimer and interactions between basic residues of the 
membrane-binding surface and phospholipid head groups 
(Figure 2.7.1). 
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Figure 2.7.1 
Model of the trimeric HIV-1 matrix protein interacting 
with a lipid membrane 
Essential and non-essential basic residues are coloured magenta and green, 
respectively, and the N-terminal myristoyl groups are drawn in red 
(adapted from Hill et a/., 1996) 
17 
The N-terminal basic region is not strictly required for the formation 
of virus particles because non-infectious virus particles that lack MA 
can be produced if a myristoyl group is placed directly upstream of 
the capsid reading frame (Lee eta/., 1994). In addition to targeting 
Gag and Gag-Pol to the membrane, MA also appears to help 
incorporate Env glycoproteins with long cytoplasmic tails into viral 
particles (Freed eta/., 1995; Mammano eta!., 1995). The array of 
threefold symmetric holes located between the matrix trimers 
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appears to be large enough to accommodate the long cytoplasmic 
tails of full-length Env (Hill eta/., 1996; Massiah eta/., 1996). 
In addition to the matrix function in viral assembly, MA facilitates 
infection of non-dividing cell types, principally macrophages. Some 
studies have shown that a subset of phosphorylated MA proteins 
are associated with viral pre-integration complexes and that MA 
contains a nuclear localisation signal (NLS) that interacts with 
Rch1, a member of the karyopherin-a family, to facilitate rapid 
nuclear transport (Gallay et a/., 1995b; Bukrinsky et a/. , 1993; 
Bukrinskaya eta/., 1996; Gallay eta/., 1996). Phosphorylation of 
Tyr131 was shown to mediate association with IN, thereby linking 
MA to the pre-integration complex (Gallay et a/., 1995a; Trono and 
Gallay, 1997). Other studies, however, have found no evidence for 
an MA NLS and suggest that phosphorylation of Tyr131 is not 
important for macrophage infection (Freed eta/. , 1995; Bukrinskaya 
eta/., 1996; Freed eta/., 1997). Instead, mutation of the putative 
MA NLS in a macrophage-tropic HIV-1 isolate decreased infectivity 
in both non-dividing and dividing cells and resulted in delayed 
proteolytic processing of the Gag polyprotein, presumably because 
the mutations affect association of MA with the membrane 
(Fouchier et a/., 1997). Additional studies are needed to clarify the 
role of MAin infection of non-dividing cells. 
2.7.2 Capsid CCA) 
The second component of the Gag polyprotein is the capsid (CA) 
which forms the core of the virus particle, with approximately 2000 
molecules per virion (Figure 2.7.2). The C-terminal domain 
(residues 152-231) functions primarily in assembly and is important 
for CA dimerisation and Gag oligomerisation (Gamble eta/., 1997). 
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appears to be large enough to accommodate the long cytoplasmic 
tails of full-length Env (Hill eta/., 1996; Massiah et a/. , 1996). 
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Mutations in theN-terminal domain (residues 1-151) do not prevent 
assembly or budding. The domain is important for infectivity, 
apparently by participating in viral coating through its association 
with a putative cellular chaperone, cyclophilin A (CypA) 
(Figure 2.7.2). 
The C-terminal domain is composed of an extended strand followed 
by four a-helices, with an extensive dimer interface (Gamble eta/., 
1997). The major homology region (MHR), a 20-amino acid 
sequence that is one of the most highly conserved within all 
retroviral Gag proteins, adopts a compact fold in which the four 
most conserved r~sidues (Gin155, Gly156, Glu159, and Arg167) 
form a stabilising hydrogen-bonding network. Additional 
hydrophobic residues from the MHR contribute to the hydrophobic 
core. The MHR is essential for particle assembly and may have a 
role in incorporation of Gag-Pol precursors through interactions with 
Gag (Srinivasakumar eta/., 1995), though not all mutants show this 
phenotype (Mammano et a/., 1994). Biochemical experiments have 
also revealed a possible role for the MHR in membrane affinity, 
perhaps reflecting exposure of hydrophobic residues (Ebbets-Reed 
eta/., 1996). 
The structures of two dimeric forms of the N-terminal domain, one 
complexed to an antibody fragment and the other complexed to 
CypA, show the same monomeric CA structure but different subunit 
interfaces (Gamble eta/. , 1996; Momany eta/., 1996). The CA-CA 
interfaces observed in the CypA complex are blocked in the 
antibody complex, but given that the C-terminal domain is largely 
responsible for dimerisation (the N-terminal domain is monomeric 
at mM concentrations), it still remains to be determined whether the 
observed N-terminal domain interfaces represent true subunit 
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interactions. The CA subunits are also seen to arrange in strips 
within a crystal, consistent with a plausible packing arrangement in 
the virion core (Gamble eta/. , 1996). Residues from an extended 
region of CA interact with CypA, with Ala88, Gly89, and Pro90 
buried in the CypA active site groove. A short spacer peptide 
located between CA and NC-p2-may also influence CypA 
incorporation into the virion (Dorfman and Gottlinger, 1996). 
Figure 2.7.2 
Model of the dimeric HIV-1 capsid protein, constructed from 
the independently characterised N-terminal core (purple) and 
C-terminal oligomerisation (cyan) domains. 
The residues that link the domains are disordered in the X-ray and NMR structures of the isolated 
domains, and could allow ca.90° re-orientations of the N-terminal domains in the intact protein 
(adapted from Gamble eta/., 1997) 
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2.7.3 Nucleocapsid (NC) 
The third component of the Gag polyprotein that coats the genomic 
RNA inside the virion core is called the nucleocapsid. The main 
function of the NC is to bind specifically to the packaging signal and 
to deliver full-length viral RNAs into the assembling virion. The 
packaging signal on the RNA, If/, is not completely defined but is 
probably composed of three hairpins located around the major 
splice donor site (Clever and Parslow, 1997; Laughrea eta/. , 1997}, 
the first of which contains the "kissing loop" involved in RNA 
dimerisation (Figure 2.7.3). Studies with a chimeric Gag containing 
NC from HIV-1 and the remainder of Gag from Moloney murine 
leukemia virus (Mo-MLV}, demonstrated that genomic HIV-1 RNA 
is preferentially packaged but that additional downstream 
sequences, which result in packaging of spliced RNAs, may 
contribute (Berkowitz et a/., 1995). The nucleocapsid is a basic 
protein that functions by means of binding single-stranded nucleic 
acids non-specifically, leading to coating of the genomic RNA, 
which presumably protects it from nucleases and compacts it within 
the core. The non-specific binding also results in a chaperone-like 
function that enhances ott'ler nucleic-acid-dependent steps in the 
life cycle, for example, by promoting annealing of the tRNA primer; 
melting of RNA secondary structures; DNA strand exchange 
reactions during reverse transcription (Huang eta/., 1997a; Guo et 
a/., 1997; Cameron et a/., 1997), or by stimulating integration 
(Carteau eta/. , 1997). 
The nucleocapsid is 55 residues long and consists of two zinc 
finger domains (of the CCHC type) and is flanked by basic amino 
acids. There are certain requirements for the NC-Ifl interaction for it 
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requires intact fingers as well as several basic amino acids 
(Figure 2.7.3; Schmalzbauer et at., 1996; Poon et at., 1996). 
The structure of the nucleocapsid has been determined by NMR 
(Summers et at., 1992; Morellet et at., 1992) and shows two well-
ordered zinc domains with a relatively flexible linker in the absence 
of RNA. The basic residues that seem to be of particular 
importance for in vitro binding (Arg?, Arg32, and Lys33) and viral 
replication (Lys11 and Lys14) are indicated, though mutation of 
Arg32 or Lys33 seems to have little or no effect on RNA packaging 
in vivo (Poon et at., 1996). Removal of zinc from the NC domains 
with disulphide-substituted benzamide inhibits viral replication (Rice 
et at., 1995), providing additional evidence of the importance of 
these structures. 
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Figure 2.7.3 
Structure of the complex formed between the HIV-1 nucleocapsid 
protein and the SL3 stem-loop recognition element of the genomic lfi-
RNA packaging signal. 
The colouring scheme of the tetraloop bases is as follows: G6, green; G7, pink; A8, blue; G9, orange. The 
colouring scheme for the Ncprotein is: N-terminal 310 helix, pink; N-terminal zinc knuckle, cyan; linker, red ; C-
terminal zinc knuckle, green ; cysteine and histidine side-chains, yellow and cyan, respective ly. 
(adapted from Turner & Summers, 1999) 
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2.7.4 p6 
p6 is important for the incorporation of Vpr during viral assembly 
and comprises the C-terminal 51 amino acids of Gag. Residues 
32-39 and three hydrophobic residues within a conserved 
sequence motif (Leu41-X42-Ser43-Leu44-Phe45-Giy46) are 
important for Vpr binding (Kondo and Gottlinger, 1996; Lu et at., 
1995). P6 also helps to mediate efficient particle release and a 
region of four amino acids (Pro 7-Thr8-Aia9-Pro1 0) has been 
implicated in this function (Huang eta/., 1995). 
2.8 ACCESSORY PROTEINS 
2.8.1 Nef 
Nef is a 206-amino acid, N-terminally myristoylated protein that, like 
Vpu, reduces the level of cellular CD4. The routing of CD4 from the 
cell surface and golgi apparatus to the lysosomes is facilitated by 
Net, resulting in receptor degradation and the prevention of 
inappropriate interactions with Env as well as Vpu. In the 
cytoplasmic tail of CD4 a dileucine-based sorting signal is located 
that is essential for Net-mediated down-regulation and is presumed 
to interact with Nef. Nef has been proposed to serve as a direct 
bridge between CD4 and the cellular endocytic machinery by 
interacting with p-COP and adpatins, which link proteins in the golgi 
apparatus and the plasma membrane to clathrin-coated pits. Net 
may enhance Env incorporation into virions, promote particle 
release, and possibly affect CD4.,. T -cell signalling pathways by 
down-regulating CD4. 
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Net can also down-regulate the expression of the MHC class I 
molecules, which may help in protecting infected cells from killing 
by cytotoxic T cells. Decreased rates of viral DNA synthesis 
following infection can also be attributed to a Net mutant virus. This 
defect can be overcome if Net is supplied in trans in virus-
producing cells but not in target cells, suggesting possible roles in 
virus assembly, maturation or entry. These roles are consistent 
with the observation that -70 Net molecules are incorporated in 
each virion. These virion-associated proteins are cleaved by PR at 
residue 57 to generate a soluble C-terminal fragment. The 
mechanism of Net incorporation has not yet been defined but is 
probably relatively non-specific, because Net can also be 
incorporated into Mo-MLV particles (Bukovsky et a/., 1997). Net 
contains a consensus SH3 domain binding sequence (PXXP) that 
mediates the binding to several Src-family proteins (e.g. Src, Lyn, 
Hck, Lck, Fyn), thereby regulating their tyrosine kinase activities 
(Figure 2.8.1) (Moarefi et a/., 1997). These interactions appear to 
be important for enhancing viral infectivity but not for down-
regulating CD4. It is not yet clear which SH3-containing proteins 
are relevant for Net function. The crystal structure of a Nef-SH3 
complex (Figure 2.8.1) shows that the PXXP motif is in a left-
handed polyproline type II helix that interacts directly with the SH3 
domain (Lee et a/., 1996). Two residues that define the motif, 
Pro72 and Pro75, are important for enhancing viral replication and 
pack against hydrophobic residues of the SH3 domain (Lee eta/., 
1996). The central core of Nef comprises two anti parallel a-helices 
packed against a layer of four anti parallel ~ stands (Fig 2.8.1) (Lee 
et a/., 1996). A hydrophobic crevice, which is presumably a ligand-
binding site, is located between the two helices and is close to Arg 
110. Arg110 has been defined as an important residue for 
association with NAK, a Net-associated serine/threonine kinase 
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related to a p21 kinase (PAK) (Sawai et a/., 1997). PAKs are 
known to bind the p21 Rho-like GTP-binding proteins Rac-1 and 
CDC42hs, suggesting possible mechanisms by which Net can 
interfere with both endocytosis and T-cell signalling (Cullen, 1996). 
However, mutations that disrupt the Nef-NAK complex do not affect 
Net-mediated CD4 down-regulation (Benichou et a/. , 1997). Net 
has also been reported to bind other cellular proteins, including 
p53, MAP kinase, and Tease-11 (Benichou et a/. , 1997), but the 
significance of these interactions remains to be determined. 
Figure 2.8.1 
Stereo-view of the HIV-1 Nef core domain 
Residues 71-120; N- and C-terminal residues in yellow and green respectively; the broken line 
represents a disordered loop bound to the Fyn(R961) SH3 domain, blue. Side-chains are drawn for 
the critical trytophan and isoleucine residues, red; of the SH3 domain and the polyproline helix of Nef 
(adapted from Turner and Summers, 1999) 
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2.8.2 Rev 
The early stages of the HIV-1 replication cycle are marked by the 
exclusive expression of the fully spliced mRNA species that encode 
the viral regulatory proteins Tat, Rev and Nef. Later, when other 
viral components are needed to assemble infectious virions, singly 
spliced and unspliced transcripts are transported to the cytoplasm, 
where they are translated and where genomic RNAs are packaged. 
Therefore, Rev is very important in this switch because it functions 
to overcome the default pathway in which mRNAs are spliced prior 
to nuclear export and further functions in the binding to the RRE 
site located in the env coding region (Figure 2.8.2). Whether Rev 
directly enhances the export of unspliced mRNAs or inhibits 
splicing has been unclear. but recent studies have revealed a 
strong tendency towards a role in export (Hope, 1997). Xenopus 
oocyte micro-injection experiments revealed that Rev is required to 
export unspliced RNAs that contain an RRE (Fischer eta/., 1995). 
Rev contains a leucine-rich nuclear export signal (NES) that allows 
it to shuttle between the nucleus and the cytoplasm (Meyer and 
Malim, 1994) that interacts with a nucleoporin-like protein 
(hRip/Rab) located at the nuclear pore (Fritz eta/., 1995; Bogerd et 
a/., 1995; Stutz eta/., 1995). 
The interaction with hRip/Rab may be bridged by CRM1, a nuclear 
export receptor that is important for Rev export (Ullman et a/., 
1997). Therefore, it is believed that the binding of Rev to the RRE 
targets the attached mRNA to the nuclear export machinery. 
Evidence exists that entry into the splicing pathway may also be 
important for Rev function due to the fact that mutating 5' splice 
sites on RRE-containing mRNAs eliminates Rev activity but 
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compensatory mutations in U1 snRNA, which bind at 5' splice sites, 
can restore activity (Lu et a/., 1990). Therefore, Rev can also 
directly inhibit splicing by preventing entry of additional snRNPs 
during the later stages of spliceosome assembly (Kjems and Sharp, 
1993). 
The RRE consists of several hairpins that bind several Rev 
monomers, nucleated by the interaction of a single monomer with a 
high-affinity site called the hairpin liB (Zemmel et a/., 1996). The 
oligomeric binding function is very important for the functioning of 
the Rev protein, mainly because it increases the concentration of 
NES sites on a single mRNA. An arginine-rich domain is 
responsible for the mediation of binding and forms an a-helix and 
specifically recognises an internal loop in the liB stem. The internal 
loop contains G:G and G:A base pairs that widen an otherwise 
narrow major groove (Figure 2.8.2). The widened groove allows 
amino acids on the Rev a-helix to recognise specific features of the 
site, primarily through hydrogen bonds between three arginines and 
specific bases and phosphates and between Asn40 and the G:A 
pair. 
© Central University of Technology, Free State
Chapter 2 29 
Figure 2.8.2 
Space-filling representation of the Rev response element 
(RRE; grey) bound to the RNA-binding segment of Rev (green). 
The Rev peptide forms an a-helix that binds within a widened major groove. 
(adapted from Turner and Summers, 1999) 
2.8.3 Tat 
The HIV-1 promoter contains a number of regulatory elements 
important for RNA polymerase II transcription and is located in the 
5'L TR. There are several sites located upstream of the start site for 
various cellular transcription factors, including sites for NF-KB, Sp1 , 
and TBP (Jones and Peterlin, 1994). The function of these cellular 
factors is to help control the rate of transcription initiation from the 
integrated provirus. Their abundance in different cell types or at 
different times likely determines whether a provirus is quiescent or 
© Central University of Technology, Free State
Chapter 2 30 
actively replicating. Transcription complexes initiated at the HIV-1 
promoter are rather inefficient at elongation and require the viral 
protein Tat to enhance the process of transcribing by polymerases. 
Under certain conditions, Tat may also enhance the rate of the 
initiation of transcription. Tat is essential for viral replication for it 
increases the production of viral mRNAs -1 00-fold. It is not yet 
clear which features of the HIV-1 promoter cause initiating 
transcription complexes to be poorly possessive, but experiments in 
which the TATA box and downstream sequences have been 
interchanged with different promoters suggest an important role for 
these regions (Jones and Peterlin, 1994). When Tat is absent, the 
polymerase generally do not transcribe beyond a few hundred 
nucleotides, although they do not appear to terminate at specific 
sites. The mechanism of how Tat causes transcribing polymerases 
to become sufficiently possessive to completely transcribe the -9-
kb viral genome is still unknown, but experiments suggest that Tat 
may assemble into transcription complexes and recruit or activate 
factors that phosphorylate the RNA polymerase II C-terminal 
domain (CTD), including the general transcription factor TFIIH and 
other novel kinases (Zhou and Sharp, 1996; Parada and Roeder, 
1996; Yang eta/. , 1996; Garcia-Martinez eta/., 1997; Cujec eta/., 
1997; Jones,1997). All these findings support a model in which Tat 
enhances phosphorylation of the CTD, a process known to occur 
as RNA polymerase II converts from an initiating to an elongation 
enzyme. 
Tat does not bind to a DNA site but rather to an RNA hairpin known 
as TAR (trans-activating response element), located at the 5' end of 
the nascent viral transcripts. An arginine-rich domain of Tat is 
involved for it helps to mediate binding to a three-nucleotide bulge 
region of TAR, with one arginine residue being primarily 
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responsible for recognition. The TAR complexed to arginine 
(Puglisi et a/., 1992; Aboul-ela et a/., 1995) shows a base-specific 
contact between the arginine side chain and a guanine in the RNA 
major groove on NMR studies (Figure 2.8.3). The complex is 
stabilised by additional contacts to the phosphate backbone and by 
the formation of a U-A:U base triplet between a bulge nucleotide 
and a base pair above the bulge. NMR studies of the full-length 86-
amino acid Tat protein have suggested that a hydrophobic core 
region of about 10 amino acids adopts a defined structure, but that 
the rest of the molecule, including the arginine-rich RNA-binding 
domain, is relatively disordered (Bayer et a/., 1995). 
Figure 2.8.3 
Space-filling representation of the bovine immunodeficiency 
virus (BIV) Tat peptide bound to the BIV TAR RNA. 
As for the HIV-RRE, binding occurs in a widened major groove. However, the BIV Tat peptide binds 
in a ~-ha irpin conformation. 
(adapted from Turner and Summers, 1999) 
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There is a likelihood that Tat requires interaction with cellular 
proteins in addition to TAR to adopt a stable structure. Another 
protein is needed to bind to the loop of the TAR hairpin, apparently 
helping to stabilise the Tat-TAR interaction (Alonso et a/., 1994). 
Functional data suggest that the loop-binding proteins are encoded 
by human chromosome 12. Several candidates have been 
identified, but none have yet been definitely shown to be essential 
for Tat activity. 
2.8.4 Vpr 
After fusion and entry, the virus is "uncoated" in the cytoplasm and 
the nucleoprotein complexes are rapidly transported to the host cell 
nucleus, mediated by the 96-amino acid Vpr protein. The 
components of the transported complexes are not completely 
defined but certainly include RT, IN, and MA (Miller et a/. , 1997) 
and probably the genomic RNA and partially reverse-transcribed 
DNA. 
The major importance of Vpr is for nuclear localisation in non-
dividing cells, such as macrophages, because it contains an NLS 
that directs transport even in the absence of mitotic nuclear 
envelope breakdown (Cohen et a/., 1996). Vpr contains two 
important putative N-terminal amphipathic a-helices and not a 
canonical karyophilic NLS (Emerman, 1996). This unusual NLS 
localises Vpr to the nuclear pores rather than to the interior of the 
nucleus and does not use an importin-dependent pathway (Gallay 
et a/., 1996; Emerman, 1996). Vpr is incorporated into viral 
particles by means of interaction with p6 and may later become 
associated with the nucleoprotein complexes through an interaction 
with the C-terminal region of MA (Sato eta/., 1996). 
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Vpr can also induce G2 cell cycle arrest prior to nuclear envelope 
breakdown and chromosome condensation, and sustained 
expression can reportedly kill T cells by apoptosis (Emerman, 
1996). The Vpr will act before dephosphorylation of the p34cdc2 
cyclin-dependent kinase by CDC25, which is required to initiate 
mitosis (Emerman, 1996). However, the G2 arrest that takes place 
occurs with Vpr from proteins from different primate lentiviruses, but 
it is not known how the activity contributes to viral replication 
(Emerman, 1996). The amino acids that are important for G2 arrest 
are situated in the C-terminal region of the Vpr and cellular proteins 
have been identified that bind Vpr, including the 65-kDa regulatory 
subunit of protein phosphatase 2A (PP2A), a serine/threonine 
phosphatase that regulates the transition from G2 to mitosis 
(Emerman, 1996). Vpr does not only function in nuclear 
localisation and cell cycle arrest, but can also influence the 
mutation rate during viral DNA synthesis (Mansky, 1996) and has 
been proposed to form an ion channel (Lamb and Pinto, 1997). 
2.8.5 Vpu 
Newly synthesised Env glycoproteins (gp160), which are later 
cleaved into SU (gp120) and TM (gp41), are sometimes held in the 
endoplasmic reticulum through interactions with newly synthesised 
CD4 molecules. The function of Vpu is to promote the degradation 
of CD4 in these complexes, thus allowing Env transport to the cell 
surface for assembly into the viral particles. Vpu is an 81 -residue 
oligomeric integral membrane protein with an N-terminal 24-residue 
hydrophobic membrane-spanning domain and a C-terminal 
cytoplasmic tail (Cohen et a/., 1996; Lamb and Pinto, 1997). Amino 
acids important for receptor binding and degradation have been 
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mapped to the C-terminal region of Vpu and to putative a-helices in 
the cytoplasmic tail of CD4 (Tiganos et a/. , 1997). Co-
immunoprecipitation experiments revealed that Vpu associates with 
a wild-type CD4 or with recombinant proteins containing the CD4 
cytoplasmic tail, but it is not yet known if the interaction is direct or 
indirect (Sour et a/., 1995). Furthermore, these complexes are 
probably very relevant to CD4 degradation because there is a direct 
correlation between the extent of Vpu association and their relative 
levels of degradation (Sour eta/., 1995). 
Post-translational modification appears to regulate the effect of Vpu 
on CD4 degradation. Vpu is phosphorylated on Ser52 and Ser56 
by a casein kinase-2-related protein, and mutation of these 
positions decreases the levels of CD4 degradation (Cohen eta/., 
1996). The mechanism by which degradation occurs is not yet 
clear but it seems to involve the cytoplasmic proteasome, because 
Vpu-mediated degradation can be blocked by proteasome inhibitors 
such as lactacystin (Fujita et a/., 1997). Vpu can also down-
regulate cell surface expression of MHC class I proteins, which 
function in the protection of the infected cells from recognition and 
killing by cytotoxic T lymphocytes (Kerkau eta/., 1997). 
In spite of its role in CD4 degradation, Vpu can also stimulate virion 
release, and it has also been proposed to be an ion channel (Lamb 
and Pinto, 1997). In Vpu mutant viruses, significantly increased 
numbers of particles either remain associated with the cell surface 
or are localised to intracellular membranes (Cohen et a/. , 1996; 
Lamb and Pinto, 1997). In contrast to Vpu-mediated CD4 
degradation, its effect on particle release requires the hydrophobic 
N-terminal domain and is not influenced by serine phosphorylation 
(Cohen et a/., 1996; Lamb and Pinto, 1997). The mechanism 
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appears to be relatively non-specific in that Vpu can also promote 
the release of heterologous retroviral particles (Cohen et a/., 1996; 
Lamb and Pinto, 1997). 
2.8.6 Vif 
Vif is a 192-residue protein that is important for the production of 
highly infectious virions. All the Vif mutant viruses show a markedly 
reduced level of viral DNA synthesis and produce highly unstable 
replication intermediates (Cohen et a/., 1996; Simon and Malim, 
1996), suggesting that Vif functions before or during DNA 
synthesis. It is intriguing that Vif mutants show defects in infectivity 
only when produced in certain cell types, designated non-
permissive or semi-permissive, but not when produced in 
permissive cells. There is a possibility that permissive cells 
produce a factor or factors that compensate(s) for a lack of Vif or 
that expression of Vif in permissive cells blocks an inhibitor of viral 
infectivity (Cohen et a/., 1996). Vif activity may be regulated by 
post-translational modification because mutation of one of three 
serine phosphorylation sites (Ser144) causes a defect in viral 
infectivity (Yang eta/., 1996). 
Compared with mature wild-type virions, Vif mutant viruses have 
similar protein and RNA contents but grossly altered core 
structures, suggesting that Vif may play a role in viral assembly 
and/or maturation (Cohen et a/., 1996). Consistent with this role, 
the infectivity defect can be complemented by supplying Vif in trans 
in virus-producing cells but not in target, non-permissive cells 
(Cohen et a/., 1996), as also seen with Nef. It has been estimated 
that 7 to 100 molecules of Vif are packaged into the virion (Camaur 
and Trono, 1996; Fouchier et a/., 1996; Karczewski and Strebel, 
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1996; Liu et a/., 1995), suggesting that Vif may function directly 
within the particle. Incorporation of Vif is probably non-specific 
because there is no apparent requirement for any viral protein or 
RNA and, like Nef, Vif can be incorporated into Mo-MLV particles 
(Camaur and Trona, 1996). 
2.9 VIRAL ENZYMES 
2.9.1 Protease (PR) 
The virion core is constructed to contain the Gag and Gag-Pol 
polyproteins, the Vif, Vpr, and Nef proteins, and the genomic RNA 
and, as the membrane coat containing SU and TM surrounds the 
particle, the virus buds from the membrane surface and is released. 
The immature particles that are formed are non-infectious. PR 
must cleave the polyproteins Gag and Gag-Pol, and conformational 
rearrangements must occur within the particle to produce a mature 
infectious virus. Although the precise timing is not clear, some of 
the "maturation" events may occur simultaneously with assembly 
and budding (Kaplan et a/., 1994). PR cleaves at several 
polyprotein sites to produce the final MA, CA, NC and p6 proteins 
from Gag and the PR, RT and IN proteins from Pol. The amount of 
Gag-Pol produced by ribosomal frame shifting and incorporation 
into the virion (-5-10% of Gag) will determine the final 
stoichiometries. Because assembly and maturation must be highly 
co-ordinated, factors that influence PR activity can have dramatic 
effects on virus production. PR, mainly functions as a dimer and is 
part of Pol, therefore the activity of PR is dependent on the 
concentration of Gag-Pol and the rate of auto-processing, which on 
the other hand may be influenced by adjacent p6 sequences 
(Zybarth and Carter, 1995). Cleavage efficiencies can vary 
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substantially among sites, thereby influencing the order of 
appearance of the different processed proteins (Dunn eta/. , 1994). 
The relative cleavage rates and the infectivity may also be 
controlled by the p2 spacer peptide located between CA and NC 
(Pettit eta/., 1994; Krausslich eta/., 1995). The processing of NC 
and p6 may be further influenced by RNA binding to the NC (Sheng 
eta/., 1997). Over-expression of PR can lead to aberrant rates of 
processing and decreased infectivity (Luukkonen eta/., 1995). 
In drug design PR has been a prime target and the crystal 
structures of many PR-inhibitor complexes have been solved, 
including peptidomimetic and non-peptide inhibitors (Figure 2.9.1a) 
(Wiodawer and Erickson, 1993). The enzyme active site is located 
at the dimer interface, with each 99-residue monomer contributing a 
catalytically essential aspartic acid (Asp25). The active site 
resembles that of other aspartyl proteases and contains a 
conserved triad sequence, Asp-Thr-Giy. Within the PR dimer are 
flexible straps that close down on the active site upon substrate 
binding (Figure 2.9.1 b). Surrounding the cleavage site is an amino 
acid side chain that binds within the hydrophobic pockets of PR, 
helping to explain some of the rate differences observed between 
different sites. Several PR inhibitors are in wide clinical use, and 
mutants resistant to multiple inhibitors have been observed (Condra 
et a/., 1995; Ridky and Leis, 1995). Resistant mutations are 
located within the inhibitor binding pockets as well as in the distant 
sites, and some mutants even show an increase in the catalytic 
activities (Schock et a/., 1996). An alternative approach to inhibitor 
design involves the use of inactive subunits that act as dominant 
negative inhibitors (McPhee eta/., 1996). 
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Figure 2.9.1 
HIV-1 protease free (a) and complexed with an inhibitor (b). 
Inhibitor binding induces a significant conformational change 
in which the "flaps" close down over the active site 
(adapted from Wlodawer and Erickson. 1993) 
2.9.2 Reverse Transcriptase CRT) 
Before any integration of the viral genome into the host 
chromosome can take place, it must first be reverse transcribed 
into duplex DNA. RT contains an RNase H domain that cleaves the 
RNA portion of RNA-DNA hybrids generated during the reaction; 
furthermore RT also catalyses both the RNA-dependent and DNA-
dependent DNA polymerisation reactions. The reverse 
transcription initiates from the 3' end of a tRNA3Lys primer annealed 
to the primer-binding site near the 5' end of the genomic RNA. RT 
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can make use of other tRNAs if complementary binding sites are 
provided, but reverse transcription is most efficient with RN~Lys 
(Oude Essink et a/., 1996). During assembly the tRNA3Lys is 
incorporated into virions and is often extended by several 
nucleotides inside the particle (Oude Essink eta/., 1996; Huang et 
a/., 1997b). The remainder of the reaction probably occurs after 
uncoating in the cytoplasm. The kinetic properties of RT during the 
initiation and elongation phases of the reaction are quite different, 
becoming highly processive during elongation, and post-
transcriptional modifications of tRNA3Lys enhance the formation of 
initiation complexes (Lanchy eta/., 1996). These kinetic transitions 
are reminiscent of those observed in transcription complexes, with 
tRNA3Lys performing a role analogous to u factor (Lanchy et a/., 
1996). After tRNA-primed initiation, reverse transcription involves 
two DNA strand transfer reactions that are catalysed by RT and 
have an important function for priming the synthesis of both minus 
and plus strands. 
RT also served as a major target for drug design and the crystal 
structures of the unliganded RT, an RT-DNA complex and RT-
inhibitor complexes have been solved (Rodgers et a/., 1995; 
Jacobo-Malina et a/., 1993; Kohlstaedt et a/., 1992; Ren et a/., 
1995). RT is a heterodimer and contains a 560-residue subunit 
(p66) (Figure 2.9.2) and a 440-residue subunit (p51) (Figure 2.9.2), 
and both of them are derived from the Pol polyprotein. Each 
subunit contains a polymerase domain composed of four sub-
domains, referred to as the fingers, palm, thumb, and connection, 
and furthermore the p66 contains an additional RNase H domain. 
In spite of identical amino acid sequences, the polymerase sub-
domains are arranged differently in the two subunits, with p66 
forming a large active-site cleft and p51 forming an inactive closed 
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structure (Wang eta/., 1994). On the p66 polymerase active site is 
a catalytic triad (Asp11 0, Asp185, and Asp186) conserved in many 
polymerases, and the 3'0H group of the primer strand in an RT-
DNA complex is positioned close to the active site for nucleophilic 
attack on the incoming nucleoside triphosphate (Jacobo-Malina et 
a/., 1993). In this complex the DNA contains both primer and 
template strands clamped between the palm, thumb and fingers 
sub-domains of p66, and is bent. Portions of the DNA near the 
active site adopt an A-form geometry expected of RNA-DNA 
hybrids or RNA duplexes bound during reverse transcription. 
Two classes of RT inhibitors are clinically in use, namely 
nucleoside analogs such as AZT and ddl that are presumed to bind 
to the polymerase active site, and non-nucleoside inhibitors such as 
nevirapine. Several non-nucleoside inhibitor-RT complexes 
structurally indicate a common hydrophobic binding site near to, but 
distinct from, the polymerase active site that rearranges to fit the 
particular drug and lock RT into an inactive conformation 
(Kohlstaedt et a/., 1992; Ren et a/., 1995). Mutations that confer 
resistance to nucleoside or non-nucleoside inhibitors map to 
different parts of RT, including regions in and around the active site 
and DNA-binding cleft, suggesting that some mutations directly 
alter the drug-binding site while others have more indirect effects 
(Ren et a/., 1995; Tantillo et a/., 1994). Structures of the 
unliganded RT show substantial variability in the positioning of the 
p66 thumb sub-domain (Rodgers eta/., 1995), indicating that large-
scale conformational rearrangements occur upon nucleic acid or 
drug binding. Such conformational changes may be important 
during reverse transcription, for example, to allow translocation of 
RT along the nucleic acid or to correctly position the RNase H and 
polymerase active sites. 
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Figure 2.9.2 
Ribbon drawings of the p51 and p66 proteins that form the 
HIV-1 RT heterodimer. 
Sub-domains are coloured as follows: fingers (blue),palm (red), thumb (green), and connection 
(yellow). 
(adapted from Jacobo-Molin a eta/., 1993) 
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2.9.3 lntegrase (IN) 
After reverse transcription, IN catalyses a series of reactions to 
integrate the viral genome into a host chromosome. IN functions in 
the removal of two 3' nucleotides from each strand of the linear viral 
DNA, leaving overhanging CA-OH ends (Katz and Skalka, 1994). 
At the ends of many retrotransposons a CA dinucleotide is situated, 
and mutations of these nucleotides substantially reduces the 
efficiency of 3'-end processing. After this process, the processed 3' 
ends are covalently joined to the 5' ends of the target DNA. This 
step is followed by integration, which probably involves additional 
cellular enzymes, wherein unpaired nucleotides at the viral 5' ends 
are removed and the ends are joined to the target site 3'ends, 
generating an integrated provirus flanked by five base-pair direct 
repeats of the target site DNA. In integration, the viral substrate 
used for integration is a linear DNA molecule consisting of a 
complete minus strand and a discontinuous plus strand, which is 
presumably completed by cellular enzymes following integration 
(Miller et a/., 1995a). In vitro systems using viral pre-integration 
complexes, or purified IN with short oligonucleotides, have helped 
define important nucleotides near the viral DNA ends, which are all 
important features of the target DNA, and the critical amino acids of 
IN (Katz and Skalka, 1994). Two sequential transesterification 
reactions are involved in the enzymatic mechanism and require no 
exogenous energy source, but an appropriate metal cofactor (either 
Mn2+ or Mg2+) is needed (Katz and Skalka, 1994). 
Within a genome integration can take place at many target sites. In 
vitro studies revealed a preference for kinked or distorted DNA, 
such as found in nucleosomes, but it is not yet clear how these 
target sites relate to those used in vivo (Miller et a/. , 1995b). 
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Suggestions have been made that interactions with other DNA-
binding proteins might target IN to specific sites, and a yeast two-
hybrid screen has identified a human Snf5-related protein with lni1 
as a possible partner (Miller and Bushman, 1995). The efficiency of 
integration is influenced by lni1, but its effect on target site selection 
in vivo is unknown. HMG I (Y), another cellular factor, is associated 
with pre-integration complexes and plays a crucial role in 
integration (Farnet and Bushman, 1997). 
IN, is active as an oligomer, probably a tetramer, and the 288-
residue monomer can be divided into three domains whose 
structures have been determined (Figure 2.9.3) (Rice eta/. , 1996). 
The N-terminal domain (residues 1-55) contains a zinc-binding site 
(coordinated by two histidines and two cysteines) and forms a 
dimer with a largely hydrophobic interface, as shown by NMR (Cai 
eta/., 1997). Each monomer contains a helix-turn-helix structure 
very similar to those found in DNA-binding proteins and exists in 
two closely related conformational states. Within the catalytic 
domain (residues 50-212) there is a D,D(35),E motif. This motif is 
conserved among integrases, is crucial for the processing and 
joining reactions, and is proposed to bind the active site metal ion 
(Rice eta/., 1996). The isolated catalytic domain cannot perform 
processing or joining reactions but can perform an apparent 
reverse reaction, termed disintegration, indicating that it contains 
the catalytic site for polynucleotidyl transfer. The crystal structure 
of the catalytic domain shows a dimeric structure, with each 
monomer containing a five-stranded ,B-sheet and six a-helices 
similar to other polynucleotidyl transfer enzymes (Dyda et a/., 
1994). Asp64 and Asp116 of the D,D(35),E motif are clearly seen 
in the structure, but Glu152 is located on a disordered loop. The 
two active sites in the dimer are too far apart to permit five base 
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pair staggered cleavage of the target DNA, suggesting either that a 
very large conformational change occurs during catalysis or, more 
likely, that IN functions as a tetramer or other oligomeric form 
during some steps of the reaction (Rice et a/., 1996; Cai et a!., 
1997). 
Figure 2.9.3 
Model of the HIV -1 tetra mer generated using independently 
solved structures of the N-terminal, core and C-terminal 
domains. 
The four molecules of tetramer are displayed in different colours 
(adapted from Cai eta/., 1997) 
The C-terminal domain (residues 220-270) has non-specific DNA-
binding activity and forms a dimer of parallel monomers, as shown 
by NMR. The structure of each monomer consists of a five-
stranded ~ barrel strikingly similar to a SH3 domain, with a saddle-
shaped groove that might accommodate double-stranded DNA and 
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containing Lys264, an important DNA-binding residue 
(Eijkelenboom et a/., 1995; Lodi et a/., 1995). The relative 
orientations of the three IN domains remain to be established (Rice 
eta/. , 1996; Cai eta/., 1997). 
2.10 HIV-1 REPLICATION CYCLE: 
Specific interactions between the viral glycoprotein gp120 and the amino-
terminal immunoglobulin domain of CD4 on the cell surface initiate the 
viral replication cycle. T lymphocytes, monocytes and macrophages of the 
immune system, all of which express CD4 receptor on the cell surface, 
can be infected with HIV-1. However, HIV-1 requires additional cell-
surface proteins to promote fusion of the viral and cellular membranes. 
CCR5 and CXCR4 are co-receptors for HIV-1 entry in vivo. Other 
additional chemokine receptors have been shown to serve as co-receptors 
for HIV-1 entry but their relevance in vivo remains to be confirmed 
(Chapham & Weiss, 1997; Doranz eta/., 1996; Feng eta/., 1996; Moore, 
1997). 
The membrane fusion reaction occurs between the lipid bilayer of the virus 
particle and the plasma membrane of the host cell and is induced by the 
viral glycoprotein gp41 . The membrane fusion is followed by a process 
called uncoating, described as a series of ill-defined events. During this 
event, CA is lost, while at least some MA, as well as NC, IN, RT and Vpr 
are thought to be retained as part of a high-molecular-weight complex. 
Reverse transcription of the genomic viral RNA into DNA is largely 
,_ 
completed. The accessory protein Vpr, present during the early stages of 
infection since it is packaged into the virion, appears to participate in the 
reverse transcription process by facilitating the initiation and influencing 
the accuracy of reverse transcription. The reverse transcription may be 
facilitated by Vpr by interacting with the lysine tRNA synthase, since this 
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reaction correlates with an inhibition of the aminoacylation of tRNAiys, the 
primer for HIV-1 reverse transcription (Goff 1990, Turner & Summers, 
1999). Vpr is thought to modulate the mutation rate of HIV-1 by 
interacting with an enzyme involved in the DNA repair pathway. The 
process of reverse transcription is also dependent on NC. NC enhances 
the reverse transcription by promoting annealing of the tRNAiys primer to 
the PBS, melting of RNA secondary structures and DNA strand transfer 
through its non-specific RNA binding features. 
The viral DNA is then transported to the nucleus as part of a high-
molecular-weight complex, now referred to as the pre-integration complex 
(PIC), once it has been synthesised. Nuclear localisation of PIC is 
directed by Vpr, which does not contain a nuclear localisation signal (NLS) 
but appears to connect the PIC to the cellular nuclear import machinery 
(Fouchier eta/., 1997; Nie eta/., 1998). Other viral components of PIC, 
such as MA, IN and the central DNA flap, may facilitate nuclear 
localisation but their exact roles remain controversial (Miller eta/., 1997). 
As part of the PIC, IN recognises the L TRs at the 5' and 3' ends of the 
viral DNA and removes the dinucleotide adjacent to a highly conserved 
CA dinucleotide, from the 3' strand of the U3 and U5 viral DNA L TRs. It 
then covalently combines the 3' ends to the 5' ends of the target cellular 
DNA in the nucleus (Turner & Summers, 1999). Finally, probably with the 
involvement of additional cellular enzymes, unpaired nucleotides at the 
viral 5' ends are removed and the ends are combined at the target site 3' 
ends, generating an integrated provirus flanked on both sides by five 
identical base pairs of the target cellular DNA. Once integrated, the 
proviral DNA remains permanently associated with the cellular DNA. 
The proviral DNA serves as template for the synthesis of the unspliced 
and spliced mRNAs, which are transported out of the nucleus and into the 
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cytoplasm. Multiple-spliced mRNAs that encode Tat, Rev and Nef are 
synthesised and exported to the cytoplasm initially. Tat functions as an 
essential transcriptional activator that binds to a mRNA hairpin known as a 
trans-activating response element (TAR) and assembles into 
transcriptional complexes with cellular proteins to stimulate transcriptional 
elongation (Turner & Summers, 1999). Rev mediates export of the 
unspliced and the singly-spliced mRNAs. Rev binds as an oligomer to the 
rev responsive element (RRE) of nascent unspliced mRNAs and recruits 
the cellular nuclear shuttling protein exportin-1 (XPO) (Ohno eta/., 1998) 
and the nuclear export factor Ran guanosine triphosphatase (in its GTP-
bound form). Rev, containing an NLS, directly mediates the export of 
these mRNAs through the CRM1 export pathway. Whether it also inhibits 
splicing is unclear. As Rev accumulates in the nucleus, more unspliced 
and singly-spliced mRNAs associated with it are shuttled out of the 
nucleus. In this process, Rev functions as a switch between the early 
synthesis of highly spliced mRNAs (encoding Tat, Rev and Nef) and the 
later synthesis of the singly-spliced (encoding Env, Vpu, Vif and Vpr) and 
unspliced (encoding the Gag and Gag-Pol proteins) mRNAs (Turner & 
Sumers, 1999). 
The Env precursor polyprotein gp120 is synthesised in the endoplasmic 
reticulum (ER) and is post-translationally modified in the ER and Golgi 
apparatus (Turner & Summers, 1999). The polyprotein is cleaved into 
gp 120 and gp41 by cellular endoproteases and transported to the cell 
membrane. Vpu binds to neosynthesised CD4 in the ER and promotes 
the degradation of CD4 by the ubiquitin-proteosome pathway (Crise et a/., 
1990; Margottin et a/. , 1998; Schubert et a/., 1998). In this way, the 
premature binding of CD4 to gp160 in the ER can be overcome and will 
result in the release of the gp160 for efficient processing and transport. 
Nef provokes the retention of neosynthesised CD4 molecules in the Golgi 
apparatus and the acceleration of their internalisation from the cell 
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surface. These CD4 molecules are then degraded in lysosomes. 
Similarly, Nef provokes the down-regulation of MHC-1 molecules on the 
surface of the infected cells by not targeting them to lysosomes but to the 
Golgi apparatus. While the down-regulation of CD4 may increase virion 
release from the cell surface and may increase the incorporation of 
envelope glycoproteins in virions, leading to the production of viruses with 
higher infectivity, the MHC-1 down-regulation protects HIV-1 infected cells 
from both cytotoxic T lymphocytes and natural killer cells (Mangasarian 
and Trona, 1997). 
The Gag and Gag-Pol polyprotein precursors are synthesised on free 
ribosomes. The N-terminally myristoylated MA domain of the polyproteins 
directs binding to the cellular membrane (Bennet eta/., 1993; Bryant and 
Ratner, 1990; Chazal eta/., 1994; Zhou eta/., 1994). A basic domain 
near the amino terminus of MA, in conjunction with other basic residues 
throughout the protein, is also thought to promote membrane binding by 
interacting with acidic phospholipids on the inner face of the lipid bilayer. 
It is speculated that the MA domain of Gag interacts with the cytoplasmic 
tail of gp41, which should be necessary for the incorporation of the Env 
glycoprotein complex into the budding virion (Mammano et a/., 1995). 
During or after transport to the cellular membrane, the Gag precursor 
recruits two copies of unspliced viral RNA and interacts with Gag-Pol 
precursor. Subsequently virus budding occurs in the form of an immature 
particle. During or immediately after budding, the Gag and the Gag-Pol 
polyproteins, are cleaved by PR to produce the viral enzymes and 
structural proteins. The structural proteins rearrange via a process called 
maturation to form an infectious virion, which is now capable of initiating a 
new round of infection. 
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2.1 1 EVOLUTION AND PHYLOGENETIC$ 
2.11.1 Phylogenetic Systematics and Classification 
Charles Darwin never mentioned the word "evolution" except in 
his last sentence in "The Origin of Species" where he used the 
word "evolved". He usually referred to the phrase "descent with 
modification." The two central features of evolution are the 
basis of evolutionary classification today; groups of organisms 
descend from a common ancestor and, with the passage of 
time, acquire modifications. 
Phylogenetic systematics, also known as cladistic analysis or 
cladistics, is the main approach for classification used in 
contemporary evolutionary biology. The German taxonomist 
Willi Hennig developed cladistics in 1950. 
Phylogenetic systematics begins with the assumption that 
evolution is a branching process. The ancestral species split 
into descendant species, and these relationships are then 
represented much like family trees represent genealogies. The 
resulting trees are referred to as phylogenies. These 
phylogenies are then subjected to testable hypotheses, 
subjected to either confirmation or rejection, depending on 
evidence. In phylogenetic systematics, groups of organisms, 
referred to as taxa, are arranged into clades, which are then 
nested into larger clades. Each of these clades should be 
monophyletic, which indicates that all members share a single 
common ancestor, and all descendants of that ancestor are 
included in the clade. On the other hand, a polyphyletic group is 
one in which the members are derived from more than one 
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common ancestor. When all of the particular clade's members 
share a common ancestor but not all taxa share the common 
ancestor, it is called a paraphyletic group 
(http://www.learner.org/channel/courses/biology/units/compev/in 
dex.html). 
2.11.2 How does Phylogenetic Systematics work? 
Like most scientists, taxonomists start with the principle that the 
shortest, most possible, and direct path is most likely to be the 
correct one and this is called parsimony. One of the most 
commonly used methods is parsimony analysis in which the 
taxonomist searches for the most parsimonious tree, the one 
that requires the fewest number of evolutionary transitions. 
The most parsimonious tree does not necessarily represent the 
true phylogenetic relationships. Sometimes certain types of 
transitions are more likely or are able to evolve more easily than 
others. This phenomenon is quite difficult to predict before the 
actual analysis is performed. Taxonomists usually resort to a 
fallback position, which indicates that all changes are equally 
likely. In molecular data in particular, a good prior knowledge of 
variation in the likelihoods of different changes exists. For 
example, certain types of mutations are more likely to occur 
than others. Transitions (changes from a purine -A or G- to the 
other purine, or a pyrimidine-Cor T- to the other pyrimidine) 
are more likely than transversions (changes from a purine to a 
pyrimidine or vice versa). Statistical techniques like maximum 
likelihood analysis, enable the taxonomists to adjust for these 
--. 
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Various types of trees can be used depending on the specific 
need. For instance, unrooted trees do not display the 
directionality of evolution but only patterns of relatedness. An 
unrooted tree can be transformed to rooted, but for any given 
unrooted tree, there are many possibilities of rooted trees. One 
approach is dependent on the identification and use of an 
outgroup, a taxon that is more distantly related than the taxa 
contained within the tree. For example, in an unrooted tree 
containing the great apes (humans, chimpanzees, gorillas, 
orangutans, and gibbons), one could use a species of monkey, 
such as baboons, as an outgroup. In practice the taxonomists 
will usually use a number of outgroups to refine the analysis 
(http://www.learner.org/channel/courses/biology/units/compev/in 
dex.html). 
2.11.3 The Application of Phylogenetic Systematics 
The methods that are used for phylogenetic systematics are 
similar for molecular and morphological characters but 
molecular data proves to be more advantageous. For instance, 
molecular data offers a large and essentially limitless set of 
characters. In theory, each nucleotide position can be 
considered as a character and can be assumed to be 
independent. The DNA of any organism has millions to billions 
of nucleotide positions. Furthermore, the large size of the 
genome makes it very unlikely that natural selection will be 
strongly driving changes at any particular nucleotide. Therefore, 
most of the nucleotide changes are "unseen" by natural 
selection, which is subjected only to mutation and random 
genetic drift. By the selection of a particular class of 
morphological characters, researchers may also bias the 
© Central University of Technology, Free State
Chapter 2 52 
Various types of trees can be used depending on the specific 
need. For instance, unrooted trees do not display the 
directionality of evolution but only patterns of relatedness. An 
unrooted tree can be transformed to rooted, but for any given 
unrooted tree, there are many possibilities of rooted trees. One 
approach is dependent on the identification and use of an 
outgroup, a taxon that is more distantly related than the taxa 
contained within the tree. For example, in an unrooted tree 
containing the great apes (humans, chimpanzees, gorillas, 
orangutans, and gibbons), one could use a species of monkey, 
such as baboons, as an outgroup. In practice the taxonomists 
will usually use a number of outgroups to refine the analysis 
(http://www.learner.org/channellcourses/biology/units/compev/in 
dex.html). 
2.11.3 The Application of Phyloaenetic Systematics 
The methods that are used for phylogenetic systematics are 
similar for molecular and morphological characters but 
molecular data proves to be more advantageous. For instance, 
molecular data offers a large and essentially limitless set of 
characters. In theory, each nucleotide position can be 
considered as a character and can be assumed to be 
independent. The DNA of any organism has millions to billions 
of nucleotide positions. Furthermore, the large size of the 
genome makes it very unlikely that natural selection will be 
strongly driving changes at any particular nucleotide. Therefore, 
most of the nucleotide changes are "unseen" by natural 
selection, which is subjected only to mutation and random 
genetic drift. By the selection of a particular class of 
morphological characters, researchers may also bias the 
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analysis in such a way that groups with certain characteristics 
cluster with others for reasons other than homology. For 
example, if the set of characters were weighted toward those 
involved in carnivory, carnivorous animals may cluster together, 
not because of homology but because of shared function. 
These problems are less likely to occur if molecular characters 
are used. 
A second advantage of molecular data is that all known life is 
based on nucleic acids, thus, studies that involve any type of 
taxa can use DNA or RNA sequence data. Some of the genes 
or regions of genes evolve very quickly. These concepts are 
very useful in studies making use of closely related taxa. 
Conversely, other genes or regions of genes evolve more 
slowly. These concepts are more useful for studies of distantly 
related organisms. In extreme circumstances, some 
evolutionarily related genes have been found in disparate 
organisms such as yeast and humans. The extent of functional 
constraint is primarily used for the determination of the rates by 
which sections of DNA evolve. Genes and positions within 
genes that are the most useful generally evolve the slowest. 
The reason for this is that they are the least able to tolerate 
mutational change without substantially reducing the fitness of 
the individuals that harbour them. Many of these conserved 
genes play a role in development. 
Phylogenetic methods can also be used to solve practical 
problems, like determination of the sources of infection from 
HIV. The rate of evolution for these retroviruses is extremely 
fast, owing it to their exceptionally high mutation rate. 
Therefore, sequences of HIV genes isolated from the same 
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infected individual can be as different as sequences of 
homologous genes in humans and birds. The rapidity of HIV's 
evolution is responsible for the havoc that H IV causes on the 
immune system. On the other hand, scientists can take 
advantage of that rapid evolution to study the relationships 
between HIV and other similar viruses. 
2.11.4 Origin of HIV-1 
Cross-species transmission events may have resulted in HIV 
infections. Five lines of evidence are used to substantiate the 
zoonotic origins of viruses: (a) similarities in viral genome 
organisation, (b) phylogenetic relatedness, (c) prevalence in the 
natural host, (d) geographic coincidence, and (e) plausible 
routes of transmission (Gao eta/., 1999). 
The origin of HIV-1 has proven to be much more difficult to 
determine than that of HIV-2 (refer to 2.11.5). The criteria used 
were the same to establish zoonotic transmission of SIVsm to 
humans and have been applied to SIVcpz. (Gao eta/., 1999). 
SIVcpz and HIV-1 were initially found to be identical in genomic 
organisation, containing a particular gene, vpu, which is not 
present in other lentiviruses (Huet eta/., 1990). Therefore, the 
similarity in genome organisation made SIVcpz a very strong 
candidate for the origin of HIV-1, but some characteristics of the 
virus raised doubts as to its legitimacy as the immediate 
precursor to HIV-1. Some of the characteristics included an 
unexpected distant relationship between one isolate of SIVcpz 
(ANT) and HIV-1 (Van den Haesevelde eta/., 1996); seemingly 
low prevalence of SIVcpz infection in wild-living chimpanzees; 
uncertain geographic coincidence between chimpanzee habitats 
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and early AIDS cases (Gonder et a/., 1997), and questions 
concerning plausible routes of transmission (Figure 2.11.4.1). 
According to a recent publication (Gao et a/. , 1999) a new 
sequence of SIVcpz was described. According to the findings of 
that analysis and other data, a conclusion was drawn that the 
HIV-1 epidemic had arisen as a consequence of SIVcpz 
transmission from a particular chimpanzee subspecies, Pan 
troglodytes troglodytes, to humans. They demonstrated that 
HIV-1 was most closely related at a phylogenetic level to SIVcpz 
from P.t. troglodytes. Indirect evidence was presented for a 
higher prevalence of natural SIVcpz infection, based on the 
discovery of viral recombination between SIVcpz viruses of 
different lineages, described geographic coincidence for all 
groups of HIV-1 (M, N, and 0) and SIVcpz from P.t. troglodytes, 
and proposed hunting and field-dressing of chimpanzees (a 
common practice in West Central Africa) as a plausible route of 
zoonotic transmission. 
Another group (Corbet et a/., 2000) emerged with further 
evidence that substantially extends these conclusions. Twenty-
nine captive chimpanzees from Cameroon were screened for 
evidence of SIVcpz infection and three animals were identified 
(CAM3, CAM4, CAM5) as seropositive. Two of the animals 
acquired their infections in the wild and the remaining one 
related to a cage transmission. The two animals (CAM3 and 
CAM5) which were naturally infected were found to be members 
of the P. t. troglodytes subspecies, and their viruses fell within 
the SIVcpz(P.t.t.) radiation (Figure 2.11.4.1 and 2.11.4.2). In 
the env region the new Cameroonian champanzee viruses were 
significantly more closely related to SIVcpzUS and YBF30 (the 
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full length representative of HIV-1 group N) than to any other 
virus within the HIV-1/SIVcpz(P.t.t.) radiation (Figure 2.11.4.2). 
According to this data there is a close geographical linkage of 
human and chimpanzee viruses and this suggested that the 
cross-species transmission event gave rise to HIV-1 group N 
occurring in Cameroon or its immediate vicinity (Corbet et a/., 
2000; Hahn eta/., 2000). 
Therefore it seems clear that HIV-1 arose as a consequence of 
SIVcpz transmission from chimpanzees to humans and that the 
P.t. troglodytes subspecies represents a natural host and 
reservoir for this virus (Hahn eta/., 2000). 
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Figure 2.11.4.1 
Evolutionary relationships of primate lentiviruses based on 
maximum-likelihood phylogenetic analysis of full-length Pol 
protein sequences 
The scale bar indicates 0.1 amino acid replacement per site after correction for multiple hits. 
· (adapted form Hahn eta/., 2000) 
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Figure 2.11.4.2 
Evolutionary relationships of members of the HIV-1/SIVcpz 
lineage based on maximum-likelihood phylogenetic analysis of 
full-length Env protein sequences. 
The three groups of HIV-1 (M, N, and 0) are Indicated in brackets on the right, as are five representative 
subtypes ofthe M group (A through F). The SIVcpz strains were isolated from either P.t.trog/odytes (p.t.t.) 
or P.t. schweinfurthli (P.t.s.) animals. The scale bar indicates 0.1 amino acid replacement per site after 
correction for multiple hits. 
(adapted from Hahn et s/., 2000) 
2.11.5 Origin of HIV-2 
HIV-2 was the first human lentiviral infection in which these 
criteria were satisfied and the simian source of the virus 
identified (namely sooty mangabeys). The five criteria were met 
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as follows: (a) HIV-2 and SIVsm share an identical genome 
structure, with each virus encoding an accessory protein, 
termed Vpx, that has not been found in any other primate 
lentivirus (Hirsch eta/., 1989). (b) SIVsm and HIV-2 strains are 
phylogenetically closely related and cannot be separated into 
distinct phylogenetic lineages according to their species of origin 
(Figure 2.11.4.1). In trees from partial gag sequences from 
many additional viruses, it has even been possible to find 
evidence of phylogenetic and geographic linkage of HIV-2 and 
SIVsm strains at a local level (Chen et a/., 1996). That is, 
SIVsm and HIV-2 sequences derived from animals and humans 
from the same immediate geographical area was found to be 
most related, which implicates hunting or other local activities as 
the route of transmission. (c) Sooty mangabeys are numerous 
in many West African countries and are infected with SIVsm at a 
substantial frequency (22% in some troops) in the wild (Chen et 
a/., 1996). (d) There is geographic coincidence between the 
natural habitat of the sooty mangabey and the areas where HIV-
2 is endemic. The historical range of the sooty mangabey 
stretches from coastal West Africa south of the Casamance 
River in Senegal to the Sassandra River in Cote d'lvoire. This 
range is in close proximity to the epicentres of the HIV-2 
epidemic in Senegal, Guinea-Bissau, Guinea "Conakry" and 
Cote d'lvoire, and it overlaps Sierra Leone and Liberia, where 
the most divergent HIV-2 strains have been identified (Chen et 
a/., 1996; Chen et a/., 1997). (e) Sooty mangabeys are 
frequently hunted for food, and orphans are kept as pets. Thus, 
there is the opportunity for frequent human contact with infected 
animals. 
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2.12 ANTIRETROVIRAL TREATMENT AND DRUG RESISTANCE 
2.12.1 Antiretroviral Drugs in Clinical Use 
The introduction of highly active antiretroviral therapy (HAART) 
has had a profound impact on the management of HIV infection. 
Suppression of HIV RNA to undetectable levels in plasma is 
possible for the first time. Furthermore, this implicates a 
decrease in morbidity and mortality through the reduction in the 
incidence of opportunistic infections for good survival. 
Currently, there are nineteen drugs approved by the FDA for the 
treatment of HIV, including 16 unique HIV-1 inhibitors. 
The FDA divides these nineteen drugs into three classes. 
Despite the availability of these medications, failure to achieve 
complete viral suppression is common in clinical practice, 
occurring at a rate of 40% to 70% (Ledergerber et a/., 1999; 
Deeks et a/., 2000; Lucas et a/., 1999). The nucleoside RT 
inhibitors (NRTis) inhibit HIV-1 replication in two ways. After 
conversion to their 5'-triphosphate form by cellular kinases, they 
compete with natural deoxynucleoside triphosphates for binding 
to RT, or for incorporation into newly synthesised viral DNA, 
thus resulting in DNA chain termination due to the absence of 
their 3'-hydroxyl group. The NRTis currently approved for use 
in the clinics are zidovudine (ZDV, AZT), didanosine (ddl), 
zalcitabine (ddC), stuvadine (d4T), lamivudine (3TC) and 
abacavir (ABC) (Table 2.12.1). 
Unlike the NRTis, which function by mimicking the structure of 
the nucleoside bases, the non-nucleoside RT inhibitors 
(NNRTis) inhibit HIV-1 RT by reversibly binding with an 
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allosteric site close to the active site of the enzyme. The 
inhibition is non-competitive with respect to template-primer and 
non-competitive or mixed with respect to nucleoside substrate. 
They are specific for the RT of HIV-1 and are not, or to a lesser 
extent, active against human cellular DNA polymerases or HIV-
2 RT, respectively (Witvrouw eta/., 1999). The NNRTis do not 
require intracellular modification to generate the active 
compound. The NNRTis currently approved for use in clinics 
are nevi rapine (NVP), delavirdine (Dl V) and efavirenz (EFV) 
(Table 2.12.1). 
Protease inhibitors (Pis) inhibit the activity of PR by binding to 
the active site using two strategies. They either mimic the 
transition state during peptide cleavage, or they fit the active site 
as a steric complement or as a symmetric inhibitor of HIV-1 
protease. The Pis presently approved are saquinavir (SQV), 
ritonavir (RTV), indinavir (IDV), nelfinavir (NFV), amprenavir 
(APV) and lopinavir (LPV) in a combination with ritonavir (LPV/r) 
(Table 2.12.1). 
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Table 2.12.1 
FDA-approved Antiretroviral Drugs (Youree and D'Aquila eta/., 2002) 
Class 
Nucleoside Analogue 
Reverse Transcriptase 
Inhibitors 
(NRTI) 
Nonnucleoside Reverse 
Transcriptase inhibitors 
(NNRTI) 
Nucleotide Analogue 
Reverse Transcriptase 
Inhibitor 
Protease Inhibitors (PI) 
Generic Name 
(abbreviation) 
Zidovudine (AZT, ZDV) 
Didanosine (ddl) 
Zalcitabine (ddC) 
Stavudine (d4T) 
Lamivudine (3TC) 
Zidovudine/Lamivudine (AZT/3TC) 
Abacavir (ABC) 
Zidovudine/Lamivudine/Abacavir 
(AZT/3TC/ABC) 
Nevirapine (NVP) 
Delavirdine (DLV) 
Efavirenz (EFV) 
Tenofovir 
Saquinavir (SQV, hgc) 
Saquinavir (SQV, sgc) 
Ritonavir (RTV) 
lndinavir (IDV) 
Nelfinavir (NFV) 
Amprenavir (APV) 
Lopinavir/Ritonavir (LPV/RTV) 
Brand Name 
Retrovir 
Videx 
Hivid 
Zerit 
Epivir 
Combivir 
Ziagen 
Trizivir 
Viramune 
Rescriptor 
Sustiva 
Vi read 
lnvirase 
Fortovase 
Norvir 
Crixivan 
Viracept 
Agenerase 
Kaletra 
61 
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2.12.2 Antiretroviral Drugs Under Development 
Various new inhibitors are under development, of which some 
may become available for clinical use within the next years. 
They can be distinguished from the currently available inhibitors 
by their more favourable pharmacokinetics, resistance profiles, 
production costs or by their new viral targets. 
Promising new NRTis are emtricitabine and DAPD. 
Emtricitabine is very similar to lamivudine, but it can be dosed 
once daily and, in vitro, it appears to be more potent (Molina et 
a/., 2000). DAPD is a new guanosine analog that is very well 
tolerated and is particularly promising because of its resistance 
profile (Richman eta/., 2000). 
Acyclic nucleoside phosphonate analogs (ANPs) possess a 
phosphonate group attached to the acyclic nucleoside moiety. 
They only need two phosphorylation steps to be converted to 
their active metabolites. After conversion to their triphosphate 
form, they compete with natural deoxynucleoside triphosphates 
for binding to RT, or for incorporation into newly synthesised 
viral DNA, thus resulting in DNA chain termination (De Clercq, 
1997). Adefovir (PMEA) and tenofovir (PMPA) are acyclic 
nucleotide analogs. Tenofovir appears promising because of its 
pharmacokinetic profile, activity, safety and resistance 
properties (Srinivas eta/., 1998; Miller eta/., 2000). 
Foscarnet (PFA) is a pyrophosphate analog that inhibits viral 
DNA polymerases including HIV-RT. It binds to the putative 
pyrophosphate binding site close to the nucleotide binding site 
of these polymerases (Oberg, 1989). It is highly active against 
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HIV-1 strains with resistance to NRTis and NNRTis. However, 
its use in clinical practice is limited by a lack of oral bio-
availability and by its side effects. Alkylglycerol analogs of PFA 
appear to have substantially greater antiviral activity than PFA 
and more favourable bio-availability characteristics (Hammond 
eta/., 2000). 
Capravirine (AG 1549) is an important new NNRTI, primarily 
because of its resistance profile. According to in vitro data, 
more than one mutation is required for resistance to be detected 
and this inhibitor retains its activity against HIV-1 strains 
resistant to nevirapine and delavirdine (Fujiwara et a/., 1998). 
Emivirine (MKC-442) structurally resembles an NRTI but 
functions as an NNRTI. It is well tolerated, with a favourable 
adverse effect profile (Szczech eta/., 2000). 
Tipranavir is a potent new non-peptidic PI effective against HIV-
1 strains resistant against peptidometic Pis (Poppe et a/., 1997; 
Larder eta/., 2000; Rusconi et a/. , 2000). BMS-232632 is a 
potent PI that shows a relatively unique resistance profile and 
may be administered once daily. It may be sensitive to HIV-1 
strains resistant to nelfinavir, saquinavir and amprenavir 
(Colonno eta/., 2000). DMP-450 is a cyclic urea compound and 
potent inhibitor of HIV-1 PR (Sierra et a/., 2000). It is an 
especially promising compound due to its low production costs. 
There has been considerable interest in the development of 
inhibitors targeting the fusion of HIV-1 to the host cell surface. 
T-20 and T-1249 are peptides that block infection by binding to 
a critical domain of gp41, thereby inhibiting fusion (Kilby et a/., 
1998). Another fusion inhibitor is AMD-3100, a bi<;:yclam that 
inhibits entry of HIV-1 into cells via selective blockade of the 
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chemokine CXCR4 co-receptor (Schols et a/ .. 1997; Donzella et 
a/., 1998). 
Witvrouw et a/. (1998) reported on one of the most active 
congeners of the series of QM96639 which was found to inhibit 
HIV type 1 replication in MT -4 cells at a concentration of 0.09 
J.!M. This compound was toxic for the host cells only at a 1 ,400-
fold higher concentration. The TTD derivatives proved effective 
against a variety of HIV-1 strains, including those that are 
resistant to AZ.T, but not against HIV-2 (ROD) or simian 
immunodeficiency virus. HIV-1 strains containing the L 1001, 
K103N, V106A, E138K, Y181C, or Y188H mutations in their RT 
gene displayed reduced sensitivity to the compounds. Their 
cross-resistance patterns correlated with that of nevirapine. 
QM96521 enhanced the anti-HIV-1 activity of AZ.T and 
didanosine in a subsynergistic manner. HIV-1 resistant virus 
containing the V179D mutation in the RT was selected after 
approximately six passages of HIV-1 in CEM cells in the 
presence of different concentrations of QM96521. From 
structure-activity relationship analysis of a wide variety of TID 
derivatives, a number of restrictions appeared as to the 
chemical modifications that were compatible with anti-HIV 
activity. Modelling studies suggest that in contrast to most other 
NNRTis, but akin to nevirapine, QM96521 does not act as a 
hydrogen bond donor in the RT -drug complex. 
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2.12.3. 
65 
Resistance 
Development of viral resistance to antiretroviral drugs used for 
treatment of human immunodeficiency virus (HIV) infection is an 
important cause of treatment failure (Richman eta/., 1994; Havlir 
eta/., 1996; Schuurman eta/., 1995; Saag eta/., 1993; D'Aquila 
eta/., 1995; Kozal eta/., 1994) and limits options for alternative 
antiretroviral regimens. Prevention, characterisation and clinical 
management of such resistance are receiving increasing 
attention. 
The virus population in a person infected with an RNA virus 
(e.g. HIV-1, hepatitis C virus) has been termed a quasi species 
(Eigen, 1993), which refers to the existence of genetically 
distinct viral variants that evolve from the initial virus inoculum. 
The variants are generated because DNA proofreading 
mechanisms that preserve the genetic composition of 
organisms with double-stranded DNA genomes do not exist for 
RNA viruses. Thus, as single stranded RNA viruses replicate, 
each newly copied genome differs from the parental virus, on 
average, by a single nucleotide (Drake, 1993; Mansky and 
Temin, 1995). 
Viral polymorphisms (genetic variants with apparently equivalent 
fitness ([replication capacity]), are commonly seen in virus 
populations in infected persons. Nucleotide differences may be 
"neutral" (no impact on fitness), deleterious (variants replicating 
less well or not at all), or confer replicative advantage if 
selective pressures such as immune responses or drug 
treatments change. These possibilities illustrate the survival 
strategy of organisms with high mutation rates that provide a 
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large pool of genetic variants able to adapt rapidly to changing 
selective pressures (Leigh Brown and Richman, 1997). 
An estimated 10 billion (1010) HIV-1 virions are produced daily in 
established HIV infection (Perelson et a/., 1996). If each 
contains on average 1 mutation per 9200-nucleotide genome, 
replication-competent virus with every possible single drug-
resistance mutation is likely to be generated daily. Double 
mutants are less likely, and the probability of 3 or more drug-
resistance mutations in the same genome is very low. 
These estimates are supported by observations in infected 
persons. Virus or HIV-1 RNA with single drug-resistance 
mutations have been isolated from treatment-naive patients or 
those infected before antiretroviral drug availability (Najera et 
a/., 1995; Wong et a/., 1997). Mathematical modelling of the 
rate of resistance emergence after nevirapine treatment in 
previously untreated persons, permitted estimates of plasma 
prevalence of HIV-1 variants with nevirapine-resistance 
mutations before treatment. About 1 in 1 000 copies/ml of 
plasma HIV-1 RNA contains the tyrosine-to-cysteine mutation at 
amino acid residue 181 (e.g. the Y181C mutation) of the reverse 
transcriptase conferring nevirapine resistance (Havlir et a/. , 
1996). 
When antiretroviral drug selective pressure is applied to viral 
quasi species in an infected person, pre-existing minor viral 
species resistant to that drug rapidly become predominant and 
are selected as the fittest species in the presence of the drug. 
For some antiretroviral drugs, such as lamivudine and certain 
non-nucleoside reverse transcriptase inhibitors (NNRTis; e.g. 
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nevirapine), a single mutation can confer high-level resistance. 
When these drugs are given in combinations only partially 
suppressing virus replication, drug-resistant mutants 
predominate within weeks 0JVei eta/., 1995; van Leeuwen eta/., 
1995; Havlir et a/., 1996). For some other drugs, such as 
zidovudine and certain protease inhibitors, high-level resistance 
requires accumulation of 3 or more resistance mutations in a 
single viral genome (Larder and Kemp., 1989; Condra et a/., 
1995; Molla et a/., 1996). These highly resistant variants 
emerge more slowly, requiring months to predominate during 
less than maximum viral suppression (Condra et a/. , 1995; 
Larder et a/., 1989), supporting the prediction that genetic 
variants with multiple mutations are present at much lower 
levels than those with single mutations in untreated patients. 
Development of high-level resistance to these drugs requires 
persistent viral replication and selective drug pressure. 
Persistent viral replication permits further viral evolution leading 
to high-level drug resistance by cumulative mutation acquisition. 
What is known about development of resistance with potent 
combination therapy? Firstly, the higher the trough plasma 
concentrations of a protease inhibitor (e.g. ritonavir) , the more 
slowly resistance mutations emerge (Molla et a/., 1996). 
Secondly, the lower the nadir of plasma HIV-1 RNA levels, the 
longer it takes for drug failure to occur (Kempf eta/., 1998). In 
patients with suppression of plasma HIV-1 RNA to below 50 
copies/ml for 1 year, no resistance mutations or other evidence 
of virus evolution was discerned, even though HIV-1 RNA and 
DNA and replication-competent virus persisted (GOnthard et a/., 
1998; Wong et a/., 1997; Finzi et a/. , 1997). Conversely, 
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patients with detectable HIV-1 RNA levels had ongoing virus 
replication and evidence of evolution. 
Nucleoside analogue reverse transcriptase inhibitors (NRTis) 
were the first class of antiretrovirals to be developed to provide 
effective antiviral therapy in the setting of HIV-1 infection 
(Loveday, 2001). These drugs compete with deoxynucleoside 
triphosphates (dNTPs) during polymerisation and act as 
premature chain terminators upon incorporation (Arts and 
Wainberg, 1996). Up to date, six NRTis have been approved 
for use in the United States, e.g., zidovudine (AZT), didanosine 
(ddl), zalcitabine (ddC), stavudine (d4T), lamivudine (3TC) and 
abacavir (ABC). In addition, tenofovir (TNV) is the leading drug 
among nucleotide reverse transcriptase inhibitors (NtRTI) and 
the only one of the class approved for use aged in patients. 
Altogether, these drugs remain the backbone of nearly all anti-
HIV treatment strategies. 
Nonnucleoside reverse transcriptase inhibitors (NNRTis) are 
non-competitive inhibitors that bind to a hydrohhobic pocket 
adjacent to the polymerase active site of RT (Deeks, 2001 ). 
This binding causes an allosteric change of the polymerase 
active site which inhibits DNA polymerisation (Esnouf et a/., 
1995). NNRTI-associated mutations are usually in the 
hydrophobic pocket and a single mutation may result in high-
level resistance to one or more NNRTI (Deeks, 2001). Three 
NNRTis are currently approved for antiretroviral therapy in the 
United States: delavirdine (DLV), efavirenz (EFV) and 
nevirapine (NVP). The most commonly observed effect of 
NNRTI resistance mutations is a change in the ratio of RNase H 
to polymerase activities (Gerondelis et al. , 1999; Archer et a/., 
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2000). However, the level of drug resistance in vitro does not 
always correlate with the likelihood of a drug-resistant variant 
emerging in vivo. While NNRTis can be potent inhibitors of HIV-
1 replication, with favourable safety and pharmacokinetic 
parameters, rapid emergence of resistant viruses both in vitro 
(Mellors et a/., 1992; Richman et a/., 1991) and in vivo (Demeter 
eta/., 2000; Havlir eta/., 1995; Staszewski eta/., 1999), often 
as the result of single nucleotide changes, has limited the 
therapeutic utility of these compounds as monotherapy. 
However, recent clinical trials of the use of NNRTis in 
combination with other antiretroviral agents have demonstrated 
an added benefit from inclusion of an NNRTI in such 
combination regimens (Carr et a/., 1996; Cheeseman et a/., 
1995; Friedland eta/., 1999; Montaner eta/., 1998; Starr eta/., 
1999). Although the viral replicative capacity of NNRTI-resistant 
viruses has not been extensively studied, available data suggest 
that NNRTI-selected single-point mutations, such as 1 03N or 
181 C plays a very important role. 
High-level resistance is conferred by a variety of single-amino-
acid changes within the binding pocket, including A98G, L 1001, 
K101E, K103N, V106A, V1081, E138K, T1391 , Y181C, Y188C, 
G190A and P236L (Buckheit et a/., 1997). In models of the 
three-dimensional structure of HIV-1 RT, these mutations 
cluster around the NNRTI binding site. The use of NNRTis in 
patients is now dependent on defining appropriate combinations 
of agents which will prevent or significantly retard the selection 
of drug-resistant virus populations or which will result in the 
selection of drug-resistant virus isolates in which mutation of 
critical amino acid residues renders the RT less fit to support 
virus reproduction. These mutations do little damage to viral 
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fitness, creating highly resistant viruses without compromising 
viral replication, thus persisting during long-term virologic failure. 
Several practical inferences can be derived from these 
principles (Table 2.12.3.1 ). Firstly, drugs for which only a single 
mutation is required for high-level resistance, e.g., lamivudine 
and nevirapine, should be reserved for use with other drugs in 
regimens designed to maximally suppress virus replication. Use 
in less suppressive regimens will select for high-level resistance 
more quickly (Richman et a/., 1994; Havlir et a/., 1996; 
Schuurman et a/., 1995). Secondly, combination regimens 
should be designed to confer the potency needed to maximally 
suppress pre-existing genetic variants and prevent replication. 
Regimens must establish a "genetic barrier" by suppressing 
minor populations with 1 or 2 mutations that could emerge with 
individual regimen components, permitting cumulative mutation 
acquisition. This requirement is more formidable in previously 
treated patients because prior treatment may have established 
a genetic archive of drug-resistant virus within peripheral blood 
mononuclear cells (PBMCs) and other tissue reservoirs 
(D'Aquila eta/., 1995). 
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Table 2.12.3.1-Practical implications of the biology of HIV-1 drug 
Resistance (Richman eta/., 1994) 
• Genetic variants of HIV with any single and probably many double 
mutations (although less likely) pre-exist in all patients before treatment is 
started. Thus, partially suppressive regimens containing lamivudine or 
certain NNRTis rapidly fail because of breakthrough replication of pre-
existing resistant variants. 
• Genetic variants with 3 or more resistance mutations probably exist 
rarely, if at all, in untreated patients. Thus, potent combination regimens 
that require many resistance mutations for viral escape are 
recommended. 
• Preventing cumulative acquisition of resistance mutations requires potent 
combination regimens that suppress virus replication to below levels of 
detection of the most sensitive assays available (about 50 copies/ml). 
• Complex mixtures of genetic variants exist in all patients. Assays for drug 
resistance, both genotypic and phenotypic, may provide information only 
on the predominant circulating variants and may miss minor variants. 
• Prior treatment may select for resistant mutants that persist in lymphoid 
tissues but are no longer predominant or even detectable in the absence 
of drug pressure. Re-treatment with the same drug may not be effective 
because of rapid selection of these mutants. Thus, genotypic and 
phenotypic assays must be interpreted in the context of drug treatment 
history 
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2.12.4 Antiretroviral Resistance Genotypes 
HIV-1 resistance to antiretroviral inhibitors can be defined as any 
change that improves viral replication in the presence of an inhibitor. It 
can be determined at a genotypic level by the detection of known 
mutations that confer phenotypic resistance. Alternatively, it can be 
determined at the phenotypic level by measuring the ability of an HIV-1 
isolate to grow in the presence of an inhibitor or by measuring the HIV-1 
RT or PR enzyme activity in the presence of an inhibitor. 
2.12.4.1 Resistance Mutations selected during Antiretroviral 
Treatment 
Figure 2.12.4.1 lists common mutations selected by protease 
inhibitors (A) as well as nucleoside reverse transcriptase 
inhibitors (NRTis) and NNRTis (8), identified largely in 
studies of monotherapy. In general, there is good 
concordance between mutations seen in laboratory selection 
experiments and those in clinical isolates from patients with 
failing treatment. However, some in vitro mutations are not 
found in patients in whom that particular drug has failed, 
e.g., the stavudine-selected V75T (Lacey and Larder, 1994) 
and delavirdine-selected P236L mutation (Dueweke et a/. , 
1993). Although, they confer resistance during in vitro virus 
passage experiments, but were rarely identified in patients in 
whom the drugs have failed (Lin eta/. , 1994). 
Some mutations selected by antiretroviral drugs directly 
affect viral enzymes and cause resistance via decreased 
drug binding, whereas others have indirect effects (Kieim et 
a/., 1994; Chow et a/., 1993; Caliendo et at., 1996). It is 
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useful to categorise resistance mutations as primary or 
secondary (Figure 2.12.4.1 ). Primary mutations are 
generally selected early in the process of resistance 
mutation accumulation, are relatively inhibitor specific, and 
may have a discernible effect on viral drug susceptibility. 
Secondary mutations accumulate in viral genomes already 
containing 1 or more primary mutations. Many secondary 
mutations alone have little or no discernible effect on 
resistance magnitude but may be selected for because they 
improve viral fitness rather than decrease drug binding to 
target enzymes. 
The distinction between primary and secondary mutations 
depicted in Figure 2. 12.4.1 A, may help explain protease 
inhibitor cross-resistance. There seems to be little overlap in 
primary mutations selected by different protease inhibitors 
(e.g., saquinavir-selected L90M and G48V; nelfinavir-
selected D30N; and amprenavir-selected 150V). By 
themselves, these primary mutations may not cause cross-
resistance to other protease inhibitors. However, there is an 
overlapping spectrum of secondary mutations in the 
protease gene selected by all protease inhibitors (Figure 
2.12.4.1A). Many of the secondary changes are 
compensatory, improving fitness of virus containing primary 
mutations without actually increasing inhibitor resistance 
(Schock et a/. , 1996). The mutations may improve 
enzymatic function by altering protease catalytic activity or 
by affecting protease substrates (e.g., making sites in gag or 
other viral precursor polypeptides more easily cleavable). 
© Central University of Technology, Free State
Chapter 2 74 
The NRTis can select for a single primary mutation (e.g., 
lamivudine), any one of a few primary mutations (e.g. , 
didanosine and zalcitabine), or an accumulation of primary 
and secondary mutations (e.g., zidovudine) (Figure 
2.12.4.1 8). Secondary mutations that compensate for 
replication impairment caused by primary resistance 
mutations are also selected by reverse transcriptase 
inhibitors (Chow eta/., 1993; Kleim eta/., 1994; Caliendo et 
a/., 1996). 
Cross-resistance among NRTis can be mediated by 
inhibitor-specific mutations and less specific secondary 
mutations, especially among drugs that bind to similar or 
adjacent viral target residues (evident for didanosine and 
zalcitabine, which select for similar mutations [Figure 
2.12.4.1 B)). Similarly, the primary mutation commonly 
selected by lamivudine confers high-level phenotypic 
resistance to this drug as well as low-level phenotypic 
resistance to didanosine, zalcitabine, and abacavir in vitro. 
The clinical significance of cross-resistance among these 
drugs has not been determined. 
Mutations selected by drug combinations may differ from 
those expected based on monotherapy experience 
(Richman et a/., 1994). A unique mutation pattern in the 
reverse transcriptase gene that confers broad cross-
resistance to all NRTis, includes the 0151 M mutation 
associated with 3 or 4 additional mutations 
(Figure 2.12.4.1 B), occasionally seen in patients with long-
term exposure to NRTis, and was first described in 
association with exposure to zidovudine-didanosine 
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combination therapy (Shafer et a/., 1 994; Shirasaka et a/., 
1993) or weekly alternating zidovudine-zalcitabine 
monotherapy supplemented briefly with didanosine 
(Shirasaka eta/., 1993). 
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Figure 2.12.4.1- Most Common Mutations in HIV-1 Genes Conferring Drug 
Resistance 
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For each amino acid residue, the letter above indicates the amino acid associated with wild-type virus; the 
italicized letters below, substitutions that confer viral resistance. Primary mutations (black bars) generally 
cause decreased inhibitor binding and are the first mutation selected. Secondary mutations (white bars) 
also contribute to drug resistance and should be considered evidence of resistance, although they may 
have less direct effect on inhibitor binding in vitro than primary mutations. The mutation selected in vitro 
(black and white bar) is rarely seen in patients having treatment failure. For indinavir, the mutations listed 
as primary may not be the first mutations selected, but they have selected in most patient isolates in 
combination with other mutations. For zalcitabine, all mutations are listed as primary because of 
inadequate clinical data to detennine the most frequent initial mutation. Amino acid abbreviations are A, 
alanine; C, cysteine; 0 , aspartate; E, glutamine; F, phenylalanine; G, glycine; H, histidine; I, isoleucine; K, 
lysine; L, leucine; M, methionine; N, asparagines; P, proline; Q, glutamine; R, arginine; S, serine; T , 
threonine; V, Valine; W , thryptophan; Y, tyrosine. Multinucleoside resistance mutational patterns A and B 
each cause resistance to zidovudine, stavudine, lamivudine, didanosine, zalcitabine, and abacavir. 
*Mutations selcted by protease inhibitors in gag cleavage sites are not listed because their contribution to 
resistance is not fully defined. t A preliminary report identifies mutations E44D and V11881 as conferring 
moderately reduced (about 10-fold) susceptibility to lamivudine with uncertain clinical significance. This 
contrasts with the greater than 100-fold reduced susceptibility to lamivudine conferred by M184Vor M1841, 
which is associated with virologic rebound (Des camps eta/., 2000). tThe mutations listed for zidovudine 
above contribute to reduced susceptibility to abacavir in vitro and in vivo and are listed as secondary, even 
though they may be present before abacavir is introduced (Larder eta/., 1999). They have also been 
reported to be uncommonly selected by stavudine plus didanosine even in the absence of prior zidovudine 
exposure. Phenotypic resistance of these mutations to stavudine or didanosine in vitro was not identified. 
The clinical significance of these mutations and of V75T on in vivo response to stavudine is not known. 
§Several insertions of 2 amino acids have been reported following T69S (or rarely T69A), including Ser-
Ser; Ser-Giy; Ser-Ala; and Thr-Ser (Larder eta/. , 1999). uFor nevirapine or delavirdine, each mutation can 
occur as an initial or subsequent mutation and affect inhibitor binding (Demeter eta/., 2000). 
(adapted from Hirsch eta/., 2000) 
2.12.4.2 Interactive Effects of Mutations on Drug Susceptibility 
Some mutations selected by one drug suppress phenotypic effects of 
another mutation, e.g., suppression of zidovudine resistance by 
didanosine-selected L74V, NNRTI-selected Y181C, and lamivudine-
selected M184V (StClair eta/., 1991 ; Larder eta/. , 1993; Tisdale eta/., 
1993; Tachedjian et a/., 1996). Molecular mechanisms for these 
interactions are not well understood. 
Lamivudine primarily selects for reverse transcriptase codon 184 
mutations whether it is given as monotherapy or in combination. 
Suppression of zidovudine resistance phenotype or delay in its 
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emergence due to M184V is common during zidovudine-lamivudine 
combination therapy (Larder et a/., 1995). Nevertheless, additional 
reverse transcriptase mutations emerge with combination zidovudine-
lamivudine therapy and eventually overcome the suppressive effect, 
resulting in high-level resistance to both drugs (Nijhuis et a/., 1997; 
Kemp et a/., 1998). The M184V mutation effect is thus likely to be 
transient and its induction less useful than maximising HIV 
suppression. The presence of this mutation should prompt 
consideration of change in therapy, unless no satisfactory therapeutic 
options remain. 
2.12.4.3 Genotypic Resistance Assays 
Assays for detecting the HIV-1 genome mutations are based upon a 
polymerase chain reaction (PCR) as the first methodological step 
(Hirsch et a/., 2000). The PCR amplifies an RNA fragment (after a 
reverse transcription step) to quantities large enough for genotyping 
(the second step). Most laboratories now analyse protease and reverse 
transcriptase gene DNA sequences but may not investigate other 
genome regions relevant for drug resistance (e.g., gag cleavage sites). 
It is still a technical challenge to amplify and genotype all regions 
implicated in protease and reverse transcriptase inhibitor resistance. 
Similar to phenotypic assays, genotypic assays require amplification of 
HIV-1 sequences from plasma containing at least 500 to 1000 HIV RNA 
copies/ml and may detect a mutant present in plasma at a level above 
10% to 50% of the total population of viruses (Schuurman et a/., 
1999a). Resistance testing is not as likely to be useful when values are 
below this level. With current methods, species constituting 20% or 
more of amplified product can usually be detected (Hanna and D'Aquila, 
2001). False positivity for mutations is possible due to carryover from 
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other HIV-1 samples in the laboratory or from random polymerase 
errors during in vitro nucleic acid synthesis. Also, unless molecular 
clones of PCR products are studied (not routinely done), it is impossible 
to be certain whether multiple positions in the sequence are physically 
linked together on the same genome; ie, it is impossible to differentiate 
a mixture of singly mutant genomes from a mixture having some 
genomes with accumulated different mutations. 
2.12.4.4 Assays used for Genotypic Analysis 
2.12.4.4.1 Point Mutation Assays 
After mutations at specific codons conferring resistance have 
been identified, specific oligonucleotides can be synthesised 
to allow selective priming and DNA synthesis or to allow 
selective hybridisation (Kozal eta/., 1996). 
A) Single Nucleotide Sequencing Assay 
The PCR reaction is performed by using a biotinylated 
primer. The biotinylated PCR product is immobilised 
on a streptavidin-coated microtitre well and then 
denatured to a single strand. An oligonucleotide 
primer with its 3' end one nucleotide upstream of the 
point mutation under analysis, is annealed and a 
single labelled ddNTP is used to extend the 
oligonucleotide primer. If the added ddNTP is 
complementary to the point mutation, extension will 
occur. The well giving a signal indicates the 
complementary base in the target. In a mixed 
population of wild type and mutant sequences a 
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signal will be found in more than one well (Kaye eta/., 
1992). 
8) Restriction Enzyme Digestion 
Vasudevachari et a/. (1996) described a rapid 
screening procedure for the detection of resistance 
mutations based on restriction enzyme digestion. The 
PCR assay is performed by using two different 
labelled primers. Restriction digestion will only occur 
when no mutations are observed at the restriction 
site. Wild type and mutant sequences will result in 
different sizes of DNA fragments. After restriction 
digestion, the various DNA fragments are separated 
on a denaturing gel and the intensities of the 
fluorescent bands can give information on the relative 
proportion of wild type and mutant at the codon being 
analysed. 
C) Selective PCR 
Selective PCR makes use of oligonucleotide primers 
developed to specifically anneal at their 3' ends to 
either the wild type or mutant codon of interest 
(Larder et a/., 1991; Anderson et a/. , 1994). 
Theoretically, during PCR, the DNA fragments are 
only generated when the 3' end of the oligonucleotide 
primers matches the target sequence. Two separate 
PCRs are performed, the first one to amplify the wild-
type sequence and the second one to amplify the 
mutant sequence. After optimisation, selective PCR 
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can yield information on the relative proportion of wild 
type and mutant at the codon being analysed (Van 
Laethem et at., 1999). 
D) RNase A Mismatch Cleavage Method 
In the RNase A mismatch cleavage method the ability 
of RNase A to recognise and cleave single-base 
mismatches in RNA-DNA hybrids is used for the 
detection of point mutations (L6pez-Galindez et a/., 
1991). An RNA fragment from a wild type sequence 
is synthesised and hybridised to yield a PCR product 
originating from a patient sample. The sequence 
differences between the RNA probe and the DNA 
target sequence generate heterohybrids, which after 
RNase treatment generate various RNA fragments. 
These RNA fragments can be separated on a 
denaturing gel resulting in characteristic patterns for 
wild type and mutant sequences respectively. 
E) Ligase Detection Reaction 
This reaction occurs by the annealing and subsequent 
ligation of two oligonucleotides. The probe 
oligonucleotide is attached to a latex bead on the 5' 
end, and its 3' end is complementary to either the wild 
type or mutant sequence. The 5' end of the detector 
oligonucleotide is phosphorylated and is designed to 
anneal to the nucleotides next to the 3' end of those 
bound by the probe oligonucleotide. The detector has 
a biotin on the 3' end. When the probe 
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oligonucleotide is complementary to the target 
sequence, the detector can be attached by ligation. 
Ligation of both oligonucleotides occurs only when the 
two bases on either side of the ligation site are 
complementary to the target. The probe and detector 
oligonucleotides are denatured from the template by 
heating and passing through a nylon membrane 
which traps the latex bead. When ligation has 
occurred, the biotin molecule is trapped in the 
membrane and can be detected with streptavidin-
horseradish peroxidase, followed by colorimetric 
detection (Frenkel eta/. , 1995) 
f) Differential Hybridisation Assay 
This assay is used for the determination of 
proportions of wild type and mutant sequences in a 
sample. PCR is performed by using one biotinylated 
primer and subsequently dispensed in a well in which 
streptavidin is covalently bound. The PCR fragment 
is denatured and hybridised with either a wild type or 
mutant probe labelled with alkaline phosphatase. The 
detection is performed by a colorimetric or 
chemiluminescent method. In order to quantify the 
amount of PCR product bound to each well, the DNA-
probe fragments are denatured again and re-
hybridised with a generic probe (Eastman et a/., 1995 
and 1998). 
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G) 
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Line Probe Assay (LiP A) 
This assay is based on reverse-hybridisation of 
biotinylated PCR product to the oligonucleotide 
probes immobilised on nitrocellulose strips. The 
probes are designed to contain mutations associated 
with resistance, or they contain wild type sequences. 
For every mutation of interest various probes have 
been immobilised on the strip to account for the 
variability of the background sequence in the vicinity 
of the codon to be analysed. Colorimetric detection of 
hybridisation is done by streptavidin-alkaline 
phosphatase (Stuyver eta/., 1997). 
H) GeneChip Technology 
This technology allows the probing of HIV-1 
sequences using high-density oligonucleotides arrays 
immobilised on a solid matrix (Southern et a/., 1992; 
GOnthard eta/., 1998a and 1998b; Anderson et a/., 
2000). The sequence and position of each probe on 
the matrix is known. The fluorescent labelled PCR 
product anneals to a probe when it is completely 
complementary. Computerised detection and 
analysis are based upon laser fluorescence scanning 
of the DNA interactions on the array. The pattern of 
hybridisation can allow the determination of the 
complete target sequence. However, it can only 
detect variants for which probes have been 
immobilised on the chip and cannot detect new, 
previously unreported, variants. This can result in 
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incomplete sequences or in an over stimulation of the 
known variants in the total virus population. 
2.12.4.4.2 DNA Sequencing Assays 
A) Dideoxy Chain Termination Sequencing 
Dideoxy chain termination sequencing provides 
information on all the nucleotides of the sequenced 
region. The target sequence is amplified using PCR 
and the sequence is determined on the incorporation 
of dideoxynucleotides. The various fragments differ in 
length and are separated by a denaturing gel. Most 
of the sequencing technologies are semi-automated 
and make use of fluorescence labelled primers or 
dideoxynucleotides. 
Commercial versus In-House Methods 
Drug resistance can either be determined 
phenotypically by cultivating (recombining presence of 
increasing drug concentrations) or genotypically by 
searching for mutations known to be associated with 
drug resistance from in vitro or in vivo data. The time-
consuming phenotypic assays will remain restricted to 
specialised laboratories. Many assays are now 
performed by many laboratories with in-house 
techniques or are offered routine virological 
diagnostics. Two commercial kits for HIV genotyping 
exist, the HIV Genotyping System (ViroSeq HIV-1 
Genotyping System), [Applied Biosystems, Foster 
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City, Calif.] and TruGene [Bayer Diagnostics, 
Fernwald, Germany]). 
The ViroSeq HIV-1 Genotyping System detects 
mutations in the RT and protease regions of the pol 
gene and provides the physician with a report 
indicating genetic evidence of viral resistance. It is a 
complete system that provides reagents for viral RNA 
isolation from plasma, RT -PCR, and sequencing 
(Mukaide eta/., 2000; Cunningham eta/., 2001). The 
entire protease gene and two-thirds of the RT gene 
are amplified to generate a 1.8 kb amplicon. The 
amplicon is used as a sequencing template for seven 
primers that generate an approximately 1.3 kb 
consensus sequence. The software compares the 
consensus sequence with a known reference, HXB-2, 
to determine mutations present in the sample. 
Finally, the ViroSeq software uses a proprietary 
algorithm to analyse the mutations and generate a 
drug resistance report. 
2.12.4.5 Phenotypic Resistance Assays 
Drug-resistant virus phenotypes are detected by measuring the 50% or 
90% inhibitory concentration (IC50 or IC90) of a drug in vitro. In 
standardised drug susceptibility assays, cells are infected with a fixed 
amount of viral inoculum, and various drug concentrations are tested to 
quantitate the drug concentration required to inhibit viral replication 
(e.g. , determine dose-response curve) compared with untreated 
infected control cells. The precise ICso or ICgo values obtained depend 
on the assay used, cell type used, antiretroviral drug tested, input viral 
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inoculum, marker of viral replication selected (e.g., measurement of 
HIV p24 antigen or reverse transcriptase activity), and time in culture 
(Johnson, 1995). Therefore, ICso or ICso values from one type of assay 
should not be compared with those obtained by another method. 
Drug susceptibility testing measures HIV ability to grow at different 
drug concentrations versus a drug-susceptible laboratory strain of virus 
or previous isolate from the same patient. In general, a 4-fold increase 
is the minimum change reliably detectable in the laboratory. Changes 
in IC50 or IC9o values that are clinically important regarding drug activity 
have not been defined. High-level HIV-1 resistance to zidovudine 
(e.g., isolates for which ICso values are ~ 1.0 ~molll) predicted more 
rapid clinical progression and death in an analysis adjusting for other 
risk factors in patients with advanced HIV disease receiving zidovudine 
monotherapy (D' Aquila eta/., 1995; Japour eta/., 1993; Montaner et 
a/., 1993). The clinical relevance of ICso or ICso values for each multi-
drug regimen component has not been defined. Also, sustained virus 
suppression may be seen in patients in whom drug-resistant virus has 
been detected (Schuurman eta/., 1995; Havlir eta/., 1995). This may 
result from achieving plasma drug levels in vivo that exceed IC50 or 
ICso values for resistant virus in vitro. 
Phenotypic assays may fail to detect evolving resistance that has not 
yet led to measurable increases in IC50 values, e.g., the K70R 
zidovudine resistance-conferring mutation emerges within 12 weeks in 
nearly half of patients receiving zidovudine monotherapy, yet its 
presence alone is not associated with measurable increases in 
zidovudine IC50 . Thus, detection of a mutant genotype may be 
expected to precede detection of an increased ICso value. Moreover, a 
limitation of all drug susceptibility assays described to date is that only 
predominant circulating viral populations are sampled to yield IC50 or 
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IC90 values. Thus, minority drug-resistant species contributing to drug 
failure or transmission of resistant virus may not be detected. 
2.12.4.5.1 Replication-based Assays 
A) Recombinant Virus Assay 
This assay starts with the amplification of the patient 
derived HIV-1 target sequence (RT, PR or PR+RT) 
using RT-PCR (Kellam eta/., 1994; Maschera eta/., 
1995; Boucher et a/., 1996; Walter et a/., 1999). 
Subsequently, the PCR product is incorporated into a 
proviral laboratory clone by means of homologous 
recombination or ligation. This process generates a 
stock of chimeric viruses. The viruses are tested for 
their ability to grow in the presence of different 
concentrations of inhibitors. Drug resistance testing 
was initially performed in a Hela plaque reduction 
assay. Later, it was modified by using a MT2/MT4-
MTI /XTT based cythopathic protection assay 
(Pauwels eta/., 1988; Jellinger eta/., 1997). 
8) PBMC p24 Growth Inhibition Assay 
The assay is standardised by the AIDS Clinical Trails 
Group and the US Department of Defence (ACTG-
DoD protocol) (Japour et a/., 1995). The patient's 
HIV-1 infected PBMCs or plasma are co-cultivated 
with uninfected phytohemagglutinin (PHA)-stimulated 
donor lymphocytes in order to grow a high-titre viral 
stock. After completion, the virus is tested for its 
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ability to grow in the presence of inhibitors by using 
serial dilutions of the inhibitors and measuring the 
production of p24 antigen by means of an ELISA test. 
C) He/a Plague Reduction Assay 
The assay involves the measurement of the number 
of plaques, reflecting virus-killed cells in a CD4+ Hela 
cell monolayer (Larder et a/. , 1990). The HIV-1 
isolates are co-cultivated in PBMCs and then used to 
infect monolayers of Hela cells in the presence of 
serial dilutions of inhibitors. The viral susceptibility to 
inhibitors is derived from the reduction of the number 
of plaques in the presence of an active inhibitor. 
2.12.4.5.2 Enzyme-based Assays 
A) Amp-RT Assay 
This assay measures the HIV-1 RT activity from 
plasma in the presence of different RTI 
concentrations (Heneine et a/., 1995; Garcia-Lerma et 
a/., 1999; Vazquez-Rosales eta/., 1999). The activity 
of the RT in plasma is detected by measuring the 
ability to produce a DNA copy of a known 
heteropolymeric RNA template by extending a 
complementary DNA oligonucleotide primer. The 
reverse-transcribed eDNA is subsequently detected 
by PCR amplification. The RT susceptibility to 
NNRTis and to the 5'-triphosphate form of NRTis is 
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ability to grow in the presence of inhibitors by using 
serial dilutions of the inhibitors and measuring the 
production of p24 antigen by means of an ELISA test. 
C) He/a Plague Reduction Assay 
The assay involves the measurement of the number 
of plaques, reflecting virus-killed cells in a CD4+ Hela 
cell monolayer (Larder et a/., 1990). The HIV-1 
isolates are co-cultivated in PBMCs and then used to 
infect monolayers of Hela cells in the presence of 
serial dilutions of inhibitors. The viral susceptibility to 
inhibitors is derived from the reduction of the number 
of plaques in the presence of an active inhibitor. 
2.12.4.5.2 Enzyme-based Assays 
A) Amp-RT Assay 
This assay measures the HIV-1 RT activity from 
plasma in the presence of different RTI 
concentrations (Heneine et a/., 1995; Garcia-Lerma et 
a/., 1999; Vazquez-Rosales et a/., 1999). The activity 
of the RT in plasma is detected by measuring the 
ability to produce a DNA copy of a known 
heteropolymeric RNA template by extending a 
complementary DNA oligonucleotide primer. The 
reverse-transcribed eDNA is subsequently detected 
by PCR amplification. The RT susceptibility to 
NNRTis and to the 5'-triphosphate form of NRTis is 
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determined based on the reduction of the PCR signal 
in the presence of an active inhibitor. 
2.12.4.6 Genotypic versus Phenotypic Resistance Assays 
Both genotypic and phenotypic assays have several advantages and 
disadvantages. They provide complementary information on the 
resistance of a HIV-1 isolate. No recommendation can be made at 
present in favour of or against these assays. 
Genotypic resistance assays can deliver results within a few days 
whereas more time is required to obtain phenotypic resistance results. 
This turn-around time can be an important factor in some clinical 
situations where results are needed as soon as possible, e.g. post-
exposure prophylaxis and primary HIV-1 infection. 
Both resistance assays have to be performed in highly specialised 
laboratory facilities. This is especially true for phenotypic resistance 
assays as they require bio-safety level 3 facilities, whereas genotypic 
resistance can be performed in a dedicated molecular biology 
laboratory. Because both types of assays require sophisticated 
technology and knowledge, a strict adherence to current laboratory 
standards is important, and also well trained and experienced 
laboratory technicians are considered as an asset. A blinded 
genotyping proficiency panel, ENVA-2, was sent to laboratories in 
Europe, North America and Australia, and demonstrated that many 
laboratories are able to detect wild type virus but that mutant virus was 
often underestimated. Only half of the laboratories were able to detect 
50/50 mixtures of wild type and mutant codons (Schuurman et a/., 
1999a and 1999b). 
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The current resistance assays, with the exception of point mutation 
assays, have difficulties to detect minor variants. Sequencing and 
phenotypic assays may differentiate a mutant only at a level of 10% to 
50% in a mixture of viruses (GOnthard eta/., 1998a; Schuurman et al., 
1999a and 1999b; Van Laethem et al., 1999). Point mutation assays 
are able to detect minor variants at a level of 1% to 5% (Stuyver et a/., 
1997; Van Laethem eta/., 1999). However, point mutation assays are 
limited to the detection of particular key mutations and their 
performance can be influenced by the variability of the background 
sequence in the vicinity of the key mutation to be analysed. 
Sequencing has the advantage of detecting all known resistance-
related mutations. Phenotypic assays even measure the effective 
sensitivity, resulting from known but also unknown resistance-related 
mutations. 
The information provided by genotypic resistance assays may be 
difficult to interpret. The current knowledge on the correlation between 
the genotypic characteristics of a HIV-1 isolate is mainly based on in 
vitro studies or monotherapy studies. This can give only a part of the 
necessary information as patients are currently treated with combination 
therapies that change in time. This results in complex patterns of 
mutations. The phenotypic effects of mutations and their interactions 
can sometimes not be predicted. Phenotypic resistance assays give a 
direct measurement of susceptibility towards the inhibitors tested, which 
includes the effect of all mutations and their interactions. The clinical 
relevance of phenotypic results, however, can also be difficult to 
interpret because the threshold at which a specific inhibitor becomes 
ineffective in vivo has not been determined yet. 
Another issue in the interpretation of genotypic results is whether the 
mutations that make up part of a set of multiples exist on a single clone 
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or are spread across multiple clones of variants. Phenotypic resistance 
assays resulting in low-level resistance may be caused by a small 
change in susceptibility of the whole virus population or a mixture of 
resistant and susceptible virus. The linkage of mutations could have 
important clinical implications, but at the moment this issue cannot 
routinely be elucidated with the current resistance assays. 
An important limitation of currently available assays is their need of 
plasma samples with a HIV-1 viral load above 1000 copies/mi. This is 
required to achieve reliable results. Otherwise non-representative 
variants could be picked up due to stochastic events during the 
experimental procedures. However, switching therapy early after 
virology failure, when the HIV-1 viral load is detectable but still very low, 
results in a better chance of response to the salvage therapy. There 
are only a few studies that provide the optimal point at which therapy 
should be changed in terms of long-term clinical outcome, but the short-
term risk of any viral replication in the presence of inhibitors is the 
development of resistance. HIV-1 viral load between 50 and 500 
copies/ml is associated with a higher risk of resistance than levels 
below 50 copies/ml (Raboud eta/., 1998). 
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3.1 STUDY OBJECTIVE 
The main objective of this study was to study the variants of HIV-1 in 
circulation in untreated patients in the Free State. This will establish a 
baseline of the variants present (including possible existing resistance 
against drugs) before the rollout of antiretroviral therapy in the province. 
3.2 STUDY DESIGN 
The study population consisted of 19 adult ARV-na"ive AIDS patients 
recruited from Tsepo House, an AIDS hospice in Bloemfontein. Initially, 
samples were taken from 32 patients, but due to haemolysis (2 samples}, 
insufficient volume of plasma (4) and non-amplification or weak 
amplification of the required fragment (8), most of which did not produce 
good quality sequences, the results of 19 patients will be presented. The 
duration of the study was approximately three years. Approval from the 
Ethics committee of the Faculty of Health Sciences, University of the Free 
State, was obtained (ETOVS 227/01). The necessary consent was 
obtained from every participant in the study (Appendix A). Every patient 
will also receive an information sheet to provide him/her with all the 
information regarding the study (Appendix A). 
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3.3 STUDY POPULATION 
3.3.1 Number of Subjects 
Nineteen HIV-positive/AIDS na'ive patients were enrolled in this 
study. Seven of the 19 patients were male while 12 were female. 
The high percentage of females represents the demographic 
distribution of HIV-infection prevalence in this region of South Africa 
and is perhaps also a reflection of the national HIV-infection 
prevalence. 
3.3.2 Justification for Inclusion and Exclusion Criteria 
The criteria were set to ensure a homogenous subject population. 
3.3.2.1 
3.3.2.2 
Inclusion Criteria 
• HIV positive/AIDS male and female patients 
between 18-65 years 
• No previous antiretroviral treatment 
• Viral Load more than 2000 copies/ml 
• CD4+ T-cell count of 100-350 cells/mm3 
• Only those giving informed consent will be 
included in the study. 
Exclusion Criteria 
• If consent from the patient cannot be obtained 
• If the patient is not an HIV positive/AIDS sufferer 
• If the viral load is less than 2000 copies/ml 
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• Patients previously on antiretroviral treatment 
• Participation in another study with an 
experimental drug within eight weeks prior to the 
first administration of the project 
• Loss of blood equal to or exceeding 500ml 
during the 8 weeks prior to the administration of 
the project 
• Being on anti-retroviral therapy or any treatment 
for chronic diseases 
3.3.3 Subject identification 
• Each enrolled subject received a number (Between 01-19) 
and retained this number throughout the study. 
• Each enrolled subject was identified by date of birth (six 
digits). 
3.3.4 Withdrawal Criteria 
3.4 SAMPLING 
Subjects had the right to withdraw from the study at any 
time, irrespective of the reason. The withdrawals would be 
handled as dropouts and would not be replaced in this study. 
Five ml of whole blood was collected in a sterile EDT A anticoagulant tube 
(Vacutainer™PPT™ Brand Tubes, Becton-Dickenson #362788 or 
equivalent) and the tube was immediately inverted 8-10 times to mix. 
The RNA was isolated from the plasma immediately after sampling and 
frozen at -70°C for later analysis. 
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The AMPLICOR HIV-1 MONITOR Test, v1 .5 is for use with plasma 
specimens only. Another tube containing 10ml of EDTA (Lavender top, 
Becton Dickinson #6454) whole blood was drawn from the subjects to 
perform the viral load counts. The plasma was separated from the whole 
blood within 6 hours by centrifuging at 800-1600 xg for 20 minutes at room 
temperature. The viral loads were either done manually or performed by 
Pathcare (pathologists), Bloemfontein. 
3.5 LABORATORY INVESTIGATIONS 
3.5.1 Viral load counts 
The AMPLICOR HIV-1 MONITOR®Test, version 1.5 (v1 .5) is an in 
vitro nucleic acid amplification test for the quantitation of Human 
Immunodeficiency Virus Type 1 (HIV-1) RNA in human plasma. 
The test is intended for use in conjunction with clinical presentation 
and other laboratory markers as an indicator of disease prognosis. 
The test can be used to assess patient prognosis by measuring the 
baseline HIV-1 RNA level or to monitor the effects of antiretroviral 
therapy by measuring changes in plasma HIV-1 RNA levels during 
the course of antiviral treatment. The manual Amplicor test was 
initially performed in the laboratories of the department of 
Haematology, Bloemfontein, while all samples were later re-tested 
by Pathcare, Bloemfontein, using the automated version of the 
assay. The manual method will be described. 
3.5.1.1 Standard Specimen and Control Preparation 
1. A 70% ethanol solution was prepared. For 12 tests, 11 .0 ml 
95% ethanol and 4.0 ml of deionised or distilled water were 
mixed. 
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One 2.0 ml screw-cap tube was labelled for each patient 
specimen and three additional tubes were labelled as HIV-1 
Negative Control [(HIV-1 (-)C) (Tris-HCI buffer, < 0.005% 
Poly rA RNA (synthetic), EDTA, 0.05% Sodium azide)] ,HIV-
1 MONITOR low Positive Control [(HIV-1l(+)C) (Tris-HCI 
buffer, < 0.001% Non-infectious in vitro transcribed RNA 
(microbial) containing HIV-1 sequences, < 0.005% Poly rA 
RNA (synthetic), EDTA, 0.05% Sodium Azide)] and HIV-1 
MONITOR High Positive Control [(HIV-1H(+)C) (Tris-HCI 
buffer, < 0.001% Non-infectious in vitro transcribed RNA 
(microbial) containing HIV-1 sequences, <0.005% Poly rA 
RNA (synthetic), EDTA, 0.05% Sodium azide]. 
3. Preparation of Standard Working Lysis Reagent. 
HIV-1 MONITOR Quantitation Standard, version 1.5 [(HIV-1 
QS, v1.5), Tris-HCI buffer, < 0.001% Non-infectious in vitro 
transcribed RNA (microbial) containing HIV-1 primer binding 
sequences and a unique probe binding region, <0.005% 
Poly rA RNA (synthetic), EDTA, Amaranth Dye, 0.05% 
Sodium azide)] was vortexed for 5-10 seconds before use. 
For each batch of 12 specimens and controls, 100 J.!l HIV-1 
QS, v1.5, was added to one bottle of HIV-1 MONITOR lysis 
Reagent [(HIV-1 l YS}, Tris-HCI buffer, 68% Guanidine 
thiocyanate, 3% Dithiothreitol, <1% Glycogen)] and mixed 
well. 
4. 600 J.!l standard working lysis reagent was added to each of 
the labelled tubes and capped. It was necessary to check 
that the Working lysis Reagent is pink to confirm that the 
Quantitation Standard was added to the lysis Reagent. 
5. Preparation of Standard Controls: 
• Negative Plasma (Human}, [(NHP), Human plasma, non-
reactive by US FDA licensed tests for antibody to HCV, 
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antibody to HIV-1/2, and HbsAg, 0.1% ProCiin® 300)] 
HIV-1 (-) C, HIV-1 L(+)C and HIV-1 H(+)C were vortexed 
for 3-5 seconds. 
• 200 J.LI NHP was added to each of the three control tubes. 
The tubes were capped and vortexed for 3-5 seconds. 
• 50 J.LI HIV-1 (-) C was added to the tube labelled "HIV-1 
(-) C" containing the Standard Working Lysis Reagent 
and NHP. The tube was then capped and vortexed for 
3-5 seconds. 
• 50 J.LI HIV-1 L(+)C was added to the tube labelled "HIV-1 
L(+)C" containing Standard Working Lysis Reagent and 
NHP. Again the tube was capped and vortexed for 3-5 
seconds. 
• 50 J.LI HIV-1 H(+)C was added to the tube labelled "HIV-1 
H(+)C" containing Standard Working Lysis Reagent and 
NHP and the tube was capped and vortexed for 3-5 
seconds. 
6. 200 J.LI of each patient's specimen was added to the 
appropriately labelled tubes containing standard working 
lysis reagent. The tubes were capped and vortexed for 3-5 
seconds. 
7. The specimen and control tubes were then incubated for 10 
minutes at room temperature. 
8. For each specimen and control tubes, the caps were 
removed, and 800 J.LI 100% isopropyl alcohol was added, 
after which the tubes were capped and vortexed for 3-5 
seconds. NB: Do not have more than one tube open at a 
time. 
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9. The specimens and controls were centrifuged [(Heraeus 
Labofuge 400 at maximum speed (14000 xg)) for 15 minutes 
at room temperature making use of orientation marks. 
10. By using a new, fine-tip transfer pipet for each tube, the 
supernatant was carefully removed and discarded from each 
tube, being careful not to disrupt the pellet. As much liquid 
as possible was removed without disturbing the pellet. The 
supernatant was withdrawn slowly, allowing the liquid to 
drain completely off the sides of the tube. 
11. 1.0 ml 70% ethanol was added to each tube, which was then 
capped and vortexed for 3-5 seconds. 
12. The tubes were then placed in a microcentrifuge with the 
orientation marks facing outward and centrifuged for 5 
minutes at maximum speed (14000 xg) at room temperature. 
13. Again a new fine-tip disposable transfer pipet was used for 
each tube, and the supernatant was carefully removed 
without disturbing the pellet. The pellet was clearly visible at 
this step and as much of the supernatant as possible was 
removed. 
14. 400 J..LI HIV-1 MONITOR Specimen Diluent, [(HIV-DIL), Tris-
HCI buffer, <0.005% Poly rA RNA (synthetic), EDT A. 0.05% 
Sodium azide)] was added to each tube which was then, re-
capped and vigorously vortexed for 10 seconds. The 
reverse transcription and amplification were started within 2 
hours of specimen and control preparation. 
15. 50 J.ll of each processed specimen and control was added to 
the appropriately labelled reaction tubes containing Working 
Master Mix. The tubes were re-capped and sealed using the 
MicroAmp cap installing tool. 
16. The positions of the controls and specimens were recorded. 
Reverse Transcription and Amplification was begun within 
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45 minutes of the time that the processed specimens and 
controls were added to the reaction tubes containing 
Working Master Mix. 
17. The prepared specimens and controls were then moved in 
the MicroAmp Tray to the Amplification/Detection Area. 
Reverse Transcription and Amplification 
Performed in Post Amplification Area -Amplification/Detection 
1. The tray/retainer assembly was placed in the thermocycler 
block. 
2. The PE Applied Biosystems GeneAmp PCR System 2400 
thermocycler was programmed for the AMPLICOR HIV-1 
MONITOR Test, version 1.5, as follows: 
HOLD Program 2 min at so•c 
HOLD Program 30 min at so•c 
10 sec at 95•c 
CYCLE Program 
(&cycles) 1 0 sec at s2•c 
1 o sec at n •c 
10 sec at go•c 
CYCLE Program 
1 o sec at ss•c (23 cycles) 
10 sec at n •c 
HOLD Program 15 min at 72•C 
3. Specimens and controls have to be removed within 15 
minutes of the start of the final HOLD program. 
4. The tray from the thermocycler was removed at any time 
during the final HOLD program, placed in the MicroAmp 
base and followed immediately. 
5. The caps were carefully removed from the reaction tubes to 
avoid creating aerosols of the amplification products. 100 Jll 
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[1] MONITOR Denaturation Solution [([1] MONITOR ON), 
1.6% Sodium hydroxides, EDTA, Amaranth dye)] was 
immediately added to each of the reaction tubes by using a 
multichannel pipettor with aerosol barrier tips and mixed by 
pipetting up and down 5 times. The denatured amplicon can 
be held at room temperature for no more than 2 hours before 
proceeding to Detection. 
Detection 
Performed in Post Amplification Area -Amplification/Detection 
1. Working Wash Solution was prepared by adding 1 volume 
10x Wash Concentrate [(10x WB), < 2% Phosphate buffer,< 
9% Sodium chloride, EDT A, < 2% Detergent, 0.5% ProCiin 
300)] to 9 volumes of distilled water and mixed well . 
2. The HIV-1 MONITOR Microwell Plate [(HIV-1 MONITOR 
MWP), MWP coated with HIV-1 specific DNA probe SK102 
(Rows A to F) and QS-specific probe CP35 (Rows G and H). 
Twelve, 8-well strips in one re-sealable pouch with 
desiccant)), was allowed to warm to room temperature 
before removal from the foil pouch. 100 ~I [2] MONITOR 
Hybridization Buffer [([2] MONITOR HYB), Sodium 
phosphate solution, < 25% Sodium thiocyanate, <0.2% 
Solubilizer)] was added to each well on the MWP to be 
tested. Rows A to F of HIV-1 MONITOR MWP are coated 
with the HIV-1-specific oligonucleotide probe; rows G and H 
are coated with the HIV-1 Quantitation Standard-specific 
oligonucleotide probe. 
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25 111 of denatured amplicon was added to the HIV-1 wells in 
row A of the MWP and mixed up and down 1 0 times with a 
12-channel pipettor with aerosol barrier tips. Serial 5 fold 
dilutions were then made in the HIV-1 wells in rows B to F by 
transferring 25 111 from row A to row B and repeated the 
mixing step. This continued to row F and row F was mixed 
as before, then 25 111 was removed and discarded. 
4. 25 111 of denatured amplicon was then added to the 
Quantitation Standard wells in row G of the MWP and mixed 
up and down 10 times with a 12-channel pipettor with 
aerosol barrier tips. 
5. 25 111 was transferred from row G to row H. After mixing 25 
111 was removed from row H and discarded. 
6. The MWP was then covered with the MWP lid and incubated 
for 1 hour at 37°C. 
7. The MWP washer (Microtitration Plate washer, ADIL 
instruments F-67300 Starsbourg, France) was then used to 
wash the MWP with the Working Wash Solution. The MWP 
washer was programmed to: 
• Aspirate the contents of the wells. 
• Fill each well to the top with Working Wash Solution, 
soak for 30 seconds and aspirate dry. 
• Repeat the Step above an additional four times. 
• After automated washing is complete, tap the plate dry. 
8. 100 111 [3] Avidin-Horseradish Peroxidase Conjugate 
(([3] AV-HRP), Tris-HCI buffer, <0.001% Avidin-horseradish 
peroxidase conjugate, Bovine gamma globulin (mammalian), 
Emulsit 25 (Dai-ichi Kogyo Seiyakui Co., ltd.), 0.1% Phenol, 
1% ProCiin 150)] was then added to each well, the MWP 
covered and incubated for 15 minutes at 37°C. 
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3.5.1.4 
9. The MWP was washed as described in Step 7. 
10. The Working Wash Substrate Solution was then prepared by 
mixing 12 ml [4A] Substrate A [([4A] SUB A), Citrate 
solution, 0.01% Hydrogen peroxide, 0.1% ProCiin 150)] and 
3 ml [4B] Substrate B [([4B] SUB B), 
0.1% 3,3',5,5'-Tetramethylbenzidine (TMB), 40% 
Oimethylformamide (OMF)]. The Working Substrate was 
prepared no more than 3 hours before use after which it was 
stored at room temperature and protected from exposure to 
direct light. 
11. 100 J ..tl of Working Substrate was added to each well. 
12. The colour was allowed to develope for 1 0 minutes at room 
temperature (20-25°C) in the dark. 
13. 100 J.!l [5] Stop Reagent [([5] STOP), 4.9% Sulfuric acid)] 
was then added to each well. 
14. The optical density (00) was then measured at 450 nm 
within 10 minutes of adding [5] STOP and the absorbance 
value was recorded for each well. 
Result Calculation 
For each specimen and control the HIV-1 RNA level was calculated 
as follows: 
1. The appropriate HIV-1 well was chosen according to: 
• The HIV-1 wells in rows A to F represented neat 1:5, 
1:25, 1:125, 1:625 and 1:3125 serial dilutions, 
respectively, of the HIV-1 amplicon. The absorbance 
values should decease with the serial dilutions, with the 
highest 0045o for each specimen and control in row A 
and the lowest 00450 in row F. 
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• The well with the lowest 004so was chosen (:?: 0.20 and ~ 
2.0 00 units). 
2. The background 00 was subtracted from the selected HIV-1 
OD value (background== 0.07 00 units). 
3. The total HIV-1 00 was calculated by multiplying the 
background-corrected OD value of the selected HIV-1 well 
by the dilution factor associated with that well . 
ROW DILUTION FACTOR 
A 1 
B 5 
c 25 
D 125 
E 625 
F 3125 
4. The appropriate Quantitation Standard well was chosen as 
follows: 
• The Quantitation Standard wells in rows G and H 
represented a neat and a 1:5 dilution, respectively, of the 
Quantitation Standard amplicon. The absorbance values 
would decrease with the serial dilutions, with the highest 
00450 for each specimen or control in row G, and the 
lowest 00450 in row H. 
• The well with the lowest 0045o was chosen (:?: 0.20 and ~ 
2.0 OD units). 
5. The background 00 was subtracted from the selected 
Quantitation Standard 00 values (Background == 0. 07 OD 
units). 
6. The total Quantitation Standard 00 was calculated by 
multiplying the background-corrected 00 value of the 
selected as well by the dilution factor associated with that 
well. 
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7. For specimens and controls processed, the HIV-1 RNA 
copies/ml plasma were calculated as follows: 
Total HIV-1 OD x Input HIV-1 QS copies/PCR x 40 = HIV-1 RNAcopies/ml 
Total QS OD 
Where: Total HIV-1 OD 
Total QS OD 
Input HIV-1 QS Copies/PCR 
40 
= 
= 
= 
= 
calculated Total HIV-1 OD 
calculated Quantitation 
Standard OD 
the number of copies of 
Quantitation Standard in each 
reaction; this information is lot 
specific. See AMPLICOR HIV-1 
MONITOR Test, version 1.5 Data 
Card. 
Sample Volume Factor to 
convert copies/PCR to copies per 
ml of plasma. 
3.5.2 HIV Genotyping 
3.5.2.1 
The genotyping was done by using both an in-house method and 
the Viroseq TM HIV-Genotyping System (supplied and supported by 
Abbott Diagnostics). 
RNA Isolation (High Pure Viral RNA Kit, Roche) was used for 
both genotyping methods 
1. Tubes with 0.2 ml blood were thawed on ice 
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The tubes with 40 IJI poly-A were thawed on ice, and 5 ml 
binding buffer (1), (with 25 ml nucleic acid binding buffer 
consisting of 4.5 M guanidin hydrochloride, 50 mM Tris-HCI 
and 30% Triton X-1 00 (w/v), pH 6.6 (25°C) added. This 
solution could be used for 1 0 specimens and could be kept 
at room temperature for three months. 
3. 200 IJI plasma was then added to 400 f.JI of binding buffer (1), 
mixed well, and allowed to stand for 1 0 minutes at room 
temperature. 
4. Every specimen was placed in a filter tube within a collection 
tube and numbered. 
5. 600 IJI was transferred to every filter tube and centrifuged for 
15 seconds in an Eppendorf Minispin at 13 500 rpm. 
6. The filter tube was removed and placed in a new collection 
tube, and the old collection tube discarded. 
7. 500 1JIInhibitor Removal Buffer (3a), [(add 20 ml ethanol p.a. 
before first use), with 33 ml buffer consisting of 5 M 
guanidine-HCI, 20 mM Tris-HCI, pH 6.6 (25°C) final 
concentration after addition of ethanol)] was added and 
centrifuged for 1 minute at 13 500 rpm. 
8. The filter tube was removed and placed in a new collection 
tube and the old collection tube discarded. 
9. 450 IJI wash buffer (3), [(add 40 ml ethanol p.a. to each vial 
before use), with 10 ml wash buffer consisting of 20 mM 
NaCI and 2 mM Tris-HCI, pH 7.5 (25°C) final concentration 
after addition of ethanol)] was added and centrifuged for 15 
seconds in an Eppendorf Minispin at 13 500 rpm. 
10. 450 IJI wash buffer (3) was added, and centrifuged for 30 
seconds in an Eppendorf Minispin at 13 500 rpm, to ensure 
that all the wash buffer was removed. 
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3.5.2.2.1 
11. The collection tube was discarded and replaced with a 
1.5 ml Eppendorf tube. 
12. 50 !JI Viroseq "RNA diluent"(Poly rA RNA (synthetic), Tris-
HCI buffer, 0.05% Sodium Azide) was carefully placed on 
the filter, and centrifuged for 1 minute at 13 500 rpm in an 
Eppendorf Minispin. 
13. The filter tube was then discarded, the Eppendorf tube 
closed and put at -70°C for long-term storage or kept on ice 
for the following step. 
RT-PCR 
Roche Titan One Tube RT -PCR System 
Important: Gloves were always worn when RNA was handled to avoid 
any contamination with RNases. 
1. The Sterile water (vial 6, H20 redistilled PCR grade), dNTP 
mix (vial 2, concentration 10 mM total), on solution (suppl), 
RNase Inhibitor (vial 3, concentration 5UIJ..LI), Control primer 
mix (vial 5, human j3-actin upstream and downstream primer, 
concentration 20 J..LM total) downstream primer, upstream 
primer Control RNA (vial 4, Human control RNA (K562 total 
RNA with MS2 carrier RNA) concentration 2 pg/J..LI) and 
Template RNA were thawed and placed on ice. 
2. All the reagents were briefly vortexed and centrifuged. 
3. The Master-Mix 1 was set up in a nuclease-free microfuge 
tube placed on ice: 
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VOLUME FOR 
VOLUME FOR FINAL 
COMPONENT CONTROL 
REACTION (1x) CONCENTRATION 
REACTION (1x) 
Sterile Water 
(Vial6) 10.51JI x IJI up to 25 1JI 
dNTP Mix 
41JI 41.11 0.2mM (Vial2) 
OTT Solution 2.51JI 2.51.11 5mM 
RNase Inhibitor 
1 1.11 1 IJI 5U (VIal3) 
Control Primer Mix 
21.11 - 0 .4 IJM (each) (VialS 
Downstream Primer 
- 0.5 1JI 0.41JM 
CR1 
Upstream Prlmet' 
0.51JI 0.41JM -
AV190-1 
Control RNA 
51JI - 10 pg (Vial4) 
Template RNA 10J!l 
1 1.19- 1 
-
pg total RNA 
TOTAL VOLUME 251JI 251JI 
(Pnmer detail refer to Appendix B) 
4. The components for the Master Mix 2 were then set up in a 
separate, nuclease-free microfuge tube placed on ice: 
VOLUME FOR CONTROL 
COMPONENT VOLUME FOR REACTION (1X) 
REACTION (1X) 
Sterile Water 
(VIal6) 141JI 141.11 
5 x RT-PCR buffer 
(Supplemented) 10 1.11 10 1.11 
Enzyme Mix 
(Vial 1, Titan 2) 
enzyme mix (AMV 
1 1.11 1 1.11 
and Expand High 
Fidelity) in 
storage buffer) 
TOTAL VOLUME 251.11 251JI 
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25 1-11 of each Master mix 1 and 2 was added to a 0.2 ml thin-
walled PCR tube on ice. After it was mixed properly the tube 
was centrifuged briefly to collect the sample at the bottom of 
the tube. 
6. The sample was placed in a thermocycler equilibrated at 
50°C and incubated for 30 min. 
7. The thermocycler was set as follows: 
CYCLES TEMPERATURE AND TIME 
1 X Denature template at 94 ·c for 2 min 
. Denaturation at 94 ·c for 30 s 
10 X . Annealing, at 55"C for 30 s 
• Elongation at 68"C for 2 min 
• Denaturation at 94 ·c for 30 s 
• Annealing, 55 •c for 30 s 
25x* • Elongation at 68 •c for 2 min cycle elongation of 5 s for each cycle (e.g., 
cycle no. 11 has additional 5 s, cycle no. 12 has additional 10 s, cycle 
no. 13 has additional15 s) 
1x A Prolonged elongation time of 7 min at 68 ·c was used. 
Nested PCR 
8. The buffer, primers, PCR product, DNTPs and Taq were 
thawed on ice. 
9. All the reagents were briefly vortexed and centrifuged. 
10. The Master-Mix 1 was set up in a separate, nuclease-free 
microfuge tube placed on ice: 
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COMPONENTS VOLUME FOR REACTION (X1) FINAL CONCENTRATION 
Buffer 5 JJI 
Primers: 
• AV190-2 0.5 JJI 
• CR2 0.5 JJI 
PCR product 2 JJI 
DNTPs 2 JJI 
Taq 1 J.ll 
Sterile Water 40 JJI 
TOTAL VOLUME 50 JJI 
(For pnmer detail refer to Appendix B) 
11. 50 j.JI of the Master mix was added to a 0.2 ml thin-walled 
PCR tube on ice. After it was mixed properly the tube was 
centrifuged briefly to collect the sample at the bottom of the 
tube. 
12. The thermocycler was set as follows: 
TEMPERATURE ("C) TIME CYCLES 
95 5 min 1 
95 30 sec 
63 45 sec 10 
72 30sec 
95 30sec 
58 45 sec 30 
72 30 sec 
72 10 min 1 
13. The samples were then analysed on a 0.8% agarose gel. 
3.5.2.3 Viroseq RT-PCR 
3.5.2.3.1 Reverse Transcription 
Important: This procedure was performed in pre-amplification Area 2 
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1. The RNA samples were thawed and vortexed for 3-5 
seconds to mix. 
2. One 0.2 ml MicroAmp reaction tube was labelled for each 
RNA sample. 
3. The HIV RT Mix (Tris-KCI buffer, < 0.1% Magnesium 
Chloride, < 0.1% dATP, dCTP, dGTP, dTTP, < 0.1% non-
infectious synthetic oligonucleotide HIV-1 primers, 0.05% 
Sodium Azide) and OTT (1 OOmM, 1.4% Dithiothreitol) were 
thawed and vortexed for 3-5 seconds. 
4. The RNAse Inhibitor (20 U/~ RNAse Inhibitor, 50% Glycerol) 
and Recombinant Murine Leukemia Virus 
5. (MUL V) Reverse Transcriptase (50 U/f.ll Recombinant MULV 
reverse transcriptase, 50% Glycerol) was removed from the 
kit. 
6. All the reagent tubes and samples were briefly centrifuged to 
collect the contents at the bottom of the tubes. 
Running the RT Reactions 
1. The RT Master mix was prepared according to the 
following table. When finished the stock solutions were 
returned to - 15 to -25°C. 
Reagent Volume for 1 Volume for 5 Volume for 15 
Reaction (1.11) Reactions (IJI) Reactions (IJI) 
HIVRTMix 8 40 120 
RNase Inhibitor 1 5 15 
MuLV Reverse Transcrlptase 1 5 15 
OTT, 100nm 0.4 2.0 6.0 
Total volume 10.4 52.0 156.0 
Note: Prepare sufflctent volume for 1-2 extra reactions to compensate for ptpettmg loss. 
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The RT Master mix was vortexed for 2-3 seconds to mix and 
centrifuged briefly to collect the contents at the bottom of the 
tube. 
Important: Keep the RT Master mix at room temperature (15-25°C) until 
you add it to the reaction tubes, but do not leave it at room 
temperature for more than 30 minutes. 
3. 10 J.JI of the viral RNA was added to a 0.2 ml PCR tube. The 
PCR tubes were kept at room temperature and the stock 
viral RNA returned to -65 to --80°C. 
4. The PCR tubes were placed in a thermocycler (ABI2700) 
that had been set to the conditions below, and the program 
begun. 
Temperature °C Time Process 
65 30 seconds Relaxes the RNA secondary strudure 
42 5 minutes Cools to the optimal enzyme activity temperature 
Press manually ·pause· and perfonn step 6 then press 
·resume 
42 60 minutes Reverse transcription 
99 5 minutes Inactivates MuLV Reverse Transcriptase 
4 Hold Holds until you are ready to proceed 
(>10 minutes) 
Note: Set the volume on the thennocycler to 20 ~·L when prompted 
5. After 1 minute at 42°C "Pause" was pressed, the caps were 
removed one by one and 10 tJI of the RT Master mix added. 
6. The samples were vortexed for 3-5 seconds to mix and 
briefly centrifuged to collect the contents at the bottom of the 
tubes. 
7. The samples were returned to the thermocycler (AB 12700) 
and "Resumen pressed. 
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After the completion of the RT program, the samples in the 
thermocycler (AB12700) were held for at least 10 minutes at 
4°C. 
9. When the program was complete the cycler was stopped 
and the samples stored at -15 to -25°C until the PCR step 
could be performed. 
3.5.2.3.3 PCR 
3.5.2.3.3.1 Setting Up the PCR: 
Important: This procedure was performed in pre-amplification area 2 
1. The samples were thawed at room temperature (15-25°C) 
and briefly centrifuged to collect the contents at the bottom 
of the tubes. 
2. The HIV PCR Mix (Tris-KCI buffer, < 0.1% Magnesium 
Cloride, <0.1% dATP, DCTP, dGTP, dTTP, dUTP, < 0.1% 
non-infectious synthetic oligonucleotide HIV-1 primers, 
0.05% Sodium Azide) was thawed and vortexed for 3-5 
seconds to mix. 
3. The AmpliTaq Gold DNA Polymerase (5 U/JJI AmpliTaq Gold, 
50% Glycerol) and AmpErase UNG (1 U/JJI uracyl N-
glycosylase, 50% Glycerol) were removed from the kit and 
all the reagents briefly centrifuged to collect at the bottom of 
the tubes. 
3.5.2.3.3.2 Perfonning the PCR Reaction 
1. The PCR Master mix was prepared and combined in a 
sterile 1.5-ml microcentrifuge tube: 
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Volume for 1 Volume for 5 Volume for 15 
Reagent 
Reaction (!il) Reactions (!ill Reactions (IJI) 
HIVPCRMix 29.5 147.5 442.5 
AmpiiTaq Gold 
0.5 2.5 7.5 
polymerase 
AmpErase UNG 1 5 15 
Total Volume 31 155 465 
2. The PCR Master mix was vortexed for 3-5 seconds to mix 
and briefly centrifuged to collect the contents at the bottom 
of the tube. 
3. 30 J.LI of PCR Master mix was added to each RT reaction 
tube containing HIV-1 eDNA The final volume was now 
50 J.!l. 
4. The thermocycler was programmed as follows: 
Temperature ("C) Time Cycles 
50 10 min 1 
93 12 min 1 
93 20 sec 
64 45 sec 40 
66 3 min 
72 10 min 1 
4 Hold -
5. The samples were taken to the thermocycler in Area 3. Area 
2 was avoided for the remainder of the day to prevent 
contamination with amplicon. 
6. The tubes were transferred to the thermocycler, and the 
program started. 
7. When the program was complete either the purification steps 
were done or the procedure was stopped and the samples 
stored at -15 to -25°C. 
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Important: Do not leave tubes on hold for more than 24 hours. The residual 
UNG activity may destroy the amplified DNA. 
3.5.2.4 Cycle Sequencing 
This procedure was performed in the post-amplification Area 3. 
3.5.2.4.1 In-house Method 
This was based on the ABI Prism BigDye Terminator v3.0 Ready 
Reaction Cycle Sequencing kit and the instructions in the product 
manual were used with a number of variations. The sequencing 
primers (XYZ) were added individually at a concentration of 3 pmol 
to 20 IJI reactions to 5 IJI of RT-PCR product (concentration 
unknown) and the following cycling program used for all reactions: 
Twenty-five cycles at 96°C for 10 seconds, 50°C for 5 seconds, 
60°C for 4 minutes; followed by soaking at 4 oc until ready to purify 
the extension products. The reactions were purified by the addition 
of 3 IJI of 3 M sodium acetate (pH 4.6), 62.5 IJI of 95% ethanol and 
14.5 IJI of deionised water. After mixing, the tubes were spun for 10 
minutes at 14 000 rpm in a bench-top centrifuge, the supernatant 
was carefully aspirated and 150 IJI of 70% ethanol added. After 
mixing, it was spun as above for 5 minutes and the supernatant 
aspirated. It was left open on the bench until no trace of ethanol 
could be seen in the tubes. The dried pellets were re-suspended in 
20 IJI of HiDi (ABI) formamide and loaded onto the sample tray of 
an ABI 31 0 automated sequencer. Dye set E was chosen for the 
50 em capillary and samples were run for 2. 5 hours. Data was 
collected using Data Collection Software version 1.1 and analysed 
using Sequencing Analysis Software version 3.7. 
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3.5.2.4.2 Viroseg Method 
3.5.2.4.2.1 Purifying the PCR products 
1. The microconcentrator was assembled. 
a) For each sample, 
- one 1.5 ml collection tube 
one Microcon Spin Column, was labelled 
b) Into each tube, the appropriately labelled Microcon Spin 
Column was inserted with the white membrane facing 
up. 
2. 300 J.LI of sterile deionised water was carefully pipetted into 
the reservoir of each microconcentrator. 
Important: Do not touch the membrane with the pipette tip. 
3. The entire 50 J.LI PCR product of each sample was pipetted 
into the water-filled reservoir of the appropriately labelled 
microconcentrator. 
Important: Do not touch the membrane with the pipette tip. 
4. Each tube was firmly sealed with the attached tube cap. 
5. The prepared microconcentrators were centrifuged at 450-
550 xg for 15 minutes. 
6. The tube caps were opened and 35 J.LI of sterile deionised 
water was carefully pipetted into the centre of each 
microconcentrator. 
Important: Do not touch the membrane with the pipette tip. 
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The microconcentrators were inverted into newly labelled 
tubes. 
a. The microconcentrators were removed from the tube 
containing filtrate. 
b. The microconcentrator was placed upside down on top 
of a new, correspondingly labelled 1.5 ml tube for each 
sample. 
c. The old tube with the filtrate was then discarded. 
8. The prepared microconcentrators were centrifuged at 450-
550 xg for 5 minutes. 
9. The microconcentrators were removed and discarded, 
retaining the samples in the tubes. 
10. Each tube was firmly sealed with the attached tube cap, and 
either the agarose gel were run, or the procedure was 
stopped and the samples stored at -15 to -25°C. 
3.5.2.4.2.2 Quantifying the DNA 
1. A 1% agarose gel was prepared using TBE and it contained 
0.5 J..lg/ml of ethidium bromide. 
2. A 1X TBE gel buffer solution was prepared. 
3. The prepared gel was placed in the gel box. 
4. Enough 1X TBE gel buffer was added to cover the gel. 
5. For each sample: 
• 5 J.!l of Agarose Gel Loading Buffer (< 0.1% 
Bromphenol blue, 40% Sucrose, < 3.7% EDTA. 0.5% 
Lauryl Sulfate Sodium) and 
• 5 J.!l of purified PCR product, was mixed 
6. The DNA Mass Ladder solution (Tris-EDTA buffer, < 0.1% 
DNA mass ladder, 0.2% Lauryl Sulfate Sodium, 17% 
Sucrose,< 0.1% Bromphenol blue) was then loaded. 
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b. 
6 J.!l in Lane 1 
3 J.!l in Lane 2 
This gave the following results: 
Bands 
Location Size (kb) 
Top 2.0 
Second 1.2 
Third 0.8 
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6 jil Lane 3 jil Lane 
(ng) (ng) 
100 50 
60 30 
40 20 
7. The remaining lanes were loaded with 10 J.!l of each sample. 
8. Electrophoresis at 10 V/cm was performed until the 
bromophenol blue had migrated at least 5 em into the gel. 
9. The gel was examined with UV light. 
10. The gel was photographed using an exposure time that did 
not saturate the film and showed the differences in intensity 
of the mass ladder fragments. 
11. The quantities of PCR products were evaluated in each 
sample by comparing the intensity of each band to the 
intensities of the Low Mass Ladder bands (see illustration 
below) 
12. The remaining PCR product was diluted for each sample 
with deionised, distilled water (ddH20) according to the 
following table. 
If the band Intensity is ... Then ... .. ....•..... .. .. ...• 
20-40 ng Adjust the sample volume to 60 Ill. 
40-60 ng Make a 1 :2 dilution with ddH20 
(1 part sample and 1 part water). 
60-100 ng Make a 1:4 dilution with ddH20 
(1 part sample and 3 parts water). 
> 100 ng Make a 1:10 dilution with ddH20 
( 1 part sample and 9 parts water). 
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Figure 3.1 Low Mass Ladder Bands 
CiJ Ot~A 3~ Ot4A s~mple j saTlp~ 2 Sdrr~Q 3 S;1,rr.;~~ 4 
~b::~  ~m!:~ Ladder 
~ ~ wJ ~ ......, .......... '\ .... 
........ ---~ 
~ ...... ~ .... Dlut~! O'i~.te OJutv A1d l.l~Qr 
1:10 I :4 1:2 to 8()f1l_ 
......... 
13. Each diluted sample was vortexed for 3-5 seconds to mix 
and briefly centrifuged to collect the contents at the bottom 
of the tube. 
14. When the procedure was complete, we proceeded to Cycle 
Sequencing. 
3.5.2.4.2.3 Cycle Sequencing 
Important: The sequencing mixes are light sensitive. Do not expose the 
mixes to light for extended periods. 
1. The HIV-1 sequencing mixes were thawed at room 
temperature. 
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Figure 3.1 Low Mass Ladder Bands 
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13. Each diluted sample was vortexed for 3-5 seconds to mix 
and briefly centrifuged to collect the contents at the bottom 
of the tube. 
14. When the procedure was complete, we proceeded to Cycle 
Sequencing. 
3.5.2.4.2.3 Cycle Sequencing 
Important: The sequencing mixes are light sensitive. Do not expose the 
mixes to light for extended periods. 
1. The HIV-1 sequencing mixes were thawed at room 
temperature. 
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A B c 
1 2 
A S1-A S2-A 
B S1-B S2-B 
c S1-C S2-C 
D S1-D S2-D 
E S1-F S2-F 
F S1-G S2-G 
G S1-H S2-H 
H S13-A S13-B 
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Then the reaction format was set up. We used the following 
option: 
• A MicroAmp optical 96-well reaction plate 
D E F G H I J K L M 
3 4 5 6 7 8 9 10 11 12 
S3-A S4-A SS-A S6-A S7-A S8-A S9-A S10-A S11-A S12-A 
S3-B S4-B SS-B S6-B S7-B S8-B S9-B S10-B S11-B S12-B 
S3-C S4-C S5-C S6-C S7-C S8-C S9-C S10-C S11-C S12-C 
S3-D S4-D SS-D S6-D S7-D S8-D S9-D S10-D S11 -D S12-D 
S3-F S4-F S5-F S6-F S7-F S8-F S9-F S10-F S11-F S12-F 
S3-G S4-G S5-G S6-G S7-G S8-G S9-G S10-G S11-G S12-G 
S3-H S4-H S5-H S6-H S7-H S8-H S9-H S10-H S11-H S12-H 
S13-C S13-D S13-F S13-G S13-H 
A 3100 plate loaded w1th sample 1 (S1) begmmng 1n column 1 of 96-well plate, S2 m column 2, and so forth. Row H 1s not used 
unless you want to run 13 samples on one plate. 
3. In each well, the combinations were as follows: 
Volume for One 
Component 
Reaction (Jd) 
Add one of the following HIV-1 SEQ mixes to each plate well: 
HIV SEQ MIX A (Big Dye TM Ready Reaction Mix, 
< 1% non-infectious synthetic oligonucleotide HIV-1 sequence primers) 
HIV SEQ MIX B (BigDyeTM Ready Reaction Mix, 
< 1% non-infectious synthetic oligonucleotide HIV-1 sequence primers) 
HIV SEQ MIX C (BigDyer" Ready Reaction Mix, 
< 1% non-infectious synthetic oligonucleotide HIV-1 sequence primers) 
HIV SEQ MIX D (Big Dye ™ Ready Reaction Mix, 
< 1% non-infectious synthetic oligonucleotide HIV-1 sequence primers) 12 
HIV SEQ MIX F (BigDyer" Ready Reaction Mix, 
< 1% non-infectious synthetic oligonucleotide HIV-1 sequence primers) 
HIV SEQ MIX G(BigDyer" Ready Reaction Mix, 
< 1% non-infectious synthetic oligonucleotide HIV-1 sequence primers) 
HIV SEQ MIX H (BigDyer" Ready Reaction Mix, 
< 1% non-infectious synthetic oligonucleotide HIV-1 sequence primers) 
Diluted, purified PCR product 8 
Final Volume 20 
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4. The MicroAmp Full Plate Cover was placed over the plate 
and centrifuged at room temperature for 5-1 0 seconds. 
5. The samples were then transferred to the thermocycler. 
6. The thermocycler was programmed according to: 
Temperature t•C) Time Cycles 
96 10sec 
50 Ssec 25 
60 4min 
4 Hold -
7. The thermocycler was started. 
8. When the program was completed either the purification 
steps were followed, or the process was stopped and the 
samples stored at -15 to -25°C. 
3.5.2.4.2.4 Purifying the Sequences: 
Note: There are three methods recommended for the purification of 
BigDye Terminator sequence reactions. In this case the 
Isopropanol precipitation method was used. 
1. The MicroAmp tray was removed from the thermocycler, and 
the MicroAmp Full Plate Cover removed. 
2. To each sample mixture was added: 
• 20 J.d of deionised water 
• 60 J.!l of 1 00% isopropanol 
3. The tubes were sealed with strip caps or adhesive foil tape. 
4. The tray was inverted several times to mix. 
5. Then the sample mixtures were incubated: 
• At room temperature 
• In the dark 
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• For 15 minutes 
After incubation the tray was centrifuged at 1500-2000 xg for 
45 minutes in a centrifuge equipped with an MTP rotor. 
7. As soon as the centrifuge stopped, the tape was carefully 
removed from the tubes without disturbing the pellets. 
8. Immediately an absorbent paper towel or Kimwipe was 
placed on top of the tray and the tray inverted. 
9. The tray was placed in the centrifuge in the inverted position, 
on top of a Kimwipe or paper towel, and centrifuged at 700 
xg for 1 minute. 
Important: Perform the inverted spin immediately after centrifugation or there 
is a loss of signal. 
3.5.2.5 
3.5.2.5.1 
10. When the centrifuge stopped, the plate was removed and 
either: 
• "Automated Sequence Detection" was done, or 
• the plate was sealed with aluminium tape and stored at -
15 to -25°C in the dark. 
Automated Sequence Detection 
Denaturing the Samples using the ABI PRISM 3100 DNA 
Analyser 
1. The foil from the dried sequencing reactions from procedure 
D4 was removed. 
2. 20 J..LI of Hi-Di™ Formamide was added to the dried 
sequencing reactions and re-suspended. 
3. The tray was covered with a full plate cover. 
4. The samples were vortexed for 3-5 seconds to mix. 
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5. The tray was briefly centrifuged to collect the contents at the 
bottom of the tube. 
6. 
7. 
8. 
9. 
The samples were heat denatured in a thermocycler at 95°C 
for 2 minutes. 
The samples were immediately placed on ice at 2-8°C. 
The full plate cover was removed from the tray. 
A 31 00 96-well septum was attached to the plate and the 
plate snapped into the 31 00 analyser retainer and base. 
The Collection Software using the ABI PRISM 3100 DNA 
Analyser 
1. The Data Collection Software was launched. 
2. From the View menu, Preferences were selected. 
3. In the setting Preferences window, the Data Analysis tab 
was selected and the following selections made: 
• Select AutoAnalysis On 
• Clear Enable BioLIMS 
• Specify the format for the Sample File Name Prefix: 
- Sample Name 
- Well position 
- <none> 
4. ClickOK 
5. The Plate View tab was selected, then New was clicked. 
6. From the Tools menu, the Plate Editor was selected. 
7. In the Plate Editor dialog box that opened: 
• Name your plate 
• Specify the application 
• Specify the plate type 
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Important: Use only letters and numbers or the symbols given below. Do not 
use any spaces. 
3.5.2.5.3 
-_(){}.+ 
8. OK was clicked to close the Plate Editor dialog box. 
9. From the Application menu, Sequencing was selected. 
10. From the Plate Type list box, a 96-well was selected. 
11 . Click Finish. 
The Plate Editor spreadsheet opened. 
The Plate Editor using the ABI PRISM 3100 DNA Analyser 
1. In the Sample Name column, the names of the samples 
were entered. 
SampleName_ Primer 
.!, 
double underscore 
• The sample name must be identical for all seven primer 
sequences of a sample. 
• The sample name and primer identification must be 
separated by two consecutive underlines (Shift plus -). 
• The primer identification contains the primer name and 
any other information unique to the specific sequence. 
For Example: 
Patient196_A 
Patient196_B 
Patient196_C etc ..... 
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Dye set 
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The following settings for each sample in the spreadsheet 
were selected: 
E 
Mobility File Dt3100POP6{BD}v2.mob 
Comments Enter your comments, if any 
BloLIMS Project 3100-Project1 
Run Module 1 StdSeq50_POP6DefaultModule 
Analysis Mode 1 BC-3100SR_Seq0ffft0ft.saz 
3. The plate record was verified for correctness, then OK was 
clicked to return to the main menu. 
Loading Samples and Starting the Run using the ABI PRISM 
DNA Analyser 
1. The plate with the denatured sequencing reactions was 
placed onto the instrument. 
• Well A1 was positioned in the upper-right corner. 
• The plate position was verified and the indicator was 
yellow. 
2. In the Pending Plate Records table, the Plate record was 
selected. 
3. The plate position indicator for the plate intended to link to 
the record was selected. 
• The plate position indicator turned green. 
• The plate records moved from the Pending Plate 
Records table to the Linked Plate Records table. 
4. The Run View tab was selected to view the run schedule. 
• Each run was selected to verify that the appropriate wells 
were highlighted. 
Important: If the well is not highlighted, it will not be analysed. 
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5. The green Run Instrument button was clicked to begin the 
run. 
6. After the run started, the fact that an electrical current was 
running through the system was verified by clicking the 
Status View tab. If there was no electrical current, there was 
a bubble in the polymer block and the options were: 
• Cancel the run. 
• Clear the bubble from the polymer block. 
• Restart the run. 
The Sequence Analysis Software using the ABI Prism 3100 
DNA Analyser. 
1. When the run was completed, the Sequence Analysis 
software was launched. 
2. All the files from the Run folder(s) were added to the Sample 
Manager. 
3. The following settings for each sample were: 
Baseealler 3100SR 
Spacing Defined by instrument 
Basecaller Setting HIV580 
Peak 1 location Set by software 
Start point Set by software 
Stop point Set by software 
DyeSet/Prlmer DT3100POP6{BD}v2.0 
Factura settings -
Matrix File -
4. The A (analyse) check box was selected for each sample. 
5. The P (print) and F (Factura) columns were cleared. 
6. Start was pressed. 
7. After analysis, the A column was checked to see whether if a 
green box appeared for each sample. 
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Important: If a sample has a red box, the sample cannot be used in the 
3.5.2.5.6 
ViroSeq software analysis. Please see the ABI Prism DNA 
Sequencing Analysis Software v. 3. 7 User's Manual for help. 
8. Proceed to "G. ViroSeq Software Analysis" followed: 
ViroSeq Software Analysis 
For detailed instructions please refer to the ViroSeq HIV-1 
Genotyping System Software Version 2.5 User Guide included with 
the ViroSeq software. The following procedures are given: 
• Creating a New Project. 
• Sample Information. 
• Editing Procedure 
• Print Report. 
3.6 PHYLOGENETIC ANALYSIS 
Sequences were aligned using Bio-edit (Hall, 1999) and the same program was 
also used to translate the nucleic acid sequence into an amino acid sequence. 
The public domain phylogenetic analysis package MEGA3 (Kumar eta/., 2004) 
was used for constructing the phylogenetic trees. The reference sequence HXB2 
was used as outgroup to anchor the sequences. 
The UPMGA algorithm was chosen for tree construction and the final trees were 
the consensus of 500 bootstrap repeats. 
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4.1 INTRODUCTION 
The primary objective of this study was to study the naturally occurring 
variants of HIV-1 present in a group of patients from the central region of 
South Africa currently not on ARV treatment. The presence of pre-existing 
mutations may aid clinicians in designing optimal ARV combinations for a 
given region or country. A secondary objective was to find a suitable 
method for doing the analysis. To begin with, published primer sequences 
and in-house methods for the different steps of the procedure were used, 
but this was changed to an established commercial system (Viroseq by 
Celera Diagnostics, marketed by Abbott Diagnostics) because of superior 
sensitivity and the fact that it is FDA approved for diagnostic use. A major 
advantage of the Viroseq system is that it uses a single RT -PCR round to 
amplify a 1.8 kb fragment for sequencing, while the in-house method 
employs a nested PCR after the first RT -PCR. This can lead to 
preferential amplification of a subset of the viral population, creating a 
skewed representation of the situation in a particular patient. Even after 
the nested RT -PCR, bands were either faint or multiple bands were 
observed, which created mixed sequence when analysed (results not 
shown). This particular in-house system was developed in Belgium to 
cope with their predominantly subtype B isolates. An in-house system for 
local use should be adapted for subtype C sequences before it can be 
used here with confidence. Therefore only the sequences obtained with 
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the Viroseq system are presented here. The aligned raw data is shown in 
Appendix C. 
The study population consisted of 19 adult ARV-na·ive AIDS patients 
recruited from Tsepo House, an AIDS hospice in Bloemfontein. Initially, 
samples were taken from 32 patients, but due to haemolysis (2 samples), 
insufficient volume of plasma (4) and non-amplification or weak 
amplification of the required fragment (8}, most of which did not produce 
good quality sequences, the results of 19 patients will be presented. The 
work reported here formed part of a study on the effect of nutritional 
supplements on the general health of terminal AIDS patients. The blood 
drawn for HIV-1/CD4 analysis was from the screening phase and so 
precludes any selection introduced by the treatment. 
Table 4.1 .1 shows a summary of the general patient information. It is 
clear from the CD4 counts that the immune systems of these patients 
were severely compromised, as the highest count was only 348 while the 
mean value was 184. This means that, according to the Department of 
Health's criteria, all of them qualify for ARV treatment. The viral loads are 
high, varying from 23 000 to > 750 000. It demonstrates how people differ 
in their response to the viral infection. All patients were in the terminal 
stage of disease, yet displayed up to thirty-fold differences in viral load. 
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Table 4.1.1 Patient Information Summary 
PATIENT VIRAL NUMBE SEX BIRTH DATE AGE CD4 LOAD SUBTYPE R 
1 Female 1973/03126 32 172 >750 000 c 
2 Male 1968/02123 37 284 40.400 c 
3 Female 1976/11/25 29 91 >750 000 c 
4 Female 1969/05/03 36 291 80 700 c 
11 Male 1958/08114 47 176 99 500 c 
12 Male 1979/03/23 26 135 436 000 c 
13 Male 1962/05/03 43 126 193 000 c 
15 Male 1960/03/03 45 108 320 000 c 
16 Male 1969/01/06 36 295 118 000 c 
17 Female 1972/0./11 33 113 146 000 c 
22 Female 1975/03/23 30 348 645 000 c 
23 Female 1957/08122 48 130 142 000 c 
24 Female 1975/0./19 30 83 10. 095 c 
25 Female 1967/07/14 38 74 270 000 c 
26 Male 1958/08114 47 305 23 200 c 
27 Female 1969/02/12 36 73 51 500 c 
29 Female 1972110/01 33 91 359 000 c 
31 Female 1969/11/09 36 314 >750 000 c 
32 Female 1973/09/24 32 232 189 000 c 
Positive B Control 
Mean 12 Female 37 181 306 916 7 Male 
4.2 PHYLOGENETIC ANALYSIS 
The sequences were trimmed by Viroseq to represent the 99 codons of 
the full protease and the first 335 codons of the reverse transcriptase 
reading frames. These were translated to amino acids and used 
separately in phylogenetic analyses to study their relatedness to each 
other (fig 4.1.1 & 4.1.2) and to other isolates (fig 4.1.3 & 4.1.4). As a first 
approach, only the group sequenced in this study were analysed. The 
protease phylogenetic tree shows tight clustering with sequence 4 forming 
a group on its own. This property is also visible in the reverse 
transcriptase tree. A practical benefit of phylogenetic analysis is to be an 
early-warning system for possible contamination of one sample by another 
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as this will show up as extremely tight clustering of some samples. The 
form and distances of the trees shown here clearly eliminate this 
possibility. 
To see how the sequences reported in this study compare with other 
South African isolates, 20 ZA sequences were randomly chosen from the 
Los Alamos HIV-1 sequence database (http://www.hiv.lanl.gov). It is clear 
from both the reverse transcriptase and protease trees (Figure 4.1.3 & 
4.1.4) that the Bloemfontein sequences do not differ appreciably from 
those found in the rest of the country, since they tend to diffuse through 
the tree rather than to cluster on their own. Some do form sub-clusters, 
but the differences are quite small. From an epidemiological perspective, 
it means that we largely have a single epidemic in the black community of 
South Africa. In white South Africans, the subtype is mostly B as in 
Europe and the United States (Dr P Schoeman, Pathcare, personal 
communication). 
Although this was a small sample, the fact that no other subtypes were 
identified, shows that the spread of "strange" subtypes like A or D is not 
that prevalent in South Africa. These subtypes are more common to 
Central and West Africa and are sometimes difficult to analyse because of 
primer site mismatches. As a result of the increasing trade with and 
movement of people to and from the rest of the continent, spreading of 
these subtypes may be expected. 
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Phylogenetic tree of the protease amino acid sequences generated in this 
study. 
HXB2 was used as outgruup. 
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Phylogenetic tree of the reverse transcriptase amino acid sequences 
generated in this study compared to a random selection of 20 other South 
African isolates. 
HXB2 was used as outgroup. 
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Phylogenetic tree of the protease amino acid sequences generated in this 
study compared to a random selection of 20 other South African isolates. 
HXB2 was used as outgroup. 
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4.3 DRUG RESISTANCE MUTATIONS 
The evolution of resistance against HIV-1 inhibitors within a patient 
depends on the generation of genetic variation and on the selection of 
drug-resistant variants during antiretroviral therapy. HIV-1 genetic 
variability is caused by the error-prone nature of HIV-1 RT and the 
absence of a proofreading 3' to 5' exonuclease activity (Roberts et a/., 
1988). Substitutions are the most commonly observed genetic change, 
but insertions and deletions are also often observed for HIV-1 . Another 
mechanism of HIV-1 genetic variability results from recombination during 
reverse transcription when viruses with different genotypes infect the 
same cell (Hu and Temin, 1990). The generation of genetic variation is 
augmented by the huge rate of HIV-1 replication in vivo. Studies of viral 
population dynamics in HIV-1 infected patients showed that during periods 
of clinical latency 108 to 1010 virions are produced every day (Coffin, 1995; 
Ho et a/. , 1995; Wei et a/., 1995). Given the high rates of replication and 
mutation of HIV-1, and the high viral burden in HIV-1 infected patients, it 
was calculated that every possible single point mutation is probably 
generated multiple times each day (Coffin, 1995). As a result, 
innumerable quasispecies evolve in individuals in the months following 
primary infection. The majority of HIV-1 variants generated will be lethal 
to the virus, while many others will have little to no effect on viral function 
or fitness. However, some mutations result in alterations to the structure 
and function of important viral proteins for viral replication, such as RT and 
PR. Therefore, these variants often have a reduced fitness in comparison 
with the wild type virus and generally exist only as minor variants in the 
viral population of untreated patients. In the presence of antiretroviral 
inhibitors, minor variants with some level of resistance will gradually 
outcompete the wild type variants. Under the continuous selective 
presence of residual replication due to the insufficient potency of the 
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treatment, additional mutations will accumulate. These can either 
increase the level of resistance or they can compensate for the reduced 
fitness induced by the initial mutations. The number of naturally occurring 
variants with some level of resistance to a particular therapy decreases 
significantly with the number of inhibitors included in the combination, as 
this would require the concomitant presence of multiple mutations which 
are statistically very unlikely to exist in the initial population of 
quasispecies. Thus, resistance development will be slower when an 
increasing number of mutations is required for resistance to the inhibitors 
and when residual virus replication is lower due to more potent 
antiretroviral therapy (Vandamme et a/., 1998}. 
4.3.1 PROTEASE INHIBITORS AND MUTATIONS 
The HIV-1 protease is the enzyme responsible for cleavage of the 
viral Gag and Gag-Pol polyprotein precursors during virion 
maturation, which yields the structural proteins and the enzymes of 
the viral particle (Miller, 2001 ; Park and Marrow, 1993}. Six HIV-1 
protease inhibitors have been approved to date in the United 
States, i.e., amprenavir (APV}, indinavir (IDV}, lopinavir (LPV}, 
nelfinavir (NFV}, ritonavir (RTV) and saquinavir (SQV). Many 
mutations associated with HIV-1 resistance to these protease 
inhibitors have now been identified (Miller, 2001 ). The protease 
gene has shown great plasticity, with polymorphisms detected in 49 
of the 99 amino acids of the HIV-1 protease monomer and 
substitutions at more than 20 amino acids being associated with 
resistance (Miller, 2001; Figure 4.1.5A & B). Although they can be 
sporadically witnessed in viral quasispecies (Lech et a/., 1996), 
most of these primary mutations are rarely found in Pl-na·ive HIV-
infected individuals, suggesting that they confer a selective 
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by other mutations (Martinez-Picado et al., 1999). Mutations have not 
only been observed within the protease but also at several protease 
cleavage sites (Doyon eta/., 1996). Growth kinetic studies have shown 
that these mutations improve the kinetics of the mutant enzyme and that 
these mutations appear to be compensatory rather than primary. 
There were seven different protease mutations found in the sequences 
reported in this study (Table 4.1.2). The most frequently found mutations 
were M361 and 193L (both in 18 of the 19 sequences). The other 
significant mutation was L63PN/A, which was located in 12 of the 
sequences analysed. K20R (8/19), 060E (3/19) and V771 (4/19) were the 
other mutations found. Kempf et a/. (2001) examined the association of 
genotypic changes in HIV-1 protease with reduced in vitro susceptibility to 
the new protease inhibitor lopinavir (previously ABT-378). To define the 
genotypic correlates of reduced in vitro susceptibility to lopinavir, they 
examined the genotypes and phenotypes of 112 viral isolates from 
subjects experiencing virologic failure of therapy with one or more other 
Pis, who entered one of the lopinavir-RTV phasel/11 studies. In this 
analysis, mutations at 11 amino acid positions in HIV-protease (positions 
54, 82, 10, 71, 46, 20, 90, 84, 24, 53, and 63, in order of greatest to least 
significance) were found to be statistically significantly associated with the 
loss of phenotypic susceptibility to lopinavir. Two statistical tests showed 
that specific mutations at 11 amino acid positions in protease (L 10F/I/RN, 
K20M/R, L241, M461/L, F53L, 154LITN, L63P, A711/LITN, V82A/F/T, 184V, 
and L90M) were associated with reduced susceptibility. Mutations at 
positions 82, 54, 10, 63, 71, and 84 were most closely associated with 
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Table 4.1.2 Summary of the protease mutations found in the sequences 
reported in this study 
Patient PROTEASE MUTATIONS 
Nr L101,V K20R M361 D60E L63P,V,A V771 193L 
1 X 
2 X X 
3 X X 
4 X X X X X 
11 X X X 
12 X X X 
13 X X X X X 
15 X X X 
16 X X X 
17 X X X X 
22 X X X 
23 X X X X X 
24 X X X X X 
25 X X X X X 
26 X X X X X 
27 X X 
29 X X 
31 X X X X 
32 X X X X 
TOTAL 3 8 18 3 12 4 18 
relatively modest (4- and 10-fold) changes in phenotype, while the 
K20M/R and F53L mutations. in conjunction with multiple other mutations, 
were associated with >20- and >40-fold-reduced susceptibility, 
respectively. It is likely that mutations in addition to those at positions 20 
and 53 will be found to contribute incrementally, in combination with 
multiple other mutations, to high-level in vitro resistance (e.g., the K20M/R 
and F53L mutations were only present in 8 of 16 and 5 of 16 viral isolates, 
respectively, in their panel with >20-fold-reduced susceptibility). As 
indicated in Table 4.1.2, K20R was very significant and was detected in 
eight of the 19 samples analysed. Each of the 16 viruses that displayed a 
>20-fold change in susceptibility contained mutations at residues 10, 54, 
63 and 82 and/or 84, along with a median of three mutations at residues 
20, 24, 46, 53, 71, and 90 (Kempf eta/., 2001). The number of protease 
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mutations from the 11 identified in these analyses (the lopinavir mutation 
score) may be useful for the interpretation of HIV genotypic resistance 
testing with respect to lopinavir-ritonavir (Kaletra) regimens, and may 
provide insight into the genetic barrier to resistance to lopinavir-ritonavir in 
both antiretroviral therapy-nai"ve and protease inhibitor-experienced 
patients. 
Muzammil eta/. (2003) characterized a mutant form of the HIV-1 protease, 
ANAM-11 , identified in clinical isolates from HIV-1 infected patients treated 
with protease inhibitors. This mutant protease contains 11 mutations, 1 0 
of which are located outside the active site 
(L 101/M361/S37D/M461/R57KIL63P/A71V/G73S/L90M/193L) and 1 within 
the active site (184V). ANAM-11 lowers the binding affinity of indinavir, 
nelfinavir, saquinavir, and ritonavir by factors of 4000, 3300, 5800, and 
80 000, respectively. Surprisingly, most of the loss in inhibitory affinity is 
due to the non-active site mutations, as demonstrated by additional 
experiments performed with a protease containing only the 1 0 non-active 
site mutations (NAM-1 0) and another containing only the active site 
mutation (A-1 ). Kinetic analysis with two different substrates yielded 
comparable catalytic efficiencies for A-1, ANAM-11 , NAM-10, and the wild 
type protease. These studies demonstrate that non-active site mutations 
can be the primary source of resistance and that their role is not limited to 
compensate for deleterious effects of active site mutations. Analysis of 
the structural stability of the proteases by differential scanning calorimetry 
reveals that ANAM-11 and NAM-1 0 are structurally more stable than the 
wild type protease, while A-1 is less stable. Together, the binding and 
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structural thermodynamic results suggest that the non-active site mutants 
affect inhibitor binding by altering the geometry of the binding site cavity 
through the accumulation of mutations within the core of the protease 
molecule. 
Rusconi eta/. (2000) examined the anti-HIV-1 activity of a novel protease 
inhibitor, PHU-140690 (tipranavir}, against patient-derived isolates 
resistant to multiple other protease inhibitors. The aim of their 
experiments was to investigate the genotypes and the in vitro phenotypes 
of resistance to tipranavir. Drug susceptibility tests with peripheral blood 
mononuclear cells and a fixed amount of infectious virus was done to 
determine the ICso and ICgo levels using PCR assays for the detection of 
drug resistance mutations in RNA in plasma and direct sequencing of 
PCR products. Phenotypic resistance to Pis was invariably related to 
genotypic mutations, as previously pointed out by Condra et a/. (1996). 
The substitutions among the amino acid residues of the protease included 
L 101, K20R, L241, M361, N37D, G48V, 154V, L63P, 164V, A71V, V771, 
V82A, 184V, and L90M. Among the viral isolates described in their study, 
four expressed nine mutations, one expressed eight mutations, one 
expressed seven mutations, one expressed six mutations, and two 
expressed three mutations (one of the protease fragments was not 
amplified). Isolates from all of the patients had developed a maximal 
degree of resistance to indinavir, ritonavir and nelfinavir. They also 
compared these mutations with the amino acid changes previously 
described in association with in vivo tipranavir administration. The 
mutations included the following: 115V, 1 of 10 isolates; E35D, (6/10); 
N37D, (3/10); R41K, (2/10); D60E, (3/10) and A71T, (1/10) and did not 
correlate with the phenotypic susceptibility to PNU-140690. Among the 
patients who participated in the phase II protocol mentioned above, only 
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D60E, A71T, and V77G were not seen at the baseline but were seen at 
week 12. Tipranavir retained a sustained antiviral activity against PI-MDR 
clinical isolates and might be useful in combination regimens with other 
antiretroviral agents for patients who have already failed other PI-
containing therapies. 
Borman et a/. (1996) were one of the first groups to report differences in 
replicative capacity in viruses resistant to the protease inhibitor ABT-
77003 (which harboured the 321 mutation). Further accumulation of 
mutations at secondary sites (461, 71V, and 82A) led to an improvement in 
fitness. A further study showed the role of the 63P/A mutation in 
improving the fitness of the 82A/F ritonavir resistance mutation, perhaps 
by compensating for the structural change around the active site of the 
enzyme (Eastman eta/., 1998). 
Although numerous, the mutations found in the protease reading frame in 
this study are thus all secondary mutations without any evidence of 
causing resistance on their own, but they may be involved in increased 
susceptibility to developing resistance to protease inhibitors. The decision 
to include protease inhibitors in the treatment of South African patients 
should be viewed against this background and it is good to know that 
protease inhibitors have been reserved for second-line therapy in case of 
failure of the first-line regimen. 
4.3.2 REVERSE TRANSCRIPTASE INHIBITORS (RTis) AND MUTATIONS 
The reverse transcriptase (RT) of human immunodeficiency virus type 1 
(HIV-1) is critical to the life cycle of HIV and is without a homologue in 
eukaryotic organisms. As such, it is an attractive target for selective 
antiviral therapy. 
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The number of reverse transcriptase mutations reported in this study 
(Table 4.1.3) is significantly less than the number of protease mutations 
found (Table 4.1 .2). In the 19 samples analysed only 5 mutations were 
found. K103N and K103R were reported once each in the 19 sequences, 
while K101E, V179D and Y318F were found in only one of the sequences 
analysed. Of these mutations, K103N is the most significant. K103R 
does not contribute to resistance (Los Alamos website 
http://www.hiv.lanl.gov/content/index). 
Table 4.1.3 Summary of the reverse transcriptase mutations found in the 
sequences reported in this study 
REVERSE TRANSCRIPTASE MUTATIONS 
Patient Nr K101E K103N K103R V179D Y318F 
1 X 
2 
3 
4 X 
11 
12 
13 X 
15 
16 
17 
22 
23 
24 X 
25 
26 
27 
29 X 
31 
32 
Total 1 1 1 1 1 
Resistance to nevirapine is associated with mutations A98G, L 1001, 
K101E/Q, K103N, V106A/I, V1081, V1790, Y181C/I, Y188C/LIH and 
G190S/A. Single mutations at positions L 1001, K103N, V106A/I, V1081, 
Y181C/I, Y188C/UH and G190S/A are sufficient to confer high level 
resistance towards nevirapine. The P236L mutation appears to be 
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relatively specific for delavirdine. However, single mutations at L 1001, 
K103N, V106A/I, V1081, Y181C/I and Y188L also confer high-level 
resistance to delavirdine. A98G, K101E/Q, V1790 and Y188C/H have 
also been observed in association with delavirdine resistance. Compared 
to nevirapine and delavirdine, efavirenz shows greater resilience to 
resistance mutations within HIV-1 RT. This is probably due to the 
repositioning of efavirenz in the NNRTI binding pocket of the mutant RT 
and to conformational rearrangements in the enzyme. High-level 
resistance is associated with single mutations at K103N, Y188L and 
G190S. Multiple mutations at A98G, L 1001, K101E/Q, V106A/1, V1081, 
V1790, Y181C/I, Y188C/H and G190A are necessary to confer high-level 
resistance to efavirenz (Schinazi eta/., 2000). 
NNRTis inhibit HIV-1 RT by interacting with a common hydrophobic 
binding site in the p66 subunit. This binding site is in close proximity to 
but distinct from the polymerase active site of the enzyme. It has been 
suggested that most of the NNRTis can adopt a conformation in which the 
compound assumes a "butterfly" shape, consisting of two wings. One 
wing is generally proximal to and the other distinct from the polymerase 
active site. The wings of the molecules usually contain significant 7t-
electron systems that can interfere with amino acid side chains of the 
NNRTI-binding pocket. Many NNRTis also form hydrogen bonds with the 
peptide main chain, "turning" the NNRTI-binding pocket. The internal 
surface of the NNRTI-binding pocket is mainly composed of hydrophobic 
amino acid residues with few hydrophilic residues in the vicinity of the 
inhibitor. Upon binding of NNRTis to the hydrophobic NNRTI-binding 
pocket in the p66 subunit, the functional groups of the highly conserved 
amino acid residues Y181 and Y188 are substantially reoriented and 
closely mimic the conformations of the equivalent side chains observed in 
the inactive p51 subunit of the enzyme. Aromatic stacking interactions 
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between aromatic rings of the NNRTI and protein residues of the 
hydrophobic pocket (Y181 , Y188, W229 and Y318); electrostatic forces 
(K101, K103 and E138); van der Waals interactions (l100, V106, V179, 
Y181 , G190, W229, l234 and Y318) and hydrogen bonding between the 
NNRTI and the main chain peptide bonds (101-102 or 103-104) 
(Fig 4.1 .6A & B), all contribute to the interaction and binding efficacies of 
the drugs in the NNRTI-specific pocket (Balzarini et a/., 1999). The 
K103N mutation is the most commonly observed mutation in vivo and 
gives cross-resistance to many NNRTis. 
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Figure 4.1 .6 
(A) Summary of reverse transcriptase mutations associated 
with resistance to RT inhibitors. 
p 
Amino acids in grey and black denote primary and secondary/compensatory mutations. respectively. 
Wild-type amino acids (HIV-1 subtype B) at the codons related to resistance to RTI are indicated. 
(Adapted from Quinones-Mateu eta/., 2001 ) 
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Figure 4.1.6 
(B) Structure of the HIV-1 RT 166, indicating amino acids 
residues associated with resistance to RTI. 
146 
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secondary mutations in black and grey respectively) 
(Adapted from Quinones-Mateu eta/., 2001 ) 
It is suggested that the observed cross-resistance with K103N is due to 
the stabilizing effect of the asparagine side chain at 103 on the unliganded 
RT structure. This could provide resistance to a wide range of NNRTis by 
giving a reduced rate of association between inhibitors and enzyme (Ren 
eta/., 2000). 
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Bacheler et a/. (2000) conducted a study dealing with HIV-1 mutations 
selected in patients failing efavirenz combination therapy. Efavirenz is a 
selective and very potent nonnucleoside inhibitor of HIV-1 reverse 
transcriptase (RT). In cell culture, efavirenz retains significant activity 
against a variety of mutant strains of HIV-1 with single amino acid 
substitutions in the RT gene which, have been associated with resistance 
to other NNRTis (Byrnes eta/., 1993; Young eta/., 1995). Cell culture 
selection experiments (Winslow et a/.. 1996) demonstrated that passage 
of the RF strain of HIV-1 in MT-2 cells or peripheral blood mononuclear 
cell culture led to a selection of mutations at amino acids positions 100, 
108, 179, and 181 of the HIV-1 RT gene. Nucleotide sequence analyses 
of the protease and RT genes (coding region for amino acids 1 to 229) of 
multiple cloned HIV-1 genomes, from virus found in the plasma of patients 
in phase II clinical studies of efavirenz combination therapy, were 
undertaken in order to identify the spectrum of mutations in plasma-borne 
HIV-1 associated with virological treatment failure. K103N was the most 
frequently observed NNRTI resistance mutation in samples from 
efavirenz-exposed patients who experienced a significant rebound in viral 
load, detected in more than 90% of cases of efavirenz-indinavir or 
efavirenz-zidovudine (ZDV)-Iamivudine (3TC) treatment failure. This 
amino acid substitution can be achieved by a single base pair change or 
point mutation (AAG or AAA to AAC or AAT). V1081 and P225H mutations 
were observed frequently, predominantly in viral genomes that also 
contained other nonnucleoside RT inhibitor (NNRTI) resistance mutations. 
L1001, K101E, K101Q, Y188H, Y188L, G190S, G190A and G190E 
mutations were also observed. K101E mutations were observed in 13.8% 
of efavirenz treatment failure patients overall, either as a single NNRTI 
resistance mutation (4.8% of patients) or linked to a variety of other 
NNRTI resistance mutations (not just K103N). V106A, Y181C, and 
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Y188C mutations, which have been associated with high levels of 
resistance to other NNRTis, were rare in the patient samples in this study, 
both before and after exposure to efavirenz. The spectrum of mutations 
observed in cases of virological treatment failure was similar for patients 
initially dosed with efavirenz at 200, 400, or 600 mg once a day and for 
patients treated with efavirenz in combination with indanivir, stavudine, or 
ZDV-3TC. The proportion of patients carrying NNRTI resistance 
mutations, usually K103N, increased dramatically at the time of initial viral 
load rebound in case of treatment failure after exposure to efavirenz. 
Viruses with multiple, linked NNRTI mutations, especially K103N-V1081 
and K103N-P225H double mutants, accumulated more slowly following 
the emergence of K1 03N mutant viruses. 
The spectrum of resistance mutations observed in vivo in patients for 
whom efavirenz combination therapy failed, as well as their relative 
frequency, was substantially different from that observed in cell culture 
selection experiments. The L 1001- K103N double mutant selected in cell 
culture (Young et a/., 1995) was relatively infrequently observed in vivo, 
occurring in 10.6% of virological failures. In the selection experiments 
described by Winslow eta/. (1996) viruses with mutations at L 100, V108, 
V179, and Y181 were described. In vivo, the L 1001 mutation was seen 
only in combination with K103N, and V1081 mutations were observed 
largely in combination with K103N. V179D and Y181C mutations were 
extremely rare in plasma virus from patients exposed to efavirenz. The 
results of characterization of the genotypic correlates of resistance to 
efavirenz in vivo emphasize that cell culture selection experiments are 
often not predictive of the types or frequencies of resistance mutations 
selected in patients receiving antiretroviral therapy. 
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A study conducted by Demeter eta/. (1998) on the safety, tolerability, and 
the antiviral activity of atevirdine (A TV}, a nonnucleoside reverse 
transcriptase inhibitor, took the form of a phase 1/11 clinical trial (ACTG 
187) of patients with CD4 counts ~ to 500/mm3. In all, 34 HIV-1-infected 
patients were randomised to receive A TV for a period of twelve weeks to 
achieve one of three serum trough levels: 5 to 13 f..lM, 14 to 22 f..lM, or 23 
to 31 f.!M. Most of the patients complained about a rash. There was no 
significant change from the baseline in HIV-1 plasma RNA mean copy 
number detected at week four. In addition, 2 to 4 patients with detectable 
baseline serum p24 antigen showed declines of >50%. HIV-1 resistance 
to A TV was detected in 41% of patients and it was most commonly 
associated with RT mutations K103N and Y181C. By contrast, the Y181C 
mutation was not detected in A TV-resistant isolates obtained from patients 
enrolled in ACTG 199, a study of A TV given in combination with 
zidovudine. Under the conditions of this study, A TV failed to demonstrate 
significant antiviral activity. However, transient in vivo activity might have 
been obscured by rapid development of resistance coupled with 
inadequate sampling at early time points following initiation of A TV 
therapy. 
4.4 CONCLUSION 
As mentioned earlier, although the sample size was very small, all the 
selected patients tested positive for subtype C, which complies with the 
demographical data set for subtype C. This is also indicative that the 
spread of "strange" subtypes like A or D is not that prevalent in South 
Africa. Different subtypes of HIV-1 possess distinct patterns of consensus 
amino acid sequences in viral proteins, including the protease, a highly 
polymorphic and flexible enzyme (Grossman eta/., 2001). Nearly 47% of 
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the 99 protease amino acids can vary naturally in wild type viruses (both 
within and between subtypes), (Kozal eta/., 1996). Resistance to one or 
more of the six presently used protease inhibitors has been associated 
with mutations at 45 amino acid positions (Condra et a/., 1995; Mammano 
eta/., 1998). Mutations at nine amino acid positions have been commonly 
designated primary or major resistance mutations (D30N, V321, M461/L, 
G48V, 150V, 154UMN, V82A/F/SfT, 184AN, N88S, and L90M), 0fVu eta/., 
2003). Other resistance mutations considered of a lesser significance are 
defined as secondary or minor mutations. Although none of the primary 
mutations occur as polymorphysims in wild type HIV-1 , several secondary 
mutations contributing to reduced susceptibility (e.g., M361 and 193L) are 
found in nearly 100% of subtype C viruses from drug-na'ive patients (Cane 
et a/., 2001; Grossman et a/., 2001 ). This statement correlates very well 
with results achieved as 95% prevalence for both M361 and 193L was 
encountered. Upon antiretroviral treatment, such differences in baseline 
polymorphisms among subtypes may result in the evolution of drug 
resistance along distinct mutational pathways, or in differences in the 
incidence of these specific pathways (Grossman eta/., 2001 ; Brenner et 
a/., 2003). These genetic differences may be clinically relevant when 
considering long-term treatment strategies for patients infected with 
different subtypes. 
However, the current ARV protocol that is employed by the State is not 
flawless. By looking at the First-line therapy (Schedule 1) regimens 
(http://www.epi.uct.ac.za/artrolloutl) quite a few mutations can be 
associated with every drug. Unless contraindicated, all patients will 
commence therapy on: 
(A) Stavudine (d4T) 40 mg every 12 hours (or 30 mg every 12 hours if< 
60kg), plus 
(B) Lamivudine (3TC) 150 mg every 12 hours, plus 
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(C) Efavirenz (EV) 600 mg at night (or 400 mg if< 40 kg) or Nevirapine 
(NVP) 200 mg daily for 2 weeks, followed by 200 mg every 12 
hours. To prevent pregnancy, injectable contraception should be 
prescribed in addition to condoms for women of child-bearing 
potential who are started on efavirenz. If unable to guarantee 
contraception for women while on therapy, nevirapine will be 
substituted for efavirenz (Appendix D). 
However, a great number of mutations have already been reported on the 
drugs mentioned above. Although the V75T mutation has been observed 
after in vitro resistance selection experiments with stavudine and it is 
associated with reduced susceptibility to stavudine (Lacey eta/. , 1994), 
this mutation is not detected in patients failing stavudine therapy. 
Zidovudine resistance mutations, such as M41 L, K?OR and T215Y, are 
seen in zidovudine-nalve patients who do not have virologic suppression 
on stavudine-containing therapy (Coakley eta/., 2000; de Mendoza eta/., 
2000). The mutation M1841N occurs rapidly in vitro and in vivo under the 
selective pressure of lamivudine, and confers high-level resistance 
(Schinazi et a/., 2000). Resistance to nevirapine is associated with 
mutations A98G, L 1001, K101E/Q, K103N, V106A/1, V1081, V1790, 
Y181C/I, Y188C/UH and G190S/A. Single mutations at positions L 1001, 
K103N, V106A/I, V1081, Y181C/I, Y188C/UH, and G190S/A are sufficient 
to confer high-level resistance to nevirapine. Compared to nevirapine and 
delavirdine, efavirenz shows greater resilience against resistance 
mutations within HIV-1 RT. This is probably due to the respositioning of 
efavirenz in the NNRTI binding pocket of the mutant RT and to 
conformational rearrangements in the enzyme. High level resistance is 
associated with single mutations at K103N, Y188, and G190S. Multiple 
mutations at A98G, L 1001, K101 E/Q, V106A/I, V1081, V1790, Y181C/I , 
Y188C/H and G190A, are necessary to confer high level resistance to 
efavirenz (Schinazi eta/. , 2000). 
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Patients may occasionally need to change a drug from the first-line 
regimen to one from the second-line regimen, because of a serious 
adverse reaction (e.g. severe rash on nevirapine, requiring a change to 
lopinavir/ritonavir, symptomatic peripheral neuropathy on stavudine, 
requiring the swap to zidovudine). However, if changing occurs the 
patient is very limited in his/her second-line treatment options. It is very 
important that the decision to change is made by a doctor with a vast 
amount of experience in antiretroviral treatment. If the patient continues to 
fail virologically despite efforts to improve adherence, his/her antiretroviral 
treatment may be changed to the second-line therapy (Schedule 2; 
http://www.epi.uct.ac.za/artrollout/). Most of the patients will commence 
schedule 2 as follows: 
(A) Didanosine (ddl) 400 mg once a day (250 mg daily if< 60 kg), plus 
(B) Zidovudine (AZT) 300 mg every 12 hours, plus 
(C) Lopinavir/ritonavir (LPV/r) 400/100 mg every 12 hours (Appendix 
E). 
There are also known mutations for second-line therapy (Schedule 2). 
Resistance to zidovudine is associated with six substitutions at codons 
M41L, D67N, K70R, L210W, T215Y/F and K219Q. These mutations 
appear to emerge in a characteristic sequence, with the first mutations 
usually appearing at codon 70. HIV-1 resistance to zidovudine results 
from the increased pyrophosphorolytic or nucleotide-dependent cleavage 
of chain-terminated viral DNA by the mutant RT combined with the 
increased processivity of the enzyme (Arion et a/., 1998; Meyer et a/. , 
1999). The most common mutation observed during didanosine 
monotherapy is L74V (St. Clair et at.. 1991). In addition to L74V, 
didanosine resistance occurs due to mutations at codons 65 and 184 
(Winters eta/. , 1997). The K65R has been isolated from several patients 
receiving long-term treatment with didanosine monotherapy. M184V also 
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decreases susceptibility to didanosine. However, it is only rarely observed 
in HIV-1 infected patients receiving didanosine. 
A different protocol consisting of a first-line therapy (Schedule 1) and a 
second-line (Schedule 2) therapy for children < than 6 months and also > 
than 6 months, exists (http://www.epi.uct.ac.za/artrolloutl). 
The above-mentioned complications indicate that it is no easy task to treat 
a patient with antiretroviral drugs, bearing in mind that there are currently 
no further treatment options available within the public sector for patients 
who fail second-line therapy. 
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Date: 
You have been asked to participate in a research study. 
You have been informed about the study by ..... .. ................ ..... .............................. . 
You may contact L Botes at 083 70 90 312 any time if you have questions about the 
research or if you are injured as a result of the research. 
You may contact the Secretariat of the Ethics Committee of the Faculty of Health 
Sciences, UFS at telephone number (051) 4052812 if you have questions about your 
rights as a research subject. 
Your participation in this research is voluntary, and you will not be penalized or lose 
benefits if you refuse to participate or decide to terminate participation. 
If you agree to participate, you will be given a signed copy of this document as well as 
the participant information sheet, which is a written summary of the research. 
The research study, including the above information has been verbally described to me. 
1 understand what my involvement in this study means. I also understand that my 
patient information will be regarded as confidential, that my participation is voluntary and 
that I could withdraw at any time. 
Signature of Participant Date 
Signature of Translator Date 
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Datum: 
---- -
U is versoek om aan 'n navorsingsstudie deel te neem. 
U is oor die studie ingelig deur ..... . ... .. ... .. ... ................. ... ... ... .. . ." ..... ... .... ..... ........ .. . 
U kan Me L Botes enige tyd kontak by 083 70 90 312 indien u vrae oor die navorsing het 
of as gevolg van die navorsing beseer is. 
U kan die Sekretariaat van die Etiekkomitee van die Fakulteit 
Gesondheidswetenskappe, UV by telefoonnommer (051) 405 2812 kontak indien u 
enige vrae het oor u regte as 'n proefpersoon. 
U deelname aan hierdie navorsing is vrywillig, en u sal nie gepenaliseer word of 
voordele verbeur as u weier om deel te neem of besluit om deelname te staak nie. 
As u instem om deel te neem, sal 'n ondertekende kopie van hierdie dokument sawel as 
die inligtingsblad, wat 'n geskrewe opsomming van die navorsing is, aan u gegee word. 
Die navorsingstudie, insluitende die bogenoemde inligting is verbaal aan my beskryf. Rk 
begryp wat my betrokkenheid by die studie beteken. Ek verstaan ook dat my pasient 
inligting konfidensieel hanteer sal word en dat my deelname vrywillig is en ek teen enige 
tyd kan onttrek. 
Handtekening van deelnemer Datum 
Hantekening van Vertaler Datum 
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Letsatsi: 
TV~f£££0 'Yft JfO W(Jf. 1(jf1(0£0 VBP)f_lJ'£ISISO:N(] 
0 kopilwe ho nka karolo thutong ya dipatlisiso. 
0 ile wa tsebiswa ka thuto en a ke ...... .. ... ..... ............. ... . ... ...... .. .. . 
0 ka nna wa ikopanya le L Botes nomorong ya 083 70 90 312 nako e nngwe lee nngwe 
ebang o nale dipotso mabapi le dipatlisiso kapa ebang o ka tswa kotsi ka baka Ia 
dipatlisiso. 
0 ka nna wa ikopanya le Mongodi wa Ethics Committee ya Faculty of Health Sciences, 
UFS nomorong ya mohala ya (051) 4052812 ebang o nale dipotso ka ditokelo tsa hao 
jwaloka eo ho etswang dipatlisiso ka yena. 
Ho nka karolo ha hao dipatlisisong tsena ke boithaopong ba hao, mme o keke wa 
fumantshwa kotlo kapa wa lahlehelwa ke menyetla ya hao ebang o ka hana kapa wa 
nka qeto ya ho kgaotsa ka ho nka karolo. 
Ha o dumela ho nka karolo, o tla nehwa khopi e saennweng ya tokomane ena hammoho 
le leqhephe Ia ba nkang karolo e leng le ngotsweng kgutsufatso ya dipatlisiso. 
Thuto ya dipatlisiso ho kenyellwa lesedi le ngotsweng ka hodimo, di ile tsa hlaloswa ho 
nna ka molomo. 
Ke utlwisisa hore ho nka karolo ha ka thutong ena ho bolelang. Ke boetse ke utlwisisa 
hore tlhahiso leseding e mabapi le dintlha tse amang botho ba ka, e tla nkwa e le sephiri 
le hore ho nka karolo ha ka ke boithaopo le hore nka nna ka ikgula nako e nngwe le e 
nngwe. 
Tshaeno ya motho ya 
nkang karolo 
Tshaeno ya mofetoledi 
Letsatsi 
Letsatsi 
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HIV Genotyping 
Dear participant, we are inviting you to be part of this clinical trail and would be 
very thankful if you could see your way open to be part of this study. Below you 
will find all the information about this study and your responsibilities as 
participant. 
The development of viral resistance to antiretroviral drugs used for treatment of 
human immunodeficiency virus (HIV) infections is an important cause of 
treatment failure and limits options for alternative antiretroviral regimens. 
Prevention, characterization, and clinical management of such resistance are 
receiving increasing attention. Having access to both treated and untreated 
patients puts us in an ideal situation to study the phenomenon of drug resistance. 
Therefore, the main objective of this study was to optimize a method for the 
detection of all variants of the HIV-1 viruses. By investigating the untreated 
patients for naturally occurring variants of the virus, important information can be 
obtained regarding the possible existence of resistance against HIV antiretroviral 
drugs. 
One visit will be made to Tsepo House, all the information regarded the study will 
be explained to all the possible candidates. Consent will be obtained from the 
candidates to draw 5ml of blood from them to be submitted to the study. The 
candidates will receive an information document and must sign a form of 
consent. 
During the initial phase of the project written approval for the protocol will be 
obtained from the Ethics Committee of the Faculty of Health Sciences, University 
of the Free State, Bloemfontein, before the first administration of study. 
Thirty-two volunteers living with HIV will be selected after the screening visit, who 
fulfilled the inclusion criteria, did not meet any of the exclusion criteria, and who 
gave written informed consent, will be entered into the study. 
© Central University of Technology, Free State
Inclusion Criteria: 
• Male and female subjects from 18 to 65 years of age that are HIV/AIDS 
positive. 
• No previous antiretroviral treatment 
• A viral load of more than 2000 copies/ml 
• CD4+T-cell counts 200-350 cells/mm3 
• Only volunteers that give informed consent will be submitted to the study. 
Withdrawal criteria: 
Subjects have the right to withdraw from the study at any time, irrespective of the 
reason, without detriment of their medical care. These patients will be handled 
as drop-outs. Participation is voluntary, and refusal to participate will involve no 
penalty or loss of benefits to which the subject is otherwise entitled to. 
Each enrolled subject will receive a number (01 - 32) and will retain this number 
throughout the study. 
Participation is voluntary and refusal to participate will involve no penalty or loss 
of benefits to which the subject is otherwise entitled; the subject may discontinue 
participation at any time without penalty or loss of benefits to which the subject is 
otherwise entitled. 
Efforts will be made to keep personal information confidential. Absolute 
confidentiality cannot be guaranteed. Personal information may be disclosed if 
required by law. 
The project is very safe. The patients will be well monitored during the collection 
of the blood specimen. 
PI9f)fJVCI}f.L I~CJJ£ICJfrz109f PO<R. qJflE q>)frz1P.!Jfl.S: 
There is no financial implication for the patients. 
© Central University of Technology, Free State
CO:Jfi.'JICT CJYE/I)f1£S OP CR!fSP.jf11ClfE!R(S} 
MeL Botes 
Dr Evan den Heever-Kriek 
Prof GHJ Pretorius 
Cell nr 
Cell nr 
Cell nr 
For reporting of complaints/problems. 
Phone nr: 051-405 2812 
083 70 90 312 (researcher) 
082 77 05 356 (researcher) 
083 63 82 093 (researcher) 
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HIV Genotipering 
Liewe deelnemer ons nooi u uit om deel te neem aan die kliniese 
navorsingstudie. Ons sal baie dankbaar wees as u u weg oopsien om deel te 
neem aan die studie. Die onderstaande inligting handel oor die studie en 'n 
uiteensetting van u verantwoordelikheid en deelname met betrekking tot die 
studie. 
Die ontwikkeling van virale weerstandigheid teen antiretrovirale middels wat 
gebruik word in die behandeling van MIV infeksies is vandag 'n baie belangrike 
oorsaak vir die mislukking van MIV behandeling en skep beperkings rakende 
alternatiewe antiretrovirale behandeling. Die voorkoming, karaktirisering en 
kliniese bestuur van sulke weerstandigheid moet voortslepend aandag geniet. 
Ons toegang tot beide behandelde en onbehandelde pasiente plaas ons in die 
ideale posisie om die verskynsel van middelweerstandigheid te bestudeer. 
Daarom, die objektief van hierdie studie was om 'n metode te optimiseer vir die 
opsporing van aile variante van die MIV-1 virusse. Deur te kyk na die 
onbehandelde pasiente kan al die natuurlike variante van die virus opgespoor 
word wat waardevolle inligting kan veskaf rakende die moontlike weerstandigheid 
teen MIV antiretrovirale middels. 
'n Eenmalige besoek sal gebring word aan Tsepo House waar daar aan die 
moontlike kandidate 'n verduideling van die studie voorgele sal word. 
T oestemming sal van die kandidate verkry word om Sml bloed van hulle te trek 
en aan die studie te onderwerp. Die kandidate sal 'n inligtingstuk van die studie 
sowel as 'n toestemmings brief onderteken. 
Tydens die aanvangsfase sal om skriftelike toestemming aansoek gedoen word 
by die Etiese Komitee van die Fakulteit Gesondheidswetenskappe, UVS, om die 
studie te onderneem. 
sqtc}q)JfE (]'()(P() £}fSil£: 
Twee en dertig vrywilligers wat MIV positief is sal gedurende die besoek 
geselekteer word, wat aan die insluitingskriteria voldoen en wat die skriftelike 
toestemmingsvorm voltooi het. 
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lnsluitingskriteria: 
o MIV positief/AIDS mans en vrouens tussen 18-65 jaar 
o Geen vorige antiretrovirale behandeling 
o "n Viruslading van meer as 2000 kopiee/ml 
o CD4 + T -sel telling van 1 00-350 selle/mm3 
o Slegs diegene wat toestemming verleen sal in die studie ingesluit word. 
Ontrekki ngskriteria: 
o Die pasient het die reg om enige tyd van die studie te onttrek, sonder dat dit 
tot nadeel van die pasient sal wees. U deelname aan hierdie navorsing is 
vrywillig, en u sal nie gepenaliseer word of voordele verbeur as u weier om 
deel te neem of besluit om deelname te staak nie. Die stakers sal hanteer 
word as uitvallers en nie in die studie vervang word nie. 
o Elke pasient sal 'n nommer ontvang (01-32) en sal die nommer behou deur 
die studie. 
V CJYE/E£NJI~f£ IS '0R~I££l{i: 
U deelname is vrywillig, en u kan weier om deel te wees van die studie. Die 
pasient het die reg om enige tyd van die studie te onttrek, sander dat dit tot 
nadeel van die pasient sal wees. U deelname aan hiedie navorsing is vrywillig, 
en u sal nie gepenaliseer word of voordele verbeur as u weier om deel te neem 
of besluit om deelname te staak nie. 
WfRPROV£17(JfE/CD: 
Daar sal gepoog word om persoonlike inligting vertroulik te hou. Volkome 
vertroulikheid kan nie gewaarborg word nie. Persoonlike inligting kan bekend 
gemaak word as die wet dit vereis. 
Die studie is baie veilig. Die pasiente sal deeglik gemonitor word tydens die 
neem van die bloedmonster. 
PIN..M{Sle£f£ I~a>£!7(flSIPS tVlfR. (])Jf£ a>}fSie!Jfl: 
Daar is geen finansiele implikasies vir die pasiente nie. 
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MeL Botes Cell nr 083 70 90 312 ( navorser) 
Dr E van den Heever -Kriek Cell nr 082 77 05 356 (navorser) 
Prof GHJ Pretorius Cell nr 083 63 82 093 (navorser) 
KONI')f1(SBPSO!NliYECJ<JfEiiYE 1/Jf!N!NP.KSP/1(1<~/I)ItRJJIJfrz' P:N 
1/0Q<RSiqt]!E{}lu 
Vir rappotering van klagtes/probleme 
Telefoonnommer: 051 405 2812 
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OUTER RT -PCR PRIMERS: 
• AV190-1 
• CR1 
gctacaytagaagaaatgatgacagcat 
ttccctacaatccccaaagtcaaggagtagaattc 
INNER PCR PRIMERS: 
• AV190-2 
• CR2 
tagaagaaatgatgacagcatgycagggagt 
caggaatttggnattccctacaatccccaaag 
SEQUENCING PRIMERS: 
• OUTS 
• OUT3 
• AV2 
• AV5 
• AV8 
• AV9 
gtacagtattagtaggacctacacctgtcaacat 
catgagaaatcacagtaattggagagcaatg 
tgtaaactccttaggggaaccaaagcact 
aaagacagctggactgtcaat 
aatacccctcccttagtgaaattatg 
cccatacaaaaggaaacat 
LUU 
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A) ALIGNED PROTEASE SEQUENCES FROM THIS STUDY: 
1 1 PQITLWQRPL VSIKVGGQIK EALLDTGADD TVLEEINLPG KWKPKMIGGI GGFIKVRQYD 60 
2 1 . R . 60 
3 1 v. D. 60 
4 1 .L. I . TR .MS R . 60 
11 1 . T .TR D. 60 
12 1 . V. 60 
13 1 T R. . TR 60 
15 1 T D. 60 
16 1 . R. 60 
17 1 R. . R . .A . 60 
22 1 E R . D. 60 
23 1 . .R. .TR . 60 
24 1 I . E 60 
25 1 . TR . D. D. . E 60 
26 1 .R. .R s 60 
27 1 E D. R. . E 60 
29 1 . . T. D . 60 
31 1 . T . I .V. D . E 60 
32 1 . .v . T. I . T 60 
HXB2 1 .v. . . T. I L .MS R. 60 
1 61 QILIEICGKK AIGTVLVGPT PVNIIGRNLL TQIGCTLNF 99 
2 61 . . . . M. L 99 
3 61 . . M. .L . 99 
4 6 1 P . Y. I .M. . L. 99 
11 61 . . . . . M. .L . 99 
12 61 p . M. . L . . 99 
13 61 . T . I .L . 99 
15 61 . VM . s . M . . v . 99 
16 6 1 .I\ . L 99 
17 6 1 .T . Q .M. L 99 
22 6 1 . . s .M. L 99 
23 61 P . I .M. .L 99 
24 61 . v . . . .M . L 99 
25 61 s . . M. L 99 
26 61 P . .Q I . .M. L 99 
27 61 .v . .M. . L 99 
29 61 s .M . L 99 
31 61 p .M. L 99 
32 61 .A. . .A . . .M. L 99 
HXB2 61 H. 99 
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8) ALIGNED REVERSE TRANSCRIPTASE SEQUENCES FROM THIS STUDY: 
1 
2 
3 
4 
11 
12 
13 
15 
16 
17 
22 
23 
24 
25 
26 
27 
29 
31 
32 
HXB2 
1 
2 
3 
4 
11 
12 
13 
15 
16 
17 
22 
23 
24 
25 
26 
27 
29 
31 
32 
HXB2 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
61 
61 
61 
61 
61 
61 
61 
61 
61 
61 
61 
61 
61 
61 
61 
61 
61 
61 
61 
6 1 
PISPIETVPV KLKPGt1DGPR VKQWPLTEEK I KALTEICEE ME KEGKITKI GPENPYNTPV 
...•.•. . . . • ........ K ......•........ A . .•...•............ .. ... 
••••. • ••• K 
•. • . • .. ...•.••.•.•. K 
.. . • . •• I ........ ... K 
... S ............... K 
. . .. ............... K 
. ........ K 
.............. .. . .. K 
. .. ... . I ........... K 
...... . .. K 
......... K 
. .. . .. .. • K 
. ... .. .. . K 
• .. • .. .. • K 
......... K 
. .. . .. . • . K 
...... . .. K 
• .. .. • • • • K 
.... M ..... 
.... . A .. .. 
. . ... A .. .. 
.. . .. A .. .. 
..... A .. .. 
..... A ... D 
. ....... D . 
.. ..... .. D 
..... A • ... 
..... I .. .. 
..... A .. .. 
.. .. . . ... I 
. ........ I 
. ...... s .. 
......... I 
..... A .. K . .. E ....... ...... ... I 
..... A ....................... . 
.... V ••• T . ..... . . S •. 
FAIKKKDSTK WRKLVDFREL NKRTQDFWEV QLGIPHPAGL KKKKSVTVLD VGDAYFSVPL 
.•. R ...... E ......... 
. Q . ....... 
. QN .. .... . 
• • R .... . . . 
... R .. .... 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
120 
120 
12 0 
12 0 
120 
120 
120 
120 
120 
120 
120 
120 
120 
1 20 
1 20 
1 20 
120 
1 20 
120 
120 
1 1 21 DENFRKYTAF TIPSINNETP GI RYQYNVLP QGWKGS PAIF QSSMTK ILEP FRAKNPEI DI 1 80 
2 121 .. D ....... ... . .. ..... .......... .......... C ....... . .. T ..... V. 1 80 
3 121 ............. . R ................ . .. . .. .. ..... I ... .. ... Q .. . LV . 1 80 
4 121 .. S ....... .... R ............. ............. C .............. D. V. 180 
11 121 .. G .. . ... ................ . ...... ..... .. ...... R ....... Q .... V . 180 
12 121 .. G. . . . . . . . . . . • . • • • . . . • • • • • . • . . . . . . . . . . . . N. • • . . . . . . . TQ .... V . 18 0 
13 1 2 1 .. G ....... ........ .. ................... .. C ................ V . 18 0 
15 1 21 .............. T .. G ....................... ..... ...... T ... D. V. 180 
16 12 1 .. G ........... T .. ... ...... .... .......... . ....... ..... Q .... V . 180 
17 
22 
23 
24 
25 
26 
27 
29 
31 
12 1 
121 
12 1 
121 
1 2 1 
. . G ...... . 
H. S ............. · .. · 
.. D ........... R .... . 
.. G .. . ........... . S . 
. KD . . . ... . 
1 2 1 . KD .... .. . 
1 2 1 .. s ................ . 
121 .. S ... .... ... . T . .. .. 
121 .. s .. ............. .. 
. v ........ 
. . . .. .. s .. 
. .. R .... ..  J . 
..... ..... ..... . .. V . 
.... I ........ Q .... V . 
. Y .............. D. I . 
....... ..... T .... VV . 
... .. ........ Q .... v . 
.•. . • R •• .... KQ .. N. V. 
. .. . I ..... .. ...... V . 
.. ..... . V . 
180 
180 
180 
180 
180 
1 80 
1 80 
1 80 
180 
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32 
HXB2 
1 21 . KD ...... . 
1 21 .. D ... . .. . 
. N • • .•..•• ••• R .•.• V . 
. ....... . ... KQ .. D. V. 
LV..J 
1 80 
18 0 
1 1 81 YQYMDDLYVG SDLEIGQHRA KIEELREHLL h~GFTTPDKK HQKEPPFLWM GYELHPDKWT 2 40 
2 
3 
4 
11 
12 
13 
15 
16 
17 
22 
23 
24 
25 
26 
27 
29 
31 
32 
HXB2 
1 
2 
3 
4 
11 
12 
13 
15 
16 
17 
22 
23 
24 
25 
26 
27 
29 
31 
32 
HXB2 
1 
2 
3 
4 
11 
12 
13 
15 
16 
17 
22 
23 
24 
25 
26 
•. . • . K ••.. 
...... .. . T 
.•.•• M •••. 
. V .• •• A ..•......•..• 
.. D .•• A . . . R ••.•...•• 
. .... . D .•. 
...... G ... 
••...• D .•• Q •.••...•• 
... L .... . . 
.•. Q .• D •.. 
• •• .. • K ... R .. L .•.••• 
. ••..• K .•.•.• L • •. ... 
•••• • • D .••.•• L ••••.. 
1 8 1 
1 8 1 
181 
181 
181 
181 
1 8 1 
181 
181 
181 
1 8 1 
181 
181 
1 8 1 
1 8 1 
181 
1 8 1 
1 8 1 
181 .• •. ... •. T ....•. Q .•• R •• L •...•. 
2 41 VQPIQLPDKD SWTVNDIQKL VGKLNWASQI YPGIKVRQLC KLLRGTKALT DIVPLTEEAE 
2 4 1 . ... K . . E . . N . . . . . . . . . . . . . . . . . . . . ... Q. KH . . . . . . . . . . . . . . I ...... . 
241 ....... E ...•....••.••... •...••..• ...• N •.•.•.• A . • •• • • • ••••••• 
2 41 ....... E •..•••.•••.••..•••...•. A •.•.••..... . • A .••.•...••.•.• 
24 1 ..... . . E.. . . . . . . . . . . . . . . . . . . . . . . . . . . • . . . . . . . . . . . . . . ...... . . . 
2 41 ....... E .•......•• •. 
2 41 ....... E.. . ........ . 
2 41 ....... E.E A .. ...... . 
2 41 .... K . • E .. 
24 1 ......... E D •. .••••• • 
24 1 ..... . . E.. . ........ . 
24 1 .... K •. E .•.••..•..•. 
2 41 I. ..... E .• H ••.••. .• • 
241 .. T.K .... E .•...• •.•. 
2 41 ....... E.. . ........ . 
241 ...... . E •• 
2 41 ....... E.E 
2 41 .... T .• E . E 
241 ....... E .. 
241 .... V .. E .. 
.... Q .• K ...•..• A . ••. 
..••• A •••• 
...... KH ....... A ••.• E .• .•• .. •• 
....• • K .•• 
• • • • • • K •• • 
. .... A .• •. 
•..•• A •• •• 
•••••• ••• .• • .•. A .••. 
. S .•.. K ... R ..•..••.. 
. S ..•........•. A •... 
.... R . K .. . 
. ...•.........• A ..• • •. . Q •...•. 
.... R.K ..... ... A .•.• . V . Q •... .. 
.... R . K ..... . .. A •.•••. I •.. D . •• 
.••••. K ... 
EVI ...... . 
30 1 LELAENREIL KEPVHGVYYD PSKELIAEIQ KQGND 335 
301 ....................... DFM .... . .. H. 335 
30 1 
301 
301 
30 1 
30 1 
30 1 
301 
301 
301 
301 
301 
301 
30 1 
...... . F .. 
.••.•• A ••• 
•••••• A ••• 
..• D ••... . ••• D . 335 
•. • D •• •. L. . •• QG 335 
... D...... . . ECN 335 
... D.. .... 335 
... D... ... 335 
... D .... I.J. 335 
... E. 335 
... D •.. . ... • . D . 335 
... D •.. ...... E . 335 
... D .••..•..• H. 335 
... D...... 335 
.• . D • .•.•... . QG 335 
... D ......... H. 335 
2 40 
240 
2 40 
2 40 
2 40 
240 
2 40 
2 40 
2 40 
2 40 
2 40 
2 40 
240 
2 40 
2 40 
2 40 
2 40 
2 40 
2 40 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
J()() 
300 
300 
300 
300 
300 
300 
300 
300 
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27 301 . . D . . Q . 335 
29 301 . A . . D. 335 
31 30 1 . D . . Q . 335 
32 30 1 . D . .H . 3 35 
HXB2 30 1 . D . . QG 335 
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C) POSSIBLE DRUG RESISTANCE AS SCORED BY THREE DIFFERENT 
ALGORITHMS: 
Susceptible Key: S 
I 
R 
Intermediate or low level resistance 
High level resistance 
PATIENT NUMBER: 
SEX: 
AGE: 
VIRAL LOAD: 
DRUG MUTATIONS: 
DRUGS: 
NRTI 3TC ABC 
ANRS s s 
HIVDB s s 
Regalnst s s 
NNRTI DLV 
ANRS 
HIVDB s 
SCORED MUTATION V1790 
Regalnst I 
PR 
RT 
AZT 
s 
s 
s 
PI APV APV RTV ATV 
ANRS s s 
HIVDB s s 
SCORED M361 M361 
MUTATION 
Regalnst s s 
1 
F 
>750 000 
M361 
V179D 
D4T DOC DOl 
s s 
s s s 
s s s 
EFV 
s 
s 
V179D 
I 
IDV LPV NFV 
s s s 
s s s 
M361 M361 M361 
s s s 
FTC TDF 
s 
s s 
s 
NVP 
s 
s 
V179D 
I 
RTV SQV TPV RTV 
s s s 
s s 
M361 M361 
s s 
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PATIENT NUMBER: 
SEX: 
AGE: 
VIRAL LOAD: 
DRUG MUTATIONS: 
DRUGS: 
NRTI 3TC ABC 
ANRS 5 5 
HIVDB s s 
Regalnst s s 
NNRTI DLV 
ANRS 
HIVDB s 
Regalnst s 
2 
M 
404 400 
PR M361 ; 193L 
RT 
AZ.T D4T DOC 
5 s 
s s s 
s s s 
EFV 
s 
s 
s 
PI APV APV RTV ATV IDV LPV 
ANRS s s s s 
HIVDB s s s s 
SCORED M361 M361 M361 M361 
MUTATION 193L 193L 193L 193L 
Regalnst s 5 s s 
LVU 
DOl FTC TDF 
5 s 
s s s 
s s 
NVP 
s 
s 
s 
NFV RTV SQV TPV RTV 
s s s s 
s s s 
M361 M361 M361 
193L 193L 193L 
s s s 
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PATIENT NUMBER: 
SEX: 
AGE: 
VIRAL LOAD: 
DRUG MUTATIONS: 
DRUGS: 
NRTI 3TC ABC 
ANRS s s 
HIVDB s s 
Regalnst s s 
NNRTI DLV 
ANRS 
HIVDB s 
Regalnst s 
3 
F 
>750 000 
PR M361 ; 193L 
RT 
AZT D4T DOC 
s s 
s s s 
s s s 
EFV 
s 
s 
s 
PI APV APV RTV ATV IDV LPV 
ANRS s s s s 
HIVDB s s s s 
SCORED M361 M361 M361 M361 
MUTATION 193L 193L 193L 193L 
Regalnst s s s s 
LUI 
DOl FTC TDF 
s s 
s s s 
s s 
NVP 
s 
s 
s 
NFV RTV SQV TPV RTV 
s S· s s 
s s s 
M361 M361 M361 
193L 193L 193L 
s s s 
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PATIENT NUMBER: 
SEX: 
AGE: 
VIRAL LOAD: 
4 
F 
80 700 
DRUG MUTATIONS: PR L 101 ; K20R ; L63P ; V771 ; 193L 
RT K101E 
DRUGS: 
NRTI 3TC ABC AZ.T D4T DOC DOl FTC TDF 
ANRS s s s s s s 
HIVDB s s s s s s s s 
Regalnst s s s s s s s 
NNRTI DLV EFV NVP 
ANRS R R 
SCORED MUTATION K101E K101E 
HIVDB s s s 
SCORED MUTATION K101E K101E K101E 
Regalnst I I I 
SCORED MUTATION K101E K101E K101E 
PI APV APV RTV ATV IDV LPV NFV RTV SQV TPV RTV 
ANRS s I s s s s s s 
SCORED L101, 
MUTATIONS K20R, 
L63P 
HIVDB s s s s s s s 
SCORED K20R, K20R, K20R, K20R, K20R, K20R, K20R, 
MUTATION L 101, L 101, L101, L 101, L101, L101, L 101, 
L63P, L63P, V771, L63P, L63P, L63P, L63P, 
193L 193L L63P, 193L 193L 193L 193L 
193L 
Reg_alnst s I s s s I s 
SCORED L101, L 101, 
MUTATIONS K20R, K20R, 
L63P, L63P 
V771, 
L89M 
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PATIENT NUMBER: 
SEX: 
AGE: 
VIRAL LOAD: 
DRUG MUTATIONS: 
DRUGS: 
NRTI 3TC ABC 
ANRS s s 
HIVDB s s 
Regalnst s s 
NNRTI DLV 
ANRS 
HIVDB s 
Regalnst s 
11 
M 
99 500 
PR K20R ; M361 ; 193L 
RT 
AZT D4T DOC DOl 
s s s 
s s s s 
s s s s 
EFV 
s 
s 
s 
PI APV APV RTV ATV IDV LPV NFV 
ANRS s s s s s 
HIVDB s s s s s 
SCORED K20R, K20R, K20R, K20R, K20R, 
MUTATION 193L, 193L, 193L, 193L, 193L, 
M361 M361 M361, M361 M361 
Regalnst s s s s s 
LV'J 
FTC TDF 
s 
s s 
s 
NVP 
s 
s 
s 
RTV SQV TPV RTV 
s s s 
s s 
K20R, K20R, 
193L, 193L, 
M361 M361 
s s 
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PATIENT NUMBER: 
SEX: 
AGE: 
VIRAL LOAD: 
DRUG MUTATIONS: 
DRUGS: 
NRTI 3TC ABC 
ANRS 
HIVDB s s 
Regalnst 
NNRTI DLV 
ANRS 
HIVDB s 
Regalnst 
12 
M 
436 000 
PR M361 ; L63P ; 193L 
RT 
AZ.T 04T DOC 
s s 
EFV 
s 
PI APV APV RTV ATV IDV LPV NFV 
ANRS 
HIVDB s s s s s 
Scored L63P L63P L63P L63P L63P 
Mutation M361 M361 M361 M361 M361 
Regalnst 
DOl FTC TDF 
s s s 
NVP 
s 
RTV SQV TPV RTV 
s s 
L63P L63P 
M361 M361 
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PATIENT NUMBER: 
SEX: 
AGE: 
VIRAL LOAD: 
DRUG MUTATIONS: 
DRUGS: 
NRTI 3TC ABC 
ANRS 
HIVDB s s 
Regalnst 
NNRTI DLV 
ANRS 
HIVDB r 
Scored Mutation Y318F 
Regalnst 
13 
M 
193 000 
PR K20R; M361 ; L63T; V771 ; 193L 
RT Y318F 
AZT D4T DOC DOl FTC 
s s s s 
EFV NVP 
s s 
Y318F Y318F 
PI APV APV RTV ATV IDV LPV NFV RTV SQV 
ANRS 
HIVDB s s s s s s s 
Scored K20R K20R K20R K20R K20R l63P K20R 
Mutation M361 M361 M361 M361 V771 M361 M361 
M361 
Regalnst 
TDF 
s 
TPV RTV 
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PATIENT NUMBER: 
SEX: 
AGE: 
VIRAL LOAD: 
DRUG MUTATIONS: 
DRUGS: 
NRTI 3TC ABC 
ANRS 
HIVDB s s 
Regalnst 
NNRTI DLV 
ANRS 
HIVDB s 
Regalnst 
15 
M 
320 000 
PR M361 ; L63V ; 193V 
RT 
AZT 04T DOC 
s s 
EFV 
s 
PI APV APV RTV ATV IDV LPV NFV 
ANRS 
HIVDB s s s s s 
Scored M361 M361 M361 M361 M361 
Mutation 
Regalnst 
,,, 
DOl FTC TDF 
s s s 
NVP 
s 
RTV SQV TPV RTV 
s s 
M361 M361 
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PATIENT NUMBER: 
SEX: 
AGE: 
VIRAL LOAD: 
DRUG MUTATIONS: 
DRUGS: 
NRTI 3TC ABC 
ANRS 
HIVDB s s 
Regalnst 
NNRTI DLV 
ANRS 
HIVDB s 
Regalnst 
16 
M 
118 000 
PR M361 ; L63A ; 193L 
RT 
AZT D4T DOC 
s s 
EFV 
s 
PI APV APV RTV ATV IDV LPV NFV 
ANRS 
HIVDB s s s s s 
Scored M361 M361 M361 M361 M361 
Mutation 
Regalnst 
DOl FTC TDF 
s s s 
NVP 
s 
RTV SQV TPV RTV 
s s 
M361 M361 
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PATIENT NUMBER: 
SEX: 
AGE: 
VIRAL LOAD: 
DRUG MUTATIONS: 
DRUGS: 
NRTI 3TC ABC 
ANRS 
HIVDB s s 
Regalnst 
NNRTI DLV 
ANRS 
HIVDB s 
Regalnst 
17 
F 
146 000 
PR K20R ; M361 ; L63T ; 193L 
RT 
AZT 04T DOC DOl 
s s s 
EFV 
s 
FTC 
s 
NVP 
s 
PI APV APV RTV ATV IDV LPV NFV RTV SQV 
ANRS 
HIVDB s s s s s s s 
Scored K20R K20R K20R K20R K20R K20R K20R 
Mutation M361 M361 M361 M361 M361 M361 M361 
Regalnst 
TDF 
s 
TPV RTV 
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PATIENT NUMBER: 
SEX: 
AGE: 
VIRAL LOAD: 
DRUG MUTATIONS: 
DRUGS: 
NRTI 3TC ABC 
ANRS 
HIVDB s s 
Regalnst 
NNRTI DLV 
ANRS 
HIVDB s 
Regalnst 
22 
F 
645 000 
PR K20R ;M361; 193L 
RT 
AZ.T 04T DOC 
s s 
EFV 
s 
PI APV APV RTV ATV IDV LPV NFV 
ANRS 
HIVDB s s s s s 
Scored K20R K20R K20R K20R K20R 
Mutation M361 M361 M361 M361 M361 
Regalnst 
215 
DOl FTC TDF 
s s s 
NVP 
s 
RTV SQV TPV RTV 
s s 
K20R K20R 
M361 M361 
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PATIENT NUMBER: 
SEX: 
AGE: 
VIRAL LOAD: 
DRUG MUTATIONS: 
DRUGS: 
NRTI 3TC ABC 
ANRS 
HIVDB s s 
Regalnst 
NNRTI DLV 
ANRS 
HIVDB s 
Regalnst 
23 
F 
142 000 
PR K20R ; M361 ; L63P ; V771; 193L 
RT 
AZ.T D4T DOC DDI FTC 
s s s s 
EFV NVP 
s s 
PI APV APV RTV ATV IDV LPV NFV RTV SQV 
ANRS 
HIVDB s s s s s s s 
Scored L63P L63P L63P L63P L63P L63P L63P 
Mutation M361 M361 M361 M361 M361 M361 M361 
K20R K20R K20R K20R V771 K20R K20R 
K20R 
Regalnst 
TDF 
s 
TPV RTV 
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PATIENT NUMBER: 
SEX: 
AGE: 
VIRAL LOAD: 
24 
F 
104 095 
DRUG MUTATIONS: PR L 101; M361; 060E; L63V; 193L 
RT K103N 
DRUGS: 
NRTI 3TC ABC AZT D4T DOC DOl FTC TDF 
ANRS s s s s s s 
HIVDB s s s s s s s s 
Regalnst s s s s s s s 
NNRTI DLV EFV NVP 
ANRS R R 
SCORED MUTATION K103N K103N 
HIVDB R R R 
SCORED MUTATION K103N K103N K103N 
Regalnst R R R 
SCORED MUTATION K103N K103N K103N 
PI APV APV RTV ATV IDV LPV NFV RTV SQV TPV RTV 
ANRS s s s s s s s s 
HIVDB s s s s s s s 
SCORED L 101, L 101, L101, L101, L101, L101, L 101, 
MUTATION L63V, L63V, L63V, L63V, L63V, L63V, L63V, 
193L, 193L, 193L, 193L, 193L, 193L, 193L, 
M361 M361 M361 M361 M361 M361 M361 
Regalnst s s s s s s s 
Lit 
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PATIENT NUMBER: 
SEX: 
AGE: 
VIRAL LOAD: 
25 
F 
270 000 
DRUG MUTATIONS: PR K20R ; M361 ; D60E ; L63S ; 193L 
RT 
DRUGS: 
NRTI 3TC ABC AZ.T D4T DOC DOl FTC TDF 
ANRS s s s s s s 
HIVDB s s s s s s s s 
Regalnst s s s s s s s 
NNRTI DLV EFV NVP 
ANRS s s 
HIVDB s s s 
Regalnst s s s 
PI APV APV RTV ATV IDV LPV NFV RTV SQV TPV RTV 
ANRS s s s s s s s s 
HIVDB s s s s s s s 
SCORED K20R, K20R, K20R, K20R. K20R, K20R, K20R, 
MUTATION 193L, 193L, 193L, 193L, 193L, 193L, 193L, 
L63S, L63S, l63S, L63S, L63S, L63S, L63S, 
M361 M361 M361 M361 M361 M361 M361 
Regalnst s s s s s s s 
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PATIENT NUMBER: 
SEX: 
AGE: 
VIRAL LOAD: 
26 
M 
23 200 
DRUG MUTATIONS: PR K20R; M361; L63P; V771; 193L 
RT 
DRUGS: 
NRTI 3TC ABC AZT D4T DOC DOl FTC TDF 
ANRS s s s s s s 
HIVDB s s s s s s s s 
Regalnst s s s s s s s 
NNRTI DLV EFV NVP 
ANRS s s 
HIVDB s s s 
Regalnst s s s 
PI APV APV RTV ATV IDV LPV NFV RTV SQV TPV RTV 
ANRS s I s s s s s s 
SCORED K20R, 
MUTATION M361, 
L63P 
HIVDB s s s s s s s 
SCORED K20R, K20R, K20R. K20R, K20R, K20R, K20R, 
MUTATION L63P, L63P, V771, L63P, L63P, L63P, L63P, 
193L, 193L, L63P, 193L, 193L, 193L, 193L, 
M361 M361 193L, M361 M361 M361 M361 
M361 
Regalnst s I s s I I s 
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PATIENT NUMBER: 
SEX: 
AGE: 
VIRAL LOAD: 
DRUG MUTATIONS: 
DRUGS: 
NRTI 3TC ABC 
ANRS s s 
HIVDB s s 
Regalnst s s 
NNRTI DLV 
ANRS 
HIVDB s 
Regalnst s 
27 
F 
51 500 
PR M361 ; 193L 
RT 
AZT D4T DOC 
s s 
s s s 
s s s 
EFV 
s 
s 
s 
PI APV APV RTV ATV IOV LPV 
ANRS s s s s 
HIVDB s s s s 
SCORED 193L, 193L, 193L, 193L, 
MUTATION M361 M361 M361 M361 
Regalnst s s s s 
DOl FTC TOF 
s s 
s s s 
s s 
NVP 
s 
s 
s 
NFV RTV SQV TPV RTV 
s s s s 
s s s 
193L, 193L, 193L, 
M361 M361 M361 
s s s 
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PATIENT NUMBER: 
SEX: 
AGE: 
VIRAL LOAD: 
DRUG MUTATIONS: 
DRUGS: 
NRTI 3TC ABC 
ANRS 
HIVOB s s 
Regalnst 
NNRTI OLV 
ANRS 
HIVOB s 
Scored Mutations K103R 
Regalnst 
29 
F 
359 000 
PR M361 ; 193L 
RT K103R 
AZT D4T 
s s 
EFV 
s 
K103R 
DOC 
PI APV APV RTV ATV IOV LPV NFV 
ANRS 
HIVOB s s s s s 
Scored M361 M361 M361 M361 M361 
Mutation 
Regalnst 
001 FTC TOF 
s s s 
NVP 
s 
K103R 
RTV SQV TPV RTV 
s s 
M361 M361 
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PATIENT NUMBER: 
SEX: 
AGE: 
VIRAL LOAD: 
DRUG MUTATIONS: 
DRUGS: 
NRTI 3TC ABC 
ANRS 
HIVDB s s 
Regalnst 
NNRTI DLV 
ANRS 
HIVDB s 
Regalnst 
31 
F 
>750 000 
PR M361 ; 060E ; L63P ; 193L 
RT 
AZT D4T DOC DOl 
s s s 
EFV 
s 
FTC 
s 
NVP 
s 
PI APV APV RTV ATV IDV LPV NFV RTV SQV 
ANRS 
HIVDB s s s s s s s 
Scored L63P L63P L63P L63P L63P L63P L63P 
Mutation M361 M361 M361 M361 M361 M361 M361 
Regalnst 
TDF 
s 
TPV RTV 
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PATIENT NUMBER: 
SEX: 
AGE: 
VIRAL LOAD: 
DRUG MUTATIONS: 
DRUGS: 
NRTI 3TC ABC 
ANRS s s 
HIVDB s s 
Regalnst s s 
NNRTI DLV 
ANRS 
HIVDB s 
Regalnst s 
32 
F 
189 000 
PR L 1 OV ; M361 ; L63A ; 193L 
RT 
AZT D4T DOC DOl 
s s s 
s s s s 
s s s s 
EFV 
s 
s 
s 
FTC TDF 
s 
s s 
s 
NVP 
s 
s 
s 
PI APV APV RTV ATV IDV LPV NFV RTV SQV TPV RTV 
ANRS s s s s s s s s 
HIVDB s s s s s s s 
SCORED L63A, L63A, L63A, L63A, L63A, L63A, L63A, 
MUTATION L10V, L10V, L10V, L10V, L10V, L10V, L10V, 
193L, 193L, 193L, 193L, 193L, 193L, 193L, 
M361 M361 M361 M361 M361 M361 M361 
Regalnst s s s s s s s 
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PATIENT NUMBER: POSITIVE CONTROL 
SEX: 
AGE: 
VIRAL LOAD: 
DRUG MUTATIONS: PR 193T 
RT 
DRUGS: 
NRTI 3TC ABC AZT D4T DOC DOl FTC TDF 
ANRS s s s s s s 
HIVDB s s s s s s s s 
Regalnst s s s s s s s 
NNRTI DLV EFV NVP 
ANRS s s 
HIVDB s s s 
Regalnst s s s 
PI APV APV RTV ATV IDV LPV NFV RTV SQV TPV RTV 
ANRS s s s s s s s s 
HIVDB s s s s s s s 
Regalnst s s s s s s s 
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}I~JX(j) 
NATIONAL TREATMENT GUIDELINES Version 2 APRIL 2004 (PAGES 12-13) 
7. An1iretroviral regimens 
7.1 Antiretroviral naive adult pat ients 
7. 1.1 First-line therapy- Schedule 1 
lJnless contraindicated. all patients will commence therapy on: 
1. Stavudine (d4T) 40 mg evAIY 12 ho .. !'S (O i' :10 m~l ewHy 12 ho .. rs if < 60 -<g). pL.~> 
2. Lam iv .. dine (:n q 1 SO mg eve1y 12 hours. pL.s 
:l. Efavii'enz (EFV) 600 mg at niqllt ioi' 400 mg if < 40 -<~J ) OR 
Nevirapine (NVP) 200 m!J daily for 2 WAe-<:s. followed by 200 mn 8VAIY 12 hours. 
• Injectable contraception should be prescribed in addit ion to condoms for women of child-bearing 
potential who are started on efavirenz. ThA antiretroviral clinic m,.st chec -<: t h<:~t contraceptive 
injections have been administered on time. 
• If unable to guarantee contraception for women while on therapy. nAv irapine will be substrtuted 
for efavirenz. Extra safety bloods will need to be ta-<:en <IS perT ;:~b le 10. 
• Patients may occasionally need to chanoe a drug from the first- line mgimen to one from the 
~;econd-line regimen. beca .. se of a serio,.s adve!'se !'eact ion (e.g. sewHe msh on nevi r~rp i ne. 
!'eq~. iring a swap to lopinavil'/ ritonavir. seve!'ely symptomatic pei'ipheral neuropathy on ~;t;:\V,.d ine . 
requiring a swap to zidovudine). Swapping limits the patient's second-line treatment options. The 
decision to swap must be made by a docto!' with anti1etroviral expe!'ience. 
7. 1.2 Second-line therapy -Schedule 2 
Patients who continue to fail virologK:ally despite effor1s to improve adherence (see section 10) may 
be clmnnAd to schedule 2. Before changing to scllAdule 2. thA patient shedd ~10 th!'ough the 
treatment madiness and education process again. Most pat ients will co mmA nCA schedule 2 as 
fo llows: 
1. Didanosine (ddl) 400 nl£1 once a day (2110 mg daily if < GO -<g) . plus 
2. Zidov ,,dinA i,AZTl 300 lnf.l AVAIY 12 hours. pL.s 
3. Lopinav i( ritonavir (LPV,.r) 400: 100 mg evAIY 12 hours. 
• DidanosinA must bA takAn alone (i.e. not wrth other medicinAs). on an Amply stomach. at IAast an 
ho .. r bAfo1e (or 2 hours after) a mAal. Tablets sho .. ld bA dissolved in at least :10 ml of w<:~ter 01 
clear apple j,.ice. No other fruit j,, ice mny be usAd to dissowA the tablets. 
• P<~ t ients sho .. ld t1y to -<:eep tlwir lopinaviliritonavir cool i< 25 dA~JI!~As CelsL.sj . 
There are currently no further treatment options available within the public sector for 
patients who fai l second-line therapy. 
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NATIONAL TREATMENT GUIDELINES Version 2 APRIL 2004 (PAGES 35-37) 
5.1 First line therapy- Schedule 1 
lJn!Hss co n1raindicated. nil children will commence therapy on: 
Children < 6 months of age : 
If tr idg1:1 av,1il;lble: 
1. St<1vudinA (d4T). pL.s 
2. Lamivudine (3TC). plus 
3. Ritonavir 
If no !ridy1:1 available: 
1. Zidov •. dine (AZT ). pL.s 
2. Lnmivudine (3TC). plus 
3. Ritonavir 
Children > 6 months of age 
If fr i<ige avnilnble: 
1. Stavudine (d4T). pl •. s 
2. Lamiv .. dine i3TC) . plus 
3. Lopinavit'ritonavir 
If no !ridgfl nvailabiA: 
1. Zidov •. dine (AZT). pl .. s 
2. Lamiv .. dine r3TC). plus 
3. Lopinavi1i ritonavir 
Switch to tablets or capsules from syr .. ps or :Jolutions as soon as possib!A . 
Children may occasionally need to change a drJg from the first-line !'egimen to one from the 
~:;econd- line regimen. becnuse of intolerance or a SE.JJ'io •. s adwHse !'eaction. Swappino lim its thH 
patient's second-line liHatment options. The decision to swap m .. st be made by a doctor with 
antirHt i'oviml expefie nee. 
If intoiArance develops to ritonavir or lopinavr..'riton<~vir. switch to rlfllfinavi r. 
Lopinavk dtonavir needs to be ~ept cool (< 25 degreEls Celsius). 
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5.2 Second-line therapy- Schedule 2 
Consider a move to second-line therapy under the tollowing conditions: 
Tnble 13: Reasons 10 move to s econd-line antiretroviral therapy in children 
Virological 
RelloY1d of \'I' a oad to 
ha~e · ·1e 
A detec~ab e v1·a oad ~·ay 
be ~o e ~a~ed I!" C-''1 d· e·1. 
J-)'0VIdl1[1 t·1at o·ow:e a"d 
e eva:ed CD4 co .. 'lt a·e 
s.Jsta ·wd 
Clinical 
Pe·s1ste'lt o·a :r · .1s~. w- c-1 s -ef·acn·y 
to :·eat~·e'lt 
New ev de1ce o' :;tage Ill disease 
Immunological 
A re·~-~s~e -~ dec n e '1 ~-e CD4 
pe·ce":age <.>ve- 2 -·o'l:":, I" t·1e 
al:se1ce of TB 
Nate: The C0-1 r•etcentrKJP. ;,'/:ouit! 
NOT /;e :::~;~asuref/ (J:,ring an 
infection ;LRT/; anrl ga:;;trOP.nte~itis intP.I'CtJin:mt intectivn- /JtJt 
s!:o;J!C'J not b'! re<.:_J,:.Jrc1ed as ~finica ! tai!vrA. pr~!P.raJ.>iy a :i:onth pv.st 
Pr~sentatit>n '11itl1 TB 'lll:iie vn tirst-iine tAsvit,tfon. 
therapy is NOT an indication ta S'llitch to It the~·e is a nJodest .Je.:iim~ in CO.J 
s~conrJ-iine t!lfo!r<>Py pP.I·(:entage 1 < 5¢ ,I anrJ it no 
TB can present as progres..~ion to stage f<liiure to thtive. tlo not change 
Ill rJi:;ease and m11st be exciurJed betof'l~ merJication. b11t monitor cioseiv 
the rlecision is ma(Je to s'llitch t,> se,:on<l-
ProcRdure for introdur.tion of !;gcond-lina t/ll'lmpy: 
• Do not rush into second-line therapy. 
• First checi( adherence: if it is not possible to improve adherence. <:tnempt directly obsAIVAd 
therapy (DOT) with a health care worker or trusted family member or friend. 
• Ens .. rfl Sflcond-line therapy dofls not include any drugs ,.sed in first-line thernpy . 
Most children will commenc;9 sehed .. le 2 as follows: 
Children < 3 years old or < 10 kg: 
If fr idye available: 
1. Didanosine (ddl). plus 
2. Zidov .. dine i,AZT ). pL.s 
:l. NevirapinH 
If no fridge available (and child praviovsly on zidovudine as part of first-line therapy): 
1. Didanosine (ddll tablets. plus 
2. Abocavir (ABC). plus 
:l. NevirapinH 
llf..llf..f 
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